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Summary   IX  
Summary 
Malaria kills hundreds of thousands of people each year and is a major impediment to social 
and economic development in endemic areas. An effective vaccine is widely regarded as an 
essential tool for sustainable malaria control. Stage-specific sterile protection can be achieved 
in rodents and human volunteers by administration of Plasmodium parasites that attenuate 
during liver-stage development by either radiation (RAS), genetic modification (GAP) or by 
chemical treatment (administration of antibiotics or drug cure). These live-attenuated whole-
organism vaccination models are commonly used as a tool to study pre-erythrocytic immune 
responses. Dissecting the underlying effector mechanisms and antigen specifities would help 
to develop a safe subunit vaccine that induces similar levels of protection as the attenuated 
parasite vaccine. In this study we, hence, focussed on the identification and characterisation of 
potential antigens involved in GAP-mediated immunity. 
First we addressed the role of the circumsporozoite protein (CSP) in GAP-induced protection. 
CSP is considered the immunodominat antigen in RAS-mediated immunity and a reasonable 
amount of data from the last decades argue for this. Nevertheless, recently several studies 
revealed that protection can also be achieved despite the absence of immune responses 
specific to CSP. Our goal was to generate a P. yoelii CSP-mutant that is no longer recognised 
by the immune system without affecting CSP function. Therefore we successfully inserted 
different point mutations into the gene sequence coding for the CD8
+
 T cell epitope of CSP. 
Transfection of wild-type P. yoelii parasites resulted in integration of the targeting constructs 
into the genomic locus. A stable CSP-mutant clone, however, was not achieved in spite of 
several applied genetic strategies. Furthermore we identified within this study novel potential 
antigens involved in GAP-mediated immunity. We compared the transcript repertoire 
expressed of Plasmodium liver-stage parasites from GAP and RAS versus wild-type in an 
attempt to detect antigens that are uniquely or differentially expressed in GAP and which may 
represent important targets of GAP-induced protective immunity. Using suppression 
subtractive hybridisation (SSH) we obtained a set of differentially expressed transcripts in 
attenuated parasites. Some transcripts were specific for RAS or GAP, respectively, others are 
shared between both attenuated parasites. One of the most abundant shared transcript that 
appeared during sequence analysis coded for a P. berghei C2-containing protein (C2CP). C2 
domains are generally involved in Ca
2+
-sensing and -signalling and proteins containing C2 
domains are described to mediate Ca
2+
-dependent vesicular fusion events. The C. elegans and 
human ferlins are well characterised proteins with characteristic cytosolic C2 domains. 
Summary   X  
Database search revealed beside the Pb C2CP one annotated Pb ferlin (FER) and a ferlin-like 
protein (FLP). The cellular functions of Plasmodial ferlins, however, are unknown. We 
therefore also aimed at the cellbiological characterisation of the identified protein family. 
Targeted gene disruption experiments revealed an essential role of Pb C2CP and Pb FER 
during blood-stage development. The main objective of this study, however, focussed on the 
investigation of the antigenic potential of this novel pre-erythrocytic antigen from the 
protection-inducing attenuated malarial parasites. Interestingly epitope prediction identified 
several high-binding Pb C2CP-specific H2
b
-restricted CD8
+
 T-cell epitopes. Indeed, we could 
show that Pb C2CP-specific cells are recognised and lysed in immunised C57BL/6 mice. 
Moreover, we were able to specifically restimulate T cells in the livers of immunised animals 
with the Pb C2CP-derived peptide T9L. Altogether, both the dissection of novel antigens 
from the protection-inducing attenuated parasites and the immunogenic capacity as shown by 
a selected critical target antigen Pb C2CP for the first time allows specific restimulation of T 
cells in the experimental GAP vaccination model. Therefore this work clears the way for 
studying effector mechanisms underlying GAP-induced immunity. This work is of 
fundamental importance to understanding the mechanisms of pre-erythrocytic immunity to 
malaria and may further pave the way for the composition of an anti-infective multi-
component subunit malarial vaccine.  
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Zusammenfassung 
Nach aktuellen Schätzungen der Weltgesundheitsorganisation WHO sterben jährlich über 
einer halben Millionen Menschen an Malaria. Die Hauptübertragungsgebiete erstrecken sich 
über weite Teile der Tropen und Subtropen. Dort behindert die Krankheit die soziale und 
wirtschaftliche Entwicklung. Ein effektiver Impfstoff gegen Malaria wird dringend benötigt 
um die Ausbreitung der Erkrankung nachhaltig kontrollieren zu können. Abgeschwächte 
Malariaerreger vermitteln bereits sterilen Schutz gegen Malaria im Nagetiermodel und in 
Probanden. Die Abschwächung des Parasiten kann dabei entweder durch Bestrahlung 
(radiation-attenuated sporozoites; RAS), genetische Manipulation (genetically-attenuated 
parasites; GAP) oder chemische Behandlung (zeitgleiche Gabe von Antibiotika oder 
Chloroquin) erfolgen. Dies führt zu einer Unterbrechung der Leberstadien Entwicklung. Das 
Verständnis der zugrunde liegenden Immunmechanismen und präsentierten Antigene, würde 
die Entwicklung eines sicheren Subunit-Impfstoffes ermöglichen, der ähnlichen Schutz 
vermittelt, wie die abgeschwächten Parasiten selbst. In dieser Arbeit sollten daher spezifische 
Immunantworten untersucht werden, die dem GAP induzierten Schutz zugrunde liegen.  
Dazu sollte als erstes die Rolle des Sporozoiten Hauptoberflächenproteins CSP 
(circumsporozoite protein) im GAP vermittelten Schutz analysiert werden. Viele 
wissenschaftliche Daten aus den letzten Jahrzehnten sprechen dafür, dass CSP das 
immunodominante Antigen im RAS induzierten Impfschutz ist. Dennoch zeigen einige 
neuere Ergebnisse, dass ein vollständiger Schutz auch ohne CSP-spezifische Immunantworten 
erreicht werden kann. Das Ziel dieser Arbeit war es daher, eine Plasmodium yoelii CSP-
Mutante zu generieren, die nicht mehr vom Immunsystem erkannt wird. Dazu wurden 
verschiedene Punktmutationen in die DNA Sequenz des beschriebenen CD8
+
 T-Zell Epitops 
SYVPSAEQI eingefügt. Die erfolgreiche Integration der dazu verwendeten Vektorkonstrukte 
in das P. yoelii Genom konnte gezeigt werden. Wir konnten jedoch trotz verschiedener 
Strategien keine stabile Mutante herstellen. Das Hauptziel dieser Arbeit war die 
Identifizierung und Charakterisierung neuer möglicher Antigene, die an der GAP induzierten 
Immunantwort beteiligt sind. Dazu verglichen wir das exprimierte Transkriptrepertoire von 
GAP, RAS und Wildtyp Plasmodium Leberstadien. Auf diese Weise wurden Transkripte 
identifiziert, die in GAP differentiell exprimiert werden und so möglicherweise als 
Zielantigene des GAP induzierten Impfschutzes dienen könnten. Ein Transkript das während 
der Sequenzanalyse am häufigsten auftauchte, kodierte für das P. berghei C2 Domänen 
Protein (C2 domain-containing protein; C2CP). C2 Domänen sind allgemein an Ca
2+
-
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abhängigen zellulären Prozessen, wie Membranfusion oder vesikulärem Transport, beteiligt. 
Bekannte Vertreter mit charakteristischen C2 Domänen sind die sogenannten Ferline, die zum 
Beispiel für den Nematoden C. elegans oder den Menschen gut beschrieben sind. In 
Datenbank Analysen fanden wir neben dem P. berghei C2CP ein annotiertes Ferlin und ein 
Ferlin-ähnliches Protein. Die zellbiologische Funktion dieser Ferlin Proteinfamilie ist in 
Plasmodium nicht bekannt. Gezielte Gen-Knockouts zeigten jedoch, dass das P. berghei 
C2CP und das verwandte Ferlin essentiell während der Blutstadienentwicklung sind. 
Außerdem wurde die Immunogenität der identifizierten Antigen-Kandidaten untersucht. 
Interessanterweise konnten in der Sequenz des Pb C2CP mehrere H2
b
-spezifische CD8
+
 T-
Zell Epitope identifiziert werden. Tatsächlich wurden Zellen, die C2CP-spezifische Peptide 
auf der Oberfläche tragen, in RAS und GAP immunisierten C57BL/6 Mäusen erkannt und 
gezielt getötet. Außerdem konnte gezeigt werden, dass in der Leber von immunisierten 
Mäusen T-Zellen spezifisch mit dem C2CP-Peptid T9L restimuliert werden können. Diese 
Ergebnisse zeigen, dass in RAS und in GAP immunisierten Mäusen in der Tat 
Immunantworten induziert werden, die spezifisch gegen das identifizierte Antigen C2CP 
gerichtet sind.  
Zusammenfassend wird in dieser Arbeit das erste mal eine antigenspezifische Immunantwort 
im GAP Vakzinierungsmodell beschrieben. Die spezifische Restimulation von T-
Lymphozyten, eröffnet nun die Möglichkeit die spezifischen Immunmechanismen 
untersuchen zu können, die dem GAP induzierten Impfschutz zugrunde liegen. Diese Arbeit 
trägt damit zum Verständnis der Leberstadien Immunologie bei und könnte weiterhin dazu 
beitragen in Zukunft einen sicheren und effektiven Subunit-Impfstoff gegen Malaria zu 
entwickeln. 
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UIS     upregulated in infective sporozoites 
UTR     untranslated region 
UV     ultra violet 
qRT PCR    quantitative real time PCR 
V     Volt 
vol     volume 
w/o     without 
WHO     World Health Organization 
WT     wildtype 
µ     micro
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1. Introduction 
1.1 Malaria  
Malaria is the world's third leading infectious killer, following HIV and tuberculosis, and 
around half of the world's population live at risk of malaria transmission (figure 1). According 
to recent estimates 1,238,000 people died from malaria in 2010 worldwide of which more 
than 56 % (699,000 cases) were children under the age of five from Sub-Saharan Africa 
(Murray et al. 2012). In endemic countries malaria has a major impact on social and economic 
development, so reduction of malaria burden remains an important challenge and is still a 
focus of extensive research.  
 
 
Figure 1. Global malaria distribution. Malaria transmission is mainly restricted to the world's tropical and 
subtropical regions. Around 3.2 billion people live at risk of malaria. The highest mortality occurs in sub-
Saharan Africa. However, Asia, Latin America, and to a lesser extent the Middle East and parts of Europe are 
also affected (source: http://www.who.int/ith/en/). 
 
Adults living in endemic areas develop a degree of immunity against malaria, due to repeated 
exposure to the malaria parasite [reviewed in (Artavanis-Tsakonas et al. 2003)]. This naturally 
acquired immunity is based on invasion-inhibitory antibodies directed against blood-stage 
antigens, like merozoite surface protein-1 (MSP1) or apical membrane antigen-1 (AMA1), 
and protects against severe symptoms and death (Riley et al. 1992) (Hodder et al. 2001). 
Sterilising immunity, however, is not achieved. Two high-risk groups suffering from severe 
symptoms of the disease and associated deaths are children and women in their first 
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pregnancy (primagravidae). Malaria symptoms reach from fever, headache and nausea to 
severe illness with anaemia, respiratory distress and cerebral malaria often leading to death. 
With an early diagnosis and appropriate treatment malaria disease can be reduced and death 
can be prevented. To date the most successful treatment is achieved with an artemisinin-based 
combination therapy (ACT). Together with the use of insecticide-treated bed nets and other 
vector control strategies [reviewed in (Ramirez et al. 2009)], these are the current 
interventions to handle malaria infection and transmission. Efforts to control malaria are 
hampered by growing resistances to anti-malarial drugs, like chloroquine and sulfadoxine-
pyrimethamine (Barnes et al. 2008). Also spreading insecticide resistance display a major 
problem [reviewed in (van den Berg 2009)]. New strategies to prevent and eliminate malaria 
infection are urgently needed. New vector control strategies, like the development of new 
insecticides or transgenic mosquitoes refractory to malaria, as well as the development of new 
effective anti-malarial drugs and ultimately the development of an effective anti-infective 
malaria vaccine are focus of intense research [reviewed in (Enayati and Hemingway 2010)].  
1.2 Plasmodium life cycle 
The protozoan parasite Plasmodium spp., the causative agent of malaria, is a member of the 
clade Apicomplexa. Plasmodium has a complex life cycle, where the parasite not only has to 
switch between an invertebrate and a vertebrate host, but also between extracellular/invasive 
and intracellular/replicative forms (figure 2). Female Anopheles spp. mosquitoes transmit and 
receive different forms of the parasite during a blood meal on a variety of vertebrate hosts. 
There are four human Plasmodium species. P. falciparum is the most widespread and most 
fatal species often causing severe symptoms leading to death. P. vivax, P. ovale and P. 
malariae cause milder disease symptoms in humans. Recently, a fifth one, P. knowlesi, whose 
natural hosts are macaques, is also transmitted by humans, especially in Malaysia (Singh B. et 
al. 2004). The rodent Plasmodium species, P. berghei and P. yoelii, share major similarities to 
the human species and depending on the mouse strain used, they can mimic different facets of 
the disease outcome, reaching from mild symptoms to cerebral malaria, which is then 
considered experimental cerebral malaria (ECM). Therefore these strains are used as model 
systems in the laboratory.  
 
Malaria infection starts with the inoculation of infectious salivary-gland sporozoites into the 
skin of the vertebrate host during blood meal of female Anopheles mosquitoes. Typically, 
only a several hundred sporozoites are injected per infectious bite (Jin et al. 2007) 
(Vanderberg 1977). Sporozoites depart from the site of injection within minutes and reach a 
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blood vessel. With the blood stream sporozoites are rapidly transported to the liver, where an 
initial replication phase occurs (pre-erythrocytic cycle). In the liver sinusoid sporozoite 
invasion is activated by the highly sulfated heparan sulfate proteoglycans (HSPGs) of 
hepatocytes (Coppi et al. 2007). Sporozoites adhere to the endothelium cells by exposure of 
the C-terminal thrombospondin repeat (TSR) domain of the circumsporozoite protein (CSP) 
(Coppi et al. 2011). Subsequently sporozoites enter the space of Disse through Kupffer cells 
and transmigrate several hepatocytes before they settle down in their final host-cell (Frevert 
2004) (Mota and Rodriguez 2001).  
 
 
Figure 2. Plasmodium life cycle. The single developmental stages are underlined and explained in the text. 
Briefly, infectious sporozoites are transmitted during blood meal and initially invade hepatocytes where they 
undergo massive replication (pre-erythrocytic cycle). Merozoites are released and invade erythrocytes. The 
asexual erythrocytic cycle starts. Some parasites differentiate into sexual stages, which are taken up by a 
mosquito during blood meal. Fertilisation occurs in the mosquito's midgut and oocysts develop inside the 
midgut's epithelium. Midgut sporozoites travel through the hemocoel to the salivary glands, where they mature. 
Infectious sporozoites are then again transmitted to the vertebrate host. (from Phillips, R. S. 2001. Clin. 
Microbiol. Rev. 14(1):208-226) 
 
Besides the above mentioned CSP, several other parasite proteins are described to be involved 
in this invasion process. Amongst them the thrombospondin-related anonymous protein 
(TRAP) is essential for parasite gliding motility and host-cell invasion (Sultan et al. 1997) 
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(Matuschewski et al. 2002). Furthermore the sporozoite microneme protein essential for cell-
traversal 2 (SPECT2) is involved in breaching the sinusoidal cell layer prior to hepatocyte 
invasion (Ishino et al. 2005). Additionally the cell-traversal protein for ookinetes and 
sporozoites (CelTOS) is necessary for passage of the sporozoite through the liver endothelium 
(Kariu et al. 2006). During invasion of the final hepatocyte the host-cell membrane is 
invaginated building the parasitophorous vacuole, whose membrane is then modified by the 
intracellular residing parasite. Inside the hepatocyte the parasite replicates asexually, a phase 
known as pre-erythrocytic or exoerythrocytic schizogony. This replication lasts, depending on 
the Plasmodium species, 2-15 days and ends with the release of thousands of first-generation 
merozoites. These infective merozoites are packed in host-cell derived vesicles, called 
merosomes, that bud from the detached host-cell and reach the liver sinusoid (Sturm et al. 
2006). These merosomes accumulate subsequently in the pulmonary capillaries, where 
merozoites are released and infect erythrocytes (Baer et al. 2007). This is the initiation of the 
disease-causing blood-stage malaria infection (asexual erythrocytic cycle). Liver-derived 
merozoites invade erythrocytes under formation of a parasitophorous vacuole. Inside the 
erythrocyte asexual replication, also called erythrocytic schizogony, starts from the ring stage 
and proceeds via the trophozoite stage to schizonts. Erythrocytes with mature schizonts 
rupture, which is associated with fever, and released merozoites invade new erythrocytes. 
Some parasites differentiate to sexual stages, the gametocytes. Sexual reproduction occurs in 
the mosquito's midgut, after the uptake of gametocytes during a blood meal. The female 
macrogamete and the male microgametes emerge from the erythrocyte inside the mosquito's 
midgut and fertilisation of the two results in a diploid zygote. Subsequently followed by 
differentiation to a motile ookinete, which actively traverses the mosquito's midgut epithelium 
and forms a so-called oocyst. Inside these oocysts the parasite undergoes meiosis and 
replicates subsequently asexual and mitotic. Mature midgut sporozoites are released into the 
hemocoel and travel to the mosquito's salivary glands. The invasion of the salivary glands is 
an active process involving also some of the afore mentioned proteins, important for 
hepatocyte invasion, like CSP and TRAP [reviewed in (Mueller et al. 2010)]. Inside the 
salivary glands sporozoites mature and infectious sporozoites are again transmitted during an 
infectious blood meal.  
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1.3 Vaccination strategies against malaria 
There are several vaccination strategies against malaria under investigation, reaching from the  
research stage to clinical trials in phase III. A variety of approaches attack different parasite-
specific targets throughout the complex life cycle and thereby might either inhibit or reduce 
clinical malaria disease (anti-disease), block malaria transmission (anti-transmission) or 
completely prevent malaria infection (anti-infective). 
 
 
Figure 3. Vaccination strategies against malaria and their targets throughout the parasite's life cycle. 
Sporozoites injected by female mosquitoes (1) invade hepatocytes (2) and replicate inside the cell (3). Budding 
vesicles filled with merozoites, called merosomes, are released into the blood (4). Pre-erythrocytic vaccines 
(anti-infective vaccines) target this initial liver-phase and completely prevent infection. In the bloodstream 
merozoites invade erythrocytes and replicate. Mature schizonts rupture and release new merozoites (5). This is 
when malaria symptoms start. Blood-stage vaccines (anti-disease vaccines) target mainly erythrocyte invasion 
and ease malaria symptoms. Some parasites differentiate into sexual gametocyte stages that are taken up by a 
mosquito during blood meal (6). Inside the mosquito's midgut gametes fertilise (7) and transform into a motile 
ookinete (8). Midgut sporozoites develop inside oocysts and travel through the hemocoel to the salivary glands, 
where they mature to infectious sporozoites (9). Targeting the parasite stages in the mosquito prevents 
transmission, these vaccines are therefore called transmission-blocking vaccines (anti-transmission vaccines). 
(from Thera and Plowe 2012. Annu. Rev. Med. 63:345–57; adapted from PATH Malaria Vaccine Initiative) 
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1.3.1 Anti-disease vaccines 
The disease-causing blood-stages, replicating inside erythrocytes, are hardly attacked by 
cellular responses as red blood cells do not express major histocompatibility complex (MHC) 
molecules. But vaccination strategies are pursued that target merozoite invasion and 
cytoadhesion of the infected erythrocyte by humoral responses. Inhibitory antibodies against 
merozoite surface protein-1 (MSP1), for example, reduce blood-stage parasitemia and ease 
malaria symptoms (Siddiqui et al. 1987) (O'Donnell et al. 2001). More recent data show, that 
these specific antibodies interfere with shedding of  MSP1 and thereby inhibit erythrocyte 
invasion (Woehlbier et al. 2010). A MSP1-based vaccine formulated with the adjuvant AS02 
(see below) induced high specific antibody titres in Malian adults and children Western 
Kenya (Thera et al. 2006). Protection, however, was not achieved with this vaccine candidate 
(Ogutu et al. 2009). Another merozoite protein, the apical membrane antigen-1 (AMA1), 
became a promising vaccine candidate as antibodies against AMA1 are associated with a 
degree of protection in naturally acquired immunity (Polley et al. 2004). Initial efficacy trials 
with AMA1-based vaccines failed to induce any protection (Sagara et al. 2009) (Ouattara et 
al. 2010). An AMA1 vaccine, however, also formulated with the AS02 adjuvant was highly 
immunogenic in a phase I trial in Malian children (Thera et al. 2010). Protection was also not 
achieved with this AMA1 vaccine candidate after experimental sporozoite challenge (Spring 
et al. 2009), but the efficacy against clinical malaria was more than 60 % when caused by the 
homologous strain used in the vaccine (Thera et al. 2011). Currently, this protection against 
clinical malaria was also observed with the merozoite surface protein-3 (MSP3) blood-stage 
vaccine candidate (Sirima et al. 2011). Interestingly, AMA1 is not only necessary for 
erythrocyte invasion, it may also play a similar role in hepatocyte invasion and might 
therefore even serve as a multi-stage vaccine candidate (Mitchell et al. 2004) (Florens et al. 
2002). Furthermore antibodies against parasite-derived erythrocyte surface proteins, the 
variant surface antigen PfEMP1, block sequestration of infected erythrocytes and therefore 
prevent severe symptoms (Kyes et al. 2001). These PfEMP1 proteins are encoded by a large 
family of var genes and therefore these highly polymorphic proteins are hardly to combine in 
an efficient vaccine (Smith et al. 1995). Nevertheless, one variant, the VAR2CSA, that 
mediates cytoadherence in placental malaria, is less polymorphic and development of such a 
placental malaria vaccine is ongoing (Avril et al. 2010). Beside the administration of subunit 
blood-stage vaccines formulated with strong adjuvants the described blood-stage antigens 
were also applied as viral vector vaccines. For example, vaccination with the human 
adenovirus AdHu5 and the modified vaccinia virus Ankara (MVA), expressing MSP1 and 
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administered in an approved prime-boost immunisation regime, induced high antigen-specific 
antibody titres and conferred protection in mice (Draper et al. 2008). In a follow-up study it 
was shown, that these viral vaccine vectors also induced CD4
+
 T-cells providing help to the 
protective B-cell responses and additionally CD8
+
 T-cells mediating anti-parasitic activity 
against liver-stages (Draper et al. 2009). All these described anti-disease malaria vaccines, 
directed against blood-stages and based on invasion-inhibitory antibodies, typically reduce 
parasite burden rather than clearance, sterilising immunity is not achieved similar to naturally 
acquired immunity. Also the parasite's life cycle proceed and malaria transmission is hardly 
impaired. 
1.3.2 Anti-transmission vaccines 
Though spreading of the parasite can very efficiently be blocked by so called transmission-
blocking vaccines. This strategy is generally based on inhibitory antibodies against gamete or 
ookinete surface proteins that are taken up by the mosquito during the blood meal and will 
block parasite fertilisation or further development in the mosquito. Thereby the parasite's life 
cycle is interrupted. Major candidates, currently under investigation as possible targets, are 
Pfs28 and Pfs25, which are important for oocyst development (Tomas et al. 2001). One 
approach based on the two proteins Pfs25 and Pvs25 from P. falciparum and P. vivax, 
respectively, showed antibody-mediated transmission-blocking activity (Wu et al. 2008). 
Strong adverse effects, due to the used adjuvant Montanide ISA 51, however, proscribed 
further trials with this vaccine candidate. Recently, also mosquito midgut proteins necessary 
for parasite invasion were investigated with respect to their potential as transmission-blocking 
vaccine candidate. The midgut-specific anopheline alanyl aminopeptidase N (AnAPN1) is a 
promising candidate currently under investigation (Mathias et al. 2012). There is one problem 
with the transmission-blocking strategies namely that these altruistic vaccines do not protect 
the vaccinated individuals, but following individuals. Therefore it is suggested to be 
administered in combination with an anti-disease vaccine. Though the smarter approach 
would be the development of an effective anti-infective vaccine, that prevents infection and 
stops transmission at the same time.   
1.3.3 Anti-infective vaccines  
An anti-infective malaria vaccine, that prevents disease and blocks transmission at the same 
time, can only be achieved by targeting the pre-erythrocytic stages, this might either be the 
invasive sporozoites or developing liver-stages. On example is the currently most advanced 
vaccine candidate, called RTS,S, that contains fragments of the circumsporozoite protein (see 
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below) including B-cell (R) and T-cell epitopes (T), fused to the hepatitis B surface antigen 
(S) and formulated with the AS adjuvant system [reviewed in (Cohen et al. 2010)]. The 
efficacy of this subunit vaccine is around 50 % in malaria-naïve adults (Kester et al. 2009) 
and similar levels of efficacy were achieved in several phase IIb field trials (Guinovart et al. 
2009) (Alonso et al. 2004) (Bejon et al. 2008). But importantly the vaccine reduced the 
occurrence of severe symptoms about almost 60 % (Bojang et al. 2001) (Alonso et al. 2004). 
Several attempts were made to improve the efficacy of the RTS,S/AS01 vaccine candidate, 
for example by adding more antigens tested with the same adjuvant system to create a multi-
stage, multi-antigen RTS,S-based vaccine (Heppner et al. 2005). Additionally it was 
demonstrated that priming with an adenovirus serotype 35 (Ad35) vector encoding CSP 
(Ad35.CS) prior to RTS,S/AS01 boosting, increased specific T-cell responses (Stewart et al. 
2007). Nevertheless the candidate malaria vaccine RTS,S/AS01 is currently investigated in a 
huge clinical phase III trial in African children. First results of this phase III trial show similar 
efficacies like in the previous phase II trials from around 50 % (Agnandji et al. 2011). The 
main protective mechanism of this vaccine candidate is based on inhibitory antibodies 
directed against the repeat region of CSP (see below). These CSP-specific antibodies are 
thought to reduce sporozoite motility and host-cell invasion (Heppner et al. 2005). In contrast 
several studies revealed only moderate T-cell responses induced by RTS,S (Pinder et al. 
2004) (Barbosa et al. 2009). Further results also revealed primarily humoral responses and 
additionally, albeit to a lesser extent, CSP-specific CD4
+
 T-cells to be elicited by RTS,S 
(Kester et al. 2009). This was supported by a more recent dataset, where the combination of 
anti-CSP antibody titres and CSP-specific TNF"
+
 CD4
+
 T-cells could account for the level of 
protection conferred by the RTS,S/AS01 candidate vaccine (Olotu et al. 2011). Although the 
results of clinical phase II and first results from phase III showed partial protection against 
natural malaria infection, the question remains whether RTS,S is the ultimate vaccine?  
Other recombinant subunit-protein vaccines but also DNA or viral vector vaccines targeting 
the pre-erythrocytic stages are under investigation. The recombinant liver stage antigen-1 
(LSA1) formulated with the adjuvants AS01 or AS02 induced high antibody titers and CD4
+
 
T-cell responses, but failed to induce protection in a phase I/II study (Cummings et al. 2010). 
In contrast a DNA prime-MVA boost vaccine encoding TRAP elicited strong INF-" 
producing CD8
+
 T-cell responses and partially protected from experimental P. falciparum 
challenge (Dunachie et al. 2006). Interestingly, the combination of a viral vector with a 
subunit protein vaccine, both based on CSP, induced high levels of protection in rodents 
(Hutchings et al. 2007). Thereby the subunit protein part, containing the immunodominant B-
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cell epitope, induces high levels of antibodies, while the viral vector vaccine elicits potent T-
cell responses against a CD8
+
 T-cell epitope (Anderson et al. 2004). Different approaches 
show promising results, the self-assembling polypeptide nanoparticle (SAPN) displaying the 
B-cell epitope of CSP, for example, induces high antibody titers and confers protection in 
rodents (Kaba et al. 2009). Finally, different whole-organism vaccination models based on 
live sporozoites (see below) showed feasibility of a protective anti-infective malaria vaccine. 
Strong protective T-cell responses are induced and directed against liver-stage maturation. T-
cells recognise antigens presented by MHC class I molecules on the surface of infected 
hepatocytes and destroy the infected cell (see below). A highly effective anti-infective malaria 
vaccine targeting the pre-erythrocytic stages would therefore prevent not only infection but 
also disease and transmission.  
1.4 Natural vaccination models  
In endemic areas adults acquire a degree of natural immunity to malaria due to repeated 
exposure to wild-type (WT) Plasmodium sporozoites [reviewed in (Artavanis-Tsakonas et al. 
2003)]. These live parasites express a pool of immunogenic antigens in its native 
configuration and thereby displaying multiple targets for protective immune responses. The 
use of WT sporozoites as a vaccine, however, is obviously proscribed because of the 
subsequent development of fulminant blood-stage malaria infections. But already in the 1970s 
it was shown that WT sporozoites, administered along with a suppressive dose of chloroquine 
(CQ) during immunisation and subsequent curative primaquine treatment, protect from 
subsequent sporozoite challenges (Beaudoin et al. 1977). Later it was shown that 
immunisation with sporozoites under CQ treatment induces protective T-cell responses 
(Roestenberg et al. 2009). Furthermore, it was described that primaquine treatment, applied 
concurrently with the sporozoite plus CQ immunisation, abolished protection, by that 
demonstrating an essential role of developing liver-stage parasites for the induction of 
protective immunity in this model (Belnoue et al. 2004). Meanwhile this sporozoite plus CQ 
immunisation model has been successfully adopted to human trials (Roestenberg et al. 2009). 
Although the immune responses are predominantly directed against liver-stages, a slight 
inhibitory effect on blood-stages was shown (Belnoue et al. 2004). Recently, protection has 
also been achieved by administration of Azithromycin during natural immunisation (Friesen 
et al. 2010). This causal prophylactic antibiotic treatment suppresses apicoplast replication 
(Shimizu et al. 2010). This natural immunisation model produces sterile merosomes unable to 
establish blood-stage infection and therefore serves as a experimental vaccine (Friesen et al. 
2010).  
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Similarly, causal-prophylactic treatment with primaquine, an anti-malarial drug that 
exclusively acts on liver-stages, in conjunction with WT sporozoite injection resulted in 
induction of protective immune responses, despite the absence of persistence (Putrianti et al. 
2009). This differs fundamentally from immunisations with other whole-organism vaccines 
where persistence is a prerequisite for protection, suggesting maybe different underlying 
immunity mechanisms and a variability in the host immune-status. Recently,  
1.5 Live sporozoite vaccination models 
The "gold standard" of attenuated whole-organism vaccines, however, remains the radiation-
attenuated sporozoite model (RAS). Rodents, monkeys and human volunteers do enjoy sterile 
protection against sporozoite challenge by administration of "-irradiated sporozoites 
(Hoffman et al. 2002, Nussenzweig et al. 1967). These irradiated sporozoites, transmitted by 
bite or injection to the mammalian host, are still able to invade hepatocytes and transform into 
liver-stages, but ultimately arrest at different time points during intrahepatic development. 
Irradiation is thought to induce multiple, random point mutations in the sporozoite's genome 
leading to a block in liver-stage development. Arresting liver-stages alert the immune system 
and thereby confer stage-specific sterile immunity. In the RAS model persistence seems to be 
important as primaquine treatment abolishes protection (Scheller and Azad 1995). Recently, it 
has been shown that Plasmodial antigen is presented up to 8 weeks after immunisation. The 
antigen is supposed to persist in lymphoid organs and is required for optimal induction and 
maintenance of CD8
+
 T-cell responses (Cockburn et al. 2010). The RAS induced immune 
response is stage-specifc as there was no response detected which is directed towards blood-
stages (Romero P. et al. 1989) (Rodrigues M. M. et al. 1991). The mechanisms behind the 
RAS induced immunity are focus of intense research, but up to now only partly understood 
(see below). Although RAS confers one hundred percent sterile protection in rodents and 
humans, such a vaccine is difficult to be licensed for human use due to several ethical and 
technical issues. So far an in vitro cultivation system is lacking for Plasmodium sporozoites 
making a large-scale production almost impossible or at least enormous laborious and 
expensive. The safety of this vaccine must be considered, as over-irradiated sporozoites fail to 
induce protection and under-irradiated sporozoites can even cause blood-stage infections 
(Silvie et al. 2002). Furthermore uniformity of the end-product cannot be achieved as 
irradiation leads to random point mutations in the genome resulting in a genetically-undefined 
sporozoite population. Despite all this obstacles the biotechnology company Sanaria Inc. 
developed the candidate vaccine PfSPZ based on irradiated sporozoites (Hoffman et al. 2010) 
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and started a first clinical trial with this candidate vaccine in January 2012 
(www.niaid.nih.gov, press release).  
Some of the above mentioned problems have recently been overcome by the generation of 
genetically-attenuated parasites (GAP). Here liver-stage arrest is achieved by depletion of 
single liver-stage essential genes, such as uis3, uis4 or p36p (Mueller et al. 2005a) (Mueller et 
al. 2005b) (van Dijk et al. 2005). Like RAS, GAP invade hepatocytes and transform into 
liver-stages, but then arrest at specific time points and thereby conferring stage-specific sterile 
protection. The GAPs that were initially described in rodent malaria have meanwhile been 
translated to P. falciparum. It was shown that P. falciparum p52(-) and p36(-) deletion 
mutants arrest during liver-stage development in cultured human hepatocytes or a chimeric 
mouse model (van Schaijk et al. 2008, VanBuskirk et al. 2009). Persistence probably plays 
also a role in the GAP experimental vaccine model as protection was abolished by primaquine 
treatment after immunisation with P. berghei uis3(-) parasites (Mueller et al. 2007). No 
persisting parasites, however, were detectable by qRT-PCR 40 hours after immunisation with 
P. yoelii uis3(-) and uis4(-) (Tarun et al. 2007). The effector mechanisms and antigenic 
specificities of the GAP induced immunity are hardly known (see below). In summary 
vaccination strategies based on live sporozoites provide ideal tools to study malaria liver-
stage immunology. 
1.6 Pre-erythrocytic antigens 
Although a number of Plasmodium pre-erythrocytic proteins have been studied as possible 
antigen candidates (Gruner et al. 2003), i.e. liver stage antigen-1 (LSA1) or thrombospondin-
related-anonymous protein (TRAP), only immune responses against the circumsporozoite 
protein (CSP) have been extensively studied so far  [reviewed in (Nardin and Nussenzweig 
1993)]. It has been shown that P. yoelii TRAP (also known as sporozoite surface protein 2) 
can activate CD8
+
 T-cells and a certain CD8
+
 T-cell clone, specific for a so far 
uncharacterised epitope, can protect naïve mice if adoptively transferred (Khusmith et al. 
1994). Another P. yoelii antigen, Py-Hep17, also known as Exp1, seems to be able to 
stimulate protective CD8
+
 T-cells, too, but specific epitopes for this protein are also unknown 
(Doolan et al. 1996). Defined pre-erythrocytic epitopes have so far only been described and 
characterised for CSP (Romero P. et al. 1989), this built the basis for extensive investigation 
of specific T-cell responses and effector mechanisms in the liver. 
  
The CS protein is, as the name already suggests, the main surface protein of sporozoites 
(Yoshida et al. 1981). It is expressed already early in midgut sporozoites and is essential for 
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sporozoite development inside the oocyst (Menard et al. 1997). In the vertebrate host CSP is 
important for sporozoite motility and involved in host-cell attachment and invasion (Cerami et 
al. 1992). 
 
 
Figure 4. Schematic primary structure of the Plasmodium circumsporozoite protein (CSP). Localisation of 
the conserved regions RI and RII are shown in the amino terminus (left) and the carboxyl terminus (right), 
respectively. The immunogenic sections are the central amino acid repeats and CD4
+
 and CD8
+
 T-cell epitopes. 
SP: signal peptide; GPI: glycosylphosphatidylinositol anchor. 
 
The CS protein can be divided into three parts, the N-terminal and the C-terminal region and 
the central repeat region (figure 4). The central repeats are also known as B-cell epitope-
region as antibodies are directed against this part of the protein (Eichinger et al. 1986). The N-
terminal and C-terminal parts contain the conserved regions RI and RII, important for host-
cell binding and gliding motility (Ancsin and Kisilevsky 2004) (Tewari et al. 2002), but also a 
number of different T-cell epitopes. To date several CD4
+ 
specific T-cell epitopes have been 
described in the amino as well as in the carboxy termini specific to different MHC-haplotypes 
(Romero P. J. et al. 1988). But so far only a single MHC class I H-2
d
-restricted CD8
+
 T-cell 
epitope for CSP (amino acids 252-260, SYIPSAEKI for P. berghei and amino acids 280-288, 
SYVPSAEQI for P. yoelii) is described. Presentation and recognition of this CD8
+
 T-cell 
epitope is strongly correlated with protection (Romero P. et al. 1989). Because of this 
dominant humoral and cellular responses directed against CSP, it has been considered as the 
major vaccine candidate since a long time. Recently, however, a series of elegant studies 
revealed that protection can be achieved despite the absence of immune responses specific to 
CSP. In transgenic mice, that were made tolerant to CSP T-cell epitopes, protection was 
greatly reduced when immunised with two doses of irradiated sporozoites. But complete 
protection could be restored with three immunisation doses (Kumar et al. 2006). This indeed 
suggests an immunodominant role for CSP, but other sub-dominant responses against other, 
still unknown pre-erythrocytic antigens must be present. In another study the P. berghei CSP 
was complemented with the P.falciparum orthologe. This transgenic parasite line has been 
used for challenge experiments after immunisation studies with P. berghei RAS. Although no 
cross-reactivity between the two heterologous CSP proteins could be shown, P. berghei RAS 
immunised mice were protected when challenged with the parasite line expressing the 
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heterologous protein (Gruner et al. 2007). Furthermore CSP was ascribed only a minor role in 
protection achieved by immunisation with live sporozoites under chloroquine prophylaxis as 
protective immunity was obtained irrespective of the origin of CSP in this vaccination model 
(Mauduit et al. 2010). These data demonstrate that sterile protection against malaria is 
independent to immune responses to CSP. Finally, in the GAP vaccination model sterile 
protection is achieved in the C57BL/6 mouse genetic background. These mice do not 
recognise the CSP CD8
+
 T-cell epitope, as they do not express the H-2k
d
 MHC class I 
molecule haplotype. Altogether these findings raise the idea that other, hitherto not yet 
identified pre-erythrocytic antigens may exist that can be targeted in order to induce 
sterilising immunity to malaria infection. Searching for new immunogenic antigens that may 
be implicated in the acquisition of protection is necessary. Interestingly, recent transcriptome 
and proteomic data of liver-stage parasites aid in improving the search for new candidates 
(Tarun et al. 2008) (Williams and Azad 2010) (Cardoso et al. 2011). 
1.7 Malaria liver-stage immunology 
Immunology to malaria liver-stage infection is investigated in field studies mainly as response 
to pre-erythrocytic stage antigens in naturally acquired immunity. Nevertheless, these studies 
in endemic areas gave only little insights into liver-stage immunology of WT malaria 
infection (Plebanski and Hill 2000) (Offeddu et al. 2012). Antibodies directed against the 
sporozoite surface proteins CSP and TRAP inhibit sporozoite invasion (Hoffman and Franke 
1994). However, there is no stringent correlate between high CSP-specific antibody titres and 
protection in malaria-exposed individuals (Riley et al. 1990) (Hoffman et al. 1987). Although 
parasite-specific CD8
+
 T-cells are found only rarely in humans (Plebanski et al. 1997) 
(Doolan et al. 1993), there is evidence that CD8
+
 T-cells execute anti-parasitic activity in vivo 
(Hill et al. 1992). Another study shows that enhanced memory T-cell responses specific to 
TRAP correlate with reduced malaria incidence (Todryk et al. 2008). While in the same study 
increased TRAP-specific CD4
+ 
CD25
high
 T-cell responses were associated with higher risk of 
clinical malaria. The immune responses to WT liver-stage infections may also be limited due 
to immune evasion and modulation mechanisms driven by the parasite [reviewed in (Casares 
and Richie 2009)].  
Therefore most research focusing on malaria liver-stage immunology utilised irradiated 
sporozoites to study induced protective immune responses in the liver. This RAS-mediated 
immunity is multi-factoral involving neutralising antibodies and interferon-gamma producing 
T-cells (Schofield et al. 1987b) (Tsuji et al. 1992). It has been shown already in the 1980s that 
antibodies against a sporozoite's surface component confer protection depending on the 
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number of sporozoites used for challenge and the antibody concentration in the serum 
(Potocnjak et al. 1980). In particular, antibodies directed against the circumsporozoite protein 
(CSP) neutralise sporozoites at the inoculation site and prevent their invasion into hepatocytes 
after RAS immunisation (Hollingdale et al. 1982). This humoral response, however, seems to 
be not crucial as B-cell deficient mice were still able to develop protective immunity after 
immunisation with RAS (Chen et al. 1977). The critical role of CD8
+
 T-cells observed for 
protective immunity has been shown in earlier studies where depletion of CD8
+
 T-cells 
reduced the immunity induced by RAS (Schofield et al. 1987b) (Weiss et al. 1988). 
Additionally, adoptive transfer experiments demonstrated that CSP-specific CD8
+
 T-cells 
conferred protection against sporozoite challenges (Rodrigues M. M. et al. 1991). These CD8
+
 
T-cells are supposed to recognise major histocompatibility complex (MHC) class I presented 
malarial antigens and direct their cytotoxic activity against infected hepatocytes (Renia et al. 
1994). How these presented antigens are processed in vivo was recently investigated. While 
CSP was cross-presented via endosomes by dendritic cells in the priming phase it had to be 
exported into the hepatocyte cytosol in order to be accessible to T-cells in the effector phase 
(Cockburn et al. 2011). The mechanisms underlying the cytotoxic activity, however, are not 
yet fully understood. There is a potential role for nitric oxide (NO) described as part of the 
downstream effector mechanism associated with protection (Nussler et al. 1993). In contrast, 
other effector molecules like Fas and perforin seem not to be important, as mice lacking one 
of these molecules can still develop protective immunity (Renggli et al. 1997) (Doolan and 
Hoffman 2000). Interferon-gamma (IFN-") produced by cytotoxic CD8+ T-cells seems to be 
the main effector cytokine in mediating anti-malarial activity. Studies in IFN-" deficient mice 
or IFN-" depletion after immunisation with irradiated sporozoites and IFN-" treatment of 
infected hepatocytes in vitro revealed a crucial role for this regulatory cytokine for mediating 
the killing of intracellular parasites by CD8
+
 T-cells (Schofield et al. 1987a).  
Additionally, it is suggested that other T-cell subsets are involved in pre-erythrocytic 
immunity in general and RAS-mediated protection in particular. There is evidence that CD4
+
 
T-cells can directly mediate RAS-induced immunity, depletion of CD4
+
 T-cells in RAS 
immunised mice significantly reduced protective immunity (Rodrigues M. et al. 1993), as 
well as a certain adoptively transferred CD4
+
 T-cell clone has shown to protect naïve mice 
from sporozoite challenge (Tsuji et al. 1990). But in the first instance CD4
+
 T-cells provide 
important helper functions. Thus, it was shown that IL-4 secreting CD4
+
 T-cells are required 
for induction and survival of the CD8
+
 T-cell response after immunisation (Carvalho et al. 
2002) (Morrot et al. 2005). In #$ T-cell deficient mice, lacking CD8+ and CD4+ T-cells, it has 
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been shown that also "% T-cells can mediate a direct anti-malaria effect (Tsuji et al. 1994). 
Moreover, it was demonstrated that "% T-cell deficient mice had a higher parasite load in the 
liver after challenge with infectious sporozoites (McKenna et al. 2000) confirming the role of 
this T-cell subset in RAS-mediated pre-erythrocytic immunity. Although it was firstly 
described that natural killer (NK) T-cells are important for inducing high antibody responses 
(Schofield et al. 1999), this was negated later (Molano et al. 2000). If not important for the 
humoral response, NK T-cells, however, seem to act against malaria liver-stages. NK T-cells 
isolated from livers of malaria-infected mice, inhibited the development of liver-stages in 
vitro (Pied et al. 2000). Furthermore, the ligand #-GalCer, which stimulates NK T-cells, was 
successfully used as adjuvant to reduce liver infection after live sporozoite injection 
(Gonzalez-Aseguinolaza et al. 2000), indeed suggesting NK T-cells to act against malaria 
liver-stages. 
Whether NK cells, which are usually associated with the innate immune system, play a role in 
immunity to malaria liver-stages is still under discussion. Depletion of NK cells with anti-
asialoGM-1 antibodies after immunisation with irradiated sporozoites, significantly 
diminished protection (Doolan and Hoffman 1999). But as asialoGM-1 is also expressed by 
activated CD8
+
 T-cells (Slifka et al. 2000), this decrease in protection could also be due to 
depletion of the latter. Moreover, depletion experiments showed a role of dendritic cells for 
priming the CD8
+
 T-cell response (Jung et al. 2002). 
Protective immune responses induced by genetically-attenuated parasites (GAP) are so far 
less characterised, but share at least in some aspects similarities to the RAS-induced 
protection. Studies in rag1-/- mice, lacking T-cells and B-cells, showed that protection is 
dependent on adaptive immune responses and adoptive transfer experiments demonstrated 
that CD8
+
 T-cells are major players. Antibodies, however, seem to be not crucial, as 
protection could also be achieved in B-cell deficient mice (Mueller et al. 2007). Moreover, the 
role of innate immune responses in the GAP induced immunity is not yet clarified, but a delay 
in pre-patency in rag1-/- mice might at least suggest a minor role of innate immune 
mechanisms (Mueller et al. 2007). Ultimately, the induced effector mechanisms and antigenic 
specificities induced by GAP, however, are so far not fully understood.  
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1.8 Aim of this study 
Malaria kills nearly one million people a year and a vaccine is urgently needed. The 
feasibility of vaccination against malaria infection has been adequately demonstrated by the 
live RAS (radiation-attenuated sporozoites) vaccine that confers sterilising immunity against 
natural malaria infection in rodents and humans. As an alternative, recent advances in gene 
targeting have permitted the generation of genetically-attenuated parasites (GAP), which are 
unable to express essential liver stage expressed genes, thus resulting in attenuated liver stage 
development. These GAPs confer to a similar degree of protection as RAS, but, so far, the 
antigenic specificity and the effector mechanisms of this protective immune response have not 
been characterised. These live-attenuated parasites provide us with an ideal tool to study 
protective immune responses. In order to develop a safe subunit vaccine that induces similar 
levels of protection we need to understand how the attenuated parasite vaccine works. The 
aim of this research is thus to characterise antigenic specificities and effector mechanisms of 
immunity induced by GAP and to compare these responses to those induced by RAS and WT 
sporozoites.  
First we wanted to create a tool to further characterise the role of the circumsporozoite protein 
(CSP) in pre-erythrocytic immunity. CSP has historically been considered as the major 
vaccine candidate, but recently several arguments revealed that protective immunity can be 
achieved independently of immune responses specific to main surface protein of sporozoites. 
Hence, we aimed at generating a P. yoelii parasite expressing a functional CS protein, 
essential for sporozoite development, that is no longer recognised by the host’s immune 
system. For that we wanted to insert several defined point mutations in the described CD8
+
 T  
cell epitope, SYVPSAEQI, and subsequently subject this novel experimental genetically- 
engineered parasite for immunisation studies. Hypothesising that CSP cannot be a protective 
antigen in the GAP experimental model, we secondly wanted to isolate and characterise novel 
antigen candidates that might be both immunogenic and protective and expressed during liver 
stage development of GAP parasites. As GAP arrest early during liver stage development not 
all proteins that are normally expressed will be transcribed. The same accounts for RAS, 
irradiation, however, induces random point mutations, liver stage arrest therefore occurs at 
different time points, the expressed repertoire is probably more heterogeneous in comparison 
to GAP. We hypothesise that proteins expressed in the liver by GAP are able to initiate 
protective immune responses. Our hypothesis prompted us to screen for liver stage antigens 
that are uniquely or differentially expressed by the attenuated liver stage parasites that will 
ultimately allow us to narrow down antigens that may be critical for immunity. We therefore 
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wanted to apply differential screening methodologies and decided for a suppression 
subtractive hybridisation (SSH), a method that allows selective enrichment of differentially 
regulated cDNAs of high and low abundance. Resulting candidates should subsequently be 
characterised in their ability to specifically restimulate T cells from GAP and RAS immunised 
mice. 
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2. Materials and methods 
2.1 Laboratory equipment  
AMAXA& Nucleofector& II  
electroporation machine    Lonza, Köln 
Analytical scales BL510     Sartorius GmbH, Göttingen 
Autoclave       Systec GmbH, Wettenberg 
Camera, DC 120 Zoom digital    Kodak, New York 
Centrifuges: 
- Megafuge 1.0R      Heraeus Instruments, Hanau 
- Microcentrifuges 5415 R, 5415 D   Eppendorf, Hamburg 
Electrophoresis System Horizon 11.14  Whatman Inc., USA 
Electrophoresis Power Supply EPS 301   Amersham Pharmacia Biotech, Freiburg 
Film developer Hyperprocessor    Amersham Pharmacia Biotech, Freiburg 
Film developing cassettes     Dr Goos suprema GmbH, Heidelberg 
Freezer - 80 ºC      Sanyo 
Freezers - 20 ºC      Liebherr, Biberach 
Fridges       Liebherr, Biberach 
Heat block thermomixer comfort    Eppendorf, Hamburg 
Haemocytometer (Neubauer)    Labotec, Labor-Technik, Göttingen 
Ice machine AF 30      Scotsman, Milano, Italy 
Incubators: 
- Hera Cell Incubator     Heraeus Instruments, Hanau 
- Shaking Incubator Innova 4000/4300   New Brunswick Scientific Co. Inc. 
- Multi-gas incubator (O2, CO2)    Mytron, Heiligenstadt 
Liquid nitrogen tank      CBS, USA 
Magnetic stirrer, Heidolph MR3001   NeoLab, Heidelberg 
Microscopes 
- Light optical microscope, Axiostar plus   Zeiss, Jena 
- Light optical microscope, Axioskop   Zeiss, Jena 
- Light optical microscope, Axiovert 25   Zeiss, Jena 
Microwave oven      MDA 
Mosquito cages      BioQuip Products Inc, USA 
PCR-machines 
Materials and methods  19  
- GeneAmp PCR system 9700    Applied Biosystems, CA USA 
- Mastercycler Gradient     Eppendorf, Hamburg 
pH-meter       Inolab, Heidelberg 
Photometer       Eppendorf, Hamburg 
Pipettes  
- Single channel pipettes 2 #l, 20 #l,  
200 #l, 1000 #l      Abimed, Langenfeld 
- 12-channel pipette 200 #l    Abimed, Langenfeld 
Pipetting aid  pipetus&    Hirschmann Laborgeräte, Eberstadt 
Precision balance     Mettler Toledo, Switzerland  
SDS-PAGE system      Amersham Pharmacia Biotech, Freiburg 
Sterile work bench Gelaire X    Flow Laboratories, Meckenheim 
Vortex Genie 2      Scientific Industries Roth, Karlsruhe 
Water bath Julabo U3     Julabo, Seelbach 
Wet blot system      Amersham Pharmacia Biotech, Freiburg 
 
2.2 Consumables 
14 ml polystyrene round bottom tubes with lid Greiner Bio-one, Frickenhausen 
15 ml polypropylene tubes with lid   Sarstedt, Nümbrecht 
50 ml polypropylene tubes with lid   Sarstedt, Nümbrecht 
6-well cell culture plates, Cellstar    Greiner Bio-one, Frickenhausen 
8-well chamber slides    Nunc, Langenselbold 
96-well round bottom plates    Greiner Bio-one, Frickenhausen 
Cell culture flasks 
- Cellstar (Filter Cap, 75 cm
2
)    Greiner Bio-one, Frickenhausen 
- Nunc Flasks Nuclon (Filter Cap, 25 cm
2
)  Nunc, Langenselbold 
Cell strainer (70 #m)     BD Biosciences, Heidelberg 
Cuvettes       Sarstedt, Nümbrecht 
Cryovials       Greiner Bio-one, Frickenhausen 
Dialysis tube membrane Nadir&   Carl Roth GmbH, Karlsruhe 
ELISpot PVDF filter plates    Millipore GmbH, Schwalbach 
Filter paper Whatman TM 3MM    Whatman, GE Healthcare, Dassel 
Gloves, Peha-soft satin     Hartmann, Heidenheim 
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Immersion oil      Zeiss, Jena 
Microscope cover slips    Marienfeld, Lauda-Königshofen 
Needles, BD Microlance     Becton Dickinson; Heidelberg 
Nitrocellulose membrane, Hybond ECL   Amersham, GE Healthcare, Freiburg 
Glass slides       Marienfeld; Lauda-Königshofen 
Parafilm       Pechiney Plastic Packaging; USA 
Pasteur capillary pipettes     Wu; Mainz 
Petri dishes (94/16 mm)     Greiner Bio-one, Frickenhausen 
Pipette filter tips, Biosphere     Sarstedt, Nümbrecht 
Pipette tips       Sarstedt, Nümbrecht 
Reaction tubes (0.5 ml, 1.5 ml, 2.0 ml)   Sarstedt, Nümbrecht 
Sterile filtration devices (500 ml)    Nalagene, Wiesbaden 
Sterile pipettes (1 ml, 5 ml, 10 ml, 25 ml), Cellstar Greiner Bio-one, Frickenhausen 
Sterile syringe filter, Filtropur (0.22 µm pore size)  Sarstedt, Nümbrecht 
Syringe, BD Microlance     Becton Dickinson, Heidelberg 
Thermo well PCR tubes (0.2 ml)    Sarstedt, Nümbrecht 
 
2.3 Strains 
2.3.1 Bacteria strains 
Escherichia coli XL1 blue Stratagene; Agilent Technologies Sales & 
Services GmbH & Co. KG 
Escherichia coli BL21-CodonPlus (DE3)-RIPL Stratagene; Agilent Technologies Sales & 
Services GmbH & Co. KG 
2.3.2 Cell lines 
Huh7 human hepatoma cell line 
2.3.3 Parasite strains 
Plasmodium yoelii 17XNL (Topley et al. 1970) 
Plasmodium berghei ANKA GFPcon (Franke-Fayard et al. 2004) 
Plasmodium berghei ANKA cl15cy1 (Hall et al. 2005) 
Plasmodium berghei NK65 (Yoeli and Most 1965) 
Plasmodium berghei NK65 uis3(-) (Mueller et al. 2005a) 
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Plasmodium berghei NK65 CS-GFP (Natarajan et al. 2001) 
2.3.4 Mosquito strains 
Anopheles stephensii NIJ    Nijmegen, Niederlande 
2.3.5 Mouse strains 
Naval Medical Research Institute    Charles River Laboratory, Sulzfeld, 
(NMRI), outbred mice     Germany 
 
C57BL/6, inbred mice     Charles River Laboratory, Sulzfeld, 
Germany 
 
2.4 Chemicals and reagents 
Chemicals were typically purchased in p.a. quality from the companies Roth, Merck, Sigma, 
Serva and AppliChem. Chemicals and reagents from other companies are listed below. 
 
Agarose       Invitrogen, Karlsruhe 
AP Conjugate Substrate Kit    Biorad Laboratories, München 
BactoTM-Agar      Difco Laboratories, Augsburg 
BactoTM-Trypton      Difco Laboratories, Augsburg 
BactoTM -Pepton      Difco Laboratories, Augsburg 
Cellulose powder CF11 (fibrous)    Whatman, GE Healthcare, Dassel 
CFSE        Invitrogen, Karlsruhe 
Heparin       Braun, Melsungen 
Nycodenz powder     Axis-Shield PoC, Oslo 
PBS-pellets       Gibco Invitrogen, Karlsruhe 
Sea salt       Alnatura 
Streptavidin-ALP     Mabtech, Sweden    
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2.5 Peptides  
Pb C2 domain-containing protein (C2CP) derived peptides were synthesied by JPT Peptide 
Technologies GmbH, Berlin. Peptide stock solutions with a concentration of 20 mM were 
dissolved in DMSO and aliquots were stored at - 80 °C.  
 
2.6 Oligonucleotides 
Oligonucleotides were ordered as custom DNA oligonucleotides in a desalted purity from 
Invitrogen, Karlsruhe. Lyophilised oligonucleotides were dissolved in ddH2O in a 
concentration of 100 #M and stored at - 20 °C. Sequences of all used oligonucleotides are 
attached under 6.1.  
 
2.7 Media, buffer and solutions 
2.7.1 Media and buffer for molecular biological methods 
LB (Luria Broth) Medium: 10 % trypton 
5 % yeast extract 
10 % NaCl 
pH 7,5; autoklave 
 
LB Agar: LB-medium; 15 g/l agar 
      
TAE (50 x): 2 M TRIS 
1M acetic acid 
50mM EDTA; pH 8.0 
 
PBS (10 x): 0.01 M KH2PO4  
1.37 M NaCl  
0.027 M KCl  
pH 7.2; autoklave 
or dissolve 20 PBS tablets (Gibco) in 1 l ddH20; autoklave 
 
PBS (1 x):  100 ml 10 x PBS, filled up with ddH2O to 1 l 
   or purchased from Invitrogen 
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TfB I:   30 mM potassium acetate 
50 mM MnCl2 
100 mM KCl 
10 mM CaCl2 
15 % glycerine 
The pH was adjusted to 5.8 with acetic acid. The buffer was sterile filtered and stored at 4 °C.  
TfB II:  10 mM MOPS 
75 mM CaCl2 
10 mM KCl 
15 % glycerine 
The pH was adjusted to 7.0 with NaOH. The buffer was sterile filtered and stored at 4 °C. 
 
2.7.2 Media and solutions for cell culture 
Cell culture media and supplements were purchased from Invitrogen or Gibco, Karlsruhe. 
 
Hepatocyte culture medium:   1 x Dulbecco’s Modified Eagle Medium,  
(DMEM complete)  10 % FCS, 1 % penicillin/streptomycin; sterile, 
stored at 4 °C 
 
Lymphocyte culture medium:  1 x RPMI medium 1640, 10 % FCS, 1 %  
(RPMI complete)     penicillin/streptomycin, 1 % glutamine,  
50 #M ß-mercaptoethanol; sterile, stored at 4 °C 
 
BMDC culture medium:   1 x Iscove's Modified Dulbecco's Medium,  
(IMDM complete)     10 % FCS, 1 % penicillin/streptomycin,  
1 % glutamine, 50 #M ß-mercaptoethanol; sterile, 
store at 4 °C 
prior to use 30 % GM-CSF (hybridoma supernatant, provided by Beatrix Schumack, Bonn) 
was added to IMDM complete and sterile filtered 
 
Cell freezing solution:  80 % FCS, 20 % DMSO 
   or 90 % FCS, 10 % DMSO mixed 1 : 1 with complete culture medium 
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2.7.3 Media, buffer and solutions for parasitological methods 
Parasite Transfection medium: 160 ml RPMI 1640 medium 
(T-medium) 40 ml FCS (US certified, heat inactivated for 30 minutes 
at 56 °C) 
60 #l Gentamycin; sterile filtered 
 
Parasite freezing solution:   10 % glycerine in Alsever's solution (Sigma) 
Nycodenz stock solution:   110.4 g Nycodenz powder   
      5 mM TRIS/HCl; pH 7.5 
      3 mM KCl 
      0.3 mM EDTA; pH 8.0 
     fill up to 400 ml with ddH2O; autoklave; store at 4 °C 
 
Pyrimethamine stock solution: 7 mg/ml Pyrimethamine in DMSO, store at 4 °C  
2.7.4 Buffer for immunological methods 
MACS buffer:  1 x PBS, 1 % FCS, 2 mM EDTA, sterile filtered, 4 °C 
 
FACS buffer:  1 x PBS, 1 % FCS, sterile filtered, 4 °C 
 
Saponin buffer: 1x PBS, 2% BSA, 0.5% Saponin; prepare fresh 
2.7.5 Buffer and solutions for biochemical methods 
Lysis buffer:   50 mM NaH2PO4 
    300 mM NaCl 
    0.05 % Tween 20 
    1 mg/ml lysozyme; adjust pH to 8.0 with NaOH   
 
2 x SDS loading dye:  250 mM TRIS/HCl pH 6.8  
6.6 % SDS  
24 % glycerine  
10 mM EDTA  
6 % ß-mercaptoethanol 
0.01 % bromophenol blue 
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Running buffer:  250 mM glycine, 25 mM TRIS, 0,1 % SDS 
 
10 x transfer buffer: 20 mM TRIS, 144 mM glycine, 0.01 % SDS 
 
1 x transfer buffer: 100 ml 10 x transfer buffer, 200 ml methanol, fill up to 1 l with ddH2O  
 
TBST:   20 mM TRIS/HCl pH 7.6, 137 mM NaCl, 0.1 % Tween20 
 
Coomassie staining solution:  50 % methanol, 10 % acidic acid, 0.125 % brilliant blue 
R-250 
 
Coomassie destaining solution:  50 % methanol, 10 % acidic acid 
 
 2 x sodium phosphate buffer: 5.3 ml 200 mM NaH2PO4 stock solution  
100 mM, pH 8.0   94.7 ml 200 mM Na2HPO4 stock solution 
100 ml ddH2O 
stock solutions can be stored at 4 °C, sodium phosphate buffer is prepared fresh 
 
Equilibration and washing buffer: 1 x sodium phosphate buffer (50 mM)  
     300 mM NaCl 
 
Elution buffer:   1 x sodium phosphate buffer (50 mM) 
     300 mM NaCl 
     250 mM imidazol 
 
2.8 Molecular biological methods 
2.8.1 Cloning of the targeting constructs for parasite transfection 
The targeting constructs pcsp!epi_me01 - me04, pcsprepl!epi_me01 - me04 and p!csprae 
for P. yoelii transfection and p!fer, p!c2cp, pferCONT, pc2cpCONT for P. berghei 
transfection were all generated using the following protocols. Vector maps of all generated 
targeting constructs are attached under 6.2.  
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2.8.1.1 Amplification of the specific DNA fragments by Polymerase chain reaction (PCR) 
Specific DNA fragments were amplified by Polymerase chain reaction (PCR) (Saiki et al. 
1985) using specific oligonucleotides. All used oligonucleotides and their sequences are 
attached under X. As templates served P. yoelii or P. berghei gDNA. For a standard PCR 
reaction 0.5 - 2 #l parasite gDNA was used in a reaction volume of 50 #l. Furthermore the 
reaction contained 50 pmol of the specific oligonucleotides (Invitrogen), 0.2 mM dNTPs, 1.5 
mM MgCl2, 1 x Taq reaction buffer (+ KCl) and 2.5 U Taq polymerase (all Fermentas) filled 
up to 50 #l with ddH2O. Reaction tubes were placed into a thermal cycler running the 
program with an initial denaturation of the dsDNA for 5 minutes at 94 °C, followed by 30 
cycles with a denaturation at 94 °C for 30 seconds, annealing of the specific oligonucleotides 
at 55 °C for 30 seconds and extension of the newly synthesised DNA strand at 60 °C for 1 
minute per amplified kilobase plus 30 seconds. A final extension for 10 minutes at 60 °C was 
carried out and amplified DNA was stored at 4 ° C for short-term and at - 20 ° C for long-
term storage. 
2.8.1.2 Analysis of DNA fragments by agarose gel electrophoresis  
Amplified DNA fragments were separated by size by agarose gel electrophoresis. For this 1 
% agarose was dissolved in 1 x TAE buffer by heating in the microwave. Ethidium bromide 
(Sigma, Taufkirchen) was added to a final concentration of 50 ng/ml. Samples were mixed 
with 1/5 volume of 6 x Orange Loading dye (Fermentas) and loaded along with 1 #g 
GeneRuler! 1 kb DNA Ladder (Fermentas) into the wells. The gel was run for 1 hour at 100 
V in 1 x TAE buffer in a Whatman Horizon 11.14 electropheresis chamber. Negatively 
charged DNA thereby migrates in direction of the anode. Separated DNA fragments were 
visualised by exposure of the DNA-intercalating ethidium bromide to UV-light and 
fluorescence was recorded with the Electrophoresis Documentation and Analysis System 120 
(Kodak).   
2.8.1.3 Purification of DNA with Qiaquick PCR purification Kit 
Amplified DNA fragments were purified with Qiaquick PCR purification Kit (Qiagen, 
Hilden) prior to digestion with restriction endonucleases and digested DNA fragments as well 
as plasmid DNA also prior to ligation according to the manufacture's manual.  
2.8.1.4 Digestion of double-stranded DNA 
Purified DNA fragments or plasmid DNA were digested with specific restriction 
endonucleases (New England Biolabs, Frankfurt) prior to ligation (preparative digest) or after 
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plasmid isolation (control digest). For the preparative digest the amplified and purified DNA 
fragments and the respective plasmid DNA were cut with the same restriction endonucleases. 
The complete purified DNA fragment or 1 - 3 #g plasmid DNA were mixed with 10 - 20 
Units of the respective restriction enzymes, 5 #l of the matching buffer (10x) and 5 #l of BSA 
(10x), if necessary, and filled up to 50 #l with ddH2O. The digest was typically incubated 
over night at 37 °C. For the control digest of isolated plasmids the approach was typically 
scaled down to 20 #l reaction volume, using only 0.5 - 1 #g DNA. The reaction was then 
incubated for 2 hours at 37 °C. All digested DNA was analysed by agarose gel electrophoresis 
as described under 2 and preparative digested DNA was purified prior to ligation as described 
under 3. Prior to parasite transfections 10 #g of the generated plasmids were digested 
completely with up to 40 Units of the respective enzymes in a volume of 100 #l over night at 
37 °C. Subsequently digested plasmid DNA was ethanol precipitated as described under 
2.8.1.11. 
2.8.1.5 Ligation of DNA 
Digested and purified DNA fragments were ligated with equally restricted plasmids in a ratio 
of 7:1 or 6:2 in a total reaction volume of 10 #l. 5 Units of the T4 ligase were used to catalyse 
the reaction in 1 x of the provided T4 ligase reaction buffer (10 x, Fermentas). The ligation 
reaction was incubated for 2 hours at room temperature or at 4 °C over night. Subsequently 
competent E. coli XL1 blue were directly transformed with the ligated DNA constructs.  
2.8.1.6 Preparation of transformation competent E. coli XL1 blue 
E.coli XL1 blue were cultured over night in LB medium with tetracycline (5 #g/ml). The over 
night culture was diluted 1 : 100 in LB medium with tetracycline (5 #g/ml) and cultivated 
shaking at 37 °C until it reached an OD600 of 0.5. The culture was cooled down on ice and 
spun for 5 minutes at 1500 x g at 4 °C.  The cell pellet of 100 ml culture was resuspended in 
30 ml cold TfBI, incubated for 15 minutes on ice and spun again for 5 minutes at 1500 x g. 
The pellet was resuspended in 8 ml TfBII and incubated another 15 minutes on ice. 200 #l 
aliquots of the suspension were frozen at - 80 °C.  
2.8.1.7 Transformation of competent E. coli XL1 blue 
Transformation competent E. coli XL1 blue, either purchased from Stratagene or prepared as 
described under 6, were thaw on ice. 35 #l of the purchased cells or 200 #l of the self-made 
competent cells were used for one transformation. Competent cells were either treated for 10 
minutes on ice with 0.68 #l ß-mercaptoethanol (1.42 M; Stratagene) and subsequently mixed 
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with 2 #l of the ligation (Stratagene competent cells) or directly mixed with 10 #l ligation 
(self-made competent cells). The cells were incubated for 30 minutes on ice, followed by a 
heat-shock for 45 seconds at 42 °C in the water bath. Cells were incubated subsequently 
another 2 minutes on ice, then 1 ml pre-warmed LB medium was added and cells were 
incubated, shaking at 37 °C for 1 hour. The cells were spread on LB agar plates with 
ampicillin (100 #g/ml) and incubated over night at 37 °C.  
2.8.1.8 Plasmid isolation with Qiaprep Spin Miniprep Kit 
After transformation single colonies were used to inoculate 3 ml LB medium with ampicillin 
(100 #g/ml) each. These cultures were incubated shaking at 37 °C over night. The over night 
cultures were spun for 2 minutes at 16,000 x g in a table-top microcentrifuge. The plasmid 
isolation from the cell pellet was performed as described in the manufacturer's manual.  
Isolated plasmids were control digested as described under 4 and resulting DNA fragments 
were analysed by agarose gel electrophoresis (2.8.1.2) to confirm successful integration of the 
DNA fragments.  
2.8.1.9 Preparation of bacteria-glycerine stocks 
For conservation of transformed E. coli containing the generated plasmids over night cultures 
were prepared as described under 8. 850 #l of the over night culture were mixed with 150 #l 
glycerine (99.5 %, Roth) in a cryovial and stored at - 80 °C.  
2.8.1.10 Determination of DNA concentration by photometric measurement 
In order to determine the DNA concentration of a plasmid preparation the DNA was typically 
diluted 1 : 100 in ddH2O. The absorption of the DNA at 260 nm was measured in a 
photometer (Eppendorf) and DNA concentration was calculated according the following 
relation:  
! 
"OD260 #  50 #  dilution factor =  concentration dsDNA µg/ml[ ]  
The purity of the DNA preparation was shown by the ratio of OD260/OD280 and typically 
ranged from 1.8 to 2.0. 
2.8.1.11 Ethanol precipitation of DNA 
Digested DNA was ethanol precipitated prior to parasite transfection. For this purpose 2.5 
volumes 100 % ethanol and 1/10 volume 3 M sodium acetate, pH 5.2, were added to the DNA 
solution and incubated at least 30 minutes at - 80 °C. After spinning for 15 minutes at 16,000 
x g the DNA pellet was washed once with ice cold 70 % ethanol and again spun for 5 minutes 
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at 16,000 x g. The ethanol was carefully removed and the DNA pellet was air dried. Finally 
the DNA was  resuspended in  1 x PBS to a final DNA concentration of 1 #g/#l. Digested and 
precipitated DNA was once more analysed by agarose gel electrophoresis and stored at - 20 
°C until parasite transfection.  
2.8.1.12 Site-directed mutagenesis of the P. yoelii circumsporozoite CD8
+
 T cell epitope 
Specific point mutations were inserted by site-directed mutagenesis into the sequences of the 
targeting constructs pCSP!epi_me01 - me04 and pCSPrepl!epi_me01 - me04. For this 
specific complementary oligonucleotides spanning the sequence coding for the Py CSP CD8
+
 
T cell epitope were designed to insert the four different mutations me01 - me04 into the DNA 
sequence. The resulting mutant sequences are shown under 3.1.1, oligonucleotide sequences 
are attached under X. Py CSP fragments were amplified by PCR as described under 1 and 
temporarily cloned into the pGEM&-T Easy T/A cloning vector (Promega) as described 
under 2.8.3.4 for mutagenesis. 20 - 50 ng of these intermediate constructs were mixed with 10 
- 50 pmol of the specific oligonucleotides, 0.2 mM dNTPs, 10 #l HF buffer (5 x, containing 
7.5 mM MgCl2; Finnzymes) and 1 Unit Phusion polymerase (Finnzymes) and filled up to 50 
#l with ddH2O. The amplification was performed in a thermal cycler starting with an initial 
denaturation at 95 °C for 30 seconds, followed by 19 cycles with a denaturation at 95 °C for 
30 seconds, annealing of the specific oligonucleotides at 55 °C for 1 minute and a DNA 
double-strand extension at 68 °C for 4:30 minutes. Thus the complete plasmid is amplified 
and mutations are inserted. The DNA was purified with Qiaquick PCR purification Kit (3). 
Methylated plasmid DNA that served as template was subsequently digested with DpnI. To 
the purified DNA 20 Units DpnI (New England Biolabs) and 5 #l supplied NEBuffer 4 (10 x) 
were added, filled up with ddH2O to 50 #l and incubated for 2 hours at 37 °C. The digest was 
either purified with Qiaquick PCR purification Kit again or the enzyme was heat-inactivated 
for 5 minutes at 80 °C. E. coli XL1 blue were transformed with this DpnI-digest as described 
under 7. Mutated Py CSP fragments were either amplified by standard PCR conditions 
(2.8.1.1) or cut from the pGEMT-easy constructs and gel extracted with Qiaquick gel 
extraction Kit (Qiagen) and subsequently cloned into the b3D targeting vector as described 
(2.8.1.2 - 11).  
2.8.2 Stage specific RNA isolation and cDNA synthesis for RT and qRT PCR 
Different parasite stages were isolated from infected mosquitos (2.10.2.4), in-vitro hepatocyte 
cultures (2.9.2) or infected blood (2.10.1.4.3). 
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2.8.2.1 Isolation of total RNA with RNeasy Mini Kit (Qiagen) 
Parasite cells were disrupted by addition of in 350 #l RLT buffer (supplied, Qiagen) 
supplemented with 1 % ß-mercaptoethanol (14.3 M) and homogenised by vortexing for 1 
minute. Total RNA was isolated from the cell lysate according to the "Animal Cell Spin" 
protocol supplied in the manufacturer's manual. Isolated RNA was stored at - 80 °C.  
2.8.2.2 Trizol extraction of total RNA 
Parasites were resuspended in 1 ml Trizol Reagent (Invitrogen), 200 #l chloroform was added 
and carefully mixed by inverting. After 3 minutes incubation at room temperature it was 
mixed again and subsequently spun for 15 minutes at 12,000 x g at 4 °C. The top aqueous 
layer, containing the RNA, was carefully transferred to a fresh RNAse-free tube (Eppendorf). 
After addition of 500 #l isopropanol (2-propanol) the solution was incubated for 10 minutes 
at room temperature and spun for 10 minutes at 12,000 x g at 4 °C. The supernatant was 
discarded and the RNA pellet was washed with 75 % ethanol and thoroughly mixed by 
vortexing. After a final centrifugation for 5 minutes at 7,500 x g at 4 °C the RNA pellet was 
air dried, resuspended in 10 #l DEPC-treated H2O and incubated for 10 minutes at 60 °C. 
Isolated RNA was stored at - 80 °C.  
2.8.2.3 DNase treatment of total RNA 
After RNA isolation remaining DNA contaminations were removed by digestion with DNase. 
The RNA was mixed with 1/10 volume of 10 x TURBO DNase buffer (Ambion) and 1 #l  
TURBO DNase (Ambion) and incubated for 30 - 45 minutes at 37 °C. 1/10 volume of the 
resuspended DNase Inactivation Reagent (Ambion) was added, mixed thoroughly and 
incubated for 2 minutes at room temperature. The reaction was centrifuged for 1 minute at 
10,000 x g and the supernatant containing the RNA was transferred to a fresh RNase-free tube 
(Eppendorf). DNase treated RNA was stored at - 80 °C. 
2.8.2.4 First strand cDNA synthesis 
RNA was transcripted into complementary DNA (cDNA) with the Fermentas "First Strand 
cDNA Synthesis Kit" according to the manufacturer's manual using random hexamer 
oligonucleotides. The initial optional denaturation step of the total RNA for 5 minutes at 65 
°C was performed. For each transcripted RNA one approach without reverse transcriptase (-
RT) was run to exclude DNA contaminations. The transcripted product was directly used for 
reverse transcriptase PCR (2.8.2.5) or quantitative Real-time PCR (2.8.2.6) or stored at - 20 
°C.  
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2.8.2.5 Reverse transcriptase PCR (RT PCR) 
A standard PCR approach was prepared as described under 2.8.1.1. In a reaction volume of 20 
#l 0.5 - 2 #l first strand cDNA (2.8.2.4) of the different parasite stages were used as template 
together with P. bergehi Ferlin and Ferlin-like protein specific oligonucleotides. For each 
sample one tube with cDNA synthesised with reverse transcriptase (+ RT) (2.8.2.4) and one - 
RT control tube were prepared. Oligonucleotides specific for the P. berghei aldolase, 
expressed constantly throughout the life cycle, were used as control. All specific 
oligonucleotides used for RT PCR are attached under X. The amplification was performed in 
a thermal cycler using the standard PCR program as described under 2.8.1.1.  
2.8.2.6 Quantitative Real-time PCR (qRT PCR) 
Quantitive real-time RT-PCRs were performed with total RNA isolated from 20 h P. berghei 
liver-stages from either wildtype (WT), radiation-attenuated (RAS) or genetically-attenuated 
(GAP) as described under 2.9.2. RNA was treated with DNAse I (Ambion) to remove 
contaminating genomic DNA. 10 - 20 ng RNA for each parasite population (WT, RAS, GAP) 
was used as a template in a first-strand cDNA synthesis using the TaqMan Gold reverse 
transcriptase kit (Invitrogen). Gene-specific oligonucleotides (designed using Primer Express 
software v2.0, Invitrogen) are attached under 6.1.8. PCR fragments were cloned into the T/A-
cloning TOPO vector (Invitrogen). Each plasmid was used 10-fold dilution to determine the 
standard curve. The standard curve hence plots the threshold value (Ct), defined as the cycle 
number at which the reporter dye fluorescent intensity increases over the background and 
over plasmid copy number. Absolute transcript copy number for each gene is calculated based 
on the external standard curve. The Real-time RT-PCR was carried out in triplicates in a 
GeneAmp® PCR System 9700 thermal cycler (Applied Biosystems) using the double-
stranded DNA binding probe SYBR Green (Applied Biosystems). Reactions were run to one 
cycle of 10 min at 95°C and 45 cycles of 15 sec at 95°C, 1 min at 60°C.  
2.8.3 Generation of subtraction libraries for Suppression Subtractive Hybridisation 
(SSH) 
Suppression Subtractive Hybridisation (SSH) is a rather fast and inexpensive method to 
identify differentially expressed transcripts in two cDNA populations. This in-vitro method 
was used to look for upregulated transcripts in early liver-stages of radiation-attenuated 
(RAS) and genetically-attenuated parasites (GAP) in comparison to wildtype (WT) liver-
stages.  
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2.8.3.1 RNA sample preparation 
For the SSH screening total RNA was isolated from RAS, GAP and WT liver-stages after 20 
hours development in cultivated hepatocytes (2.9.2). For this purpose salivary gland 
sporozoites from uis3(-) and WT P. yoelii 17XNL strain were isolated on day 14-17 post 
mosquito infection (2.10.2.3). Uis3(-) sporozoites are, like WT sporozoites, motile, invasive 
and transform into liver-stages inside hepatocytes but then uis3(-) liver-stages arrest after 
around 24 hours and do not develop to mature liver schizonts. These genetically-attenuated 
parasites (GAP) confer to a stage specific protection against subsequent WT sporozoite 
challenges. Liver-stage arrestment is also achieved by "-irradiation of WT sporozoites with a 
dose of 150 Gray, resulting in so called radiation-attenuated sporozoites (RAS). 25,000 - 
35,000 of these RAS, GAP and WT sporozoites were incubated for 90 minutes with 25,000 
cultivated Huh7 hepatocytes on 8-well chamber slides (nunc). After invasion of the 
sporozoites, hepatocytes were cultivated in DMEM complete/anti-contamination cocktail for 
20 hours. Liver-stages were harvested as described (2.9.2) and total RNA was isolated using 
the Qiagen RNeasy Mini Kit (2.8.2.1).  
2.8.3.2 cDNA synthesis with SMART! method 
The SMART! technology (Clontech) is a very sensitive method to synthesise high-quality 
cDNA from small amounts of total RNA. For the first strand cDNA synthesis 0.4 - 0.6 #g 
total liver-stage RNA (2.8.3.1) were used. The transcription to cDNA was performed 
according to the manufacturer's manual using the "SMART cDNA synthesis protocol for 
Clontech PCR-Select! cDNA subtraction" (sections VII. - IX.).  
2.8.3.3 PCR-Select! cDNA subtraction 
The cDNA subtraction was performed using the "PCR-Select™ cDNA subtraction Kit" 
(Clontech). The RsaI digested and purified cDNA produced with the "SMART™ PCR cDNA 
Synthesis Kit" (Clontech) was directly used for adaptor ligation (Clontech manual section 
IV.F.). All following steps were performed according to the manufacturer's manual.  
2.8.3.4 T/A cloning 
Resulting sequences from the cDNA subtraction were directly cloned into the T/A cloning 
vector pGEM&-T Easy (Promega). The thymidine(T)-overhangs of the vector can be directly 
ligated with the adenosine(A)-overhangs of the cDNA sequences. DNA sequences were 
purified prior to ligation with Qiaquick PCR purification Kit (Qiagen). 50 ng of the pGEM&-
T Easy vector were ligated with 3 #l of the cDNA sequence mix using 3 Units of the supplied 
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T4 ligase and 2 x Rapid Ligation Buffer (Promega). The reaction was incubated for 1 hour at 
room temperature and subsequently E. coli XL1 blue were transformed with the ligation 
mixture as described before. The growth on LB agar plates containing ampicillin (100 #g/ml), 
20 #g/ml X-Gal (bromo-chloro-indolyl-galactopyranoside) and 0.1 mM IPTG (isopropyl-$-D-
thiogalactopyranosid) allowed selection for blue (no insert) and white (insert integrated) 
colonies. White colonies were picked for sequencing and either plasmids were isolated using 
the Qiaprep Spin Miniprep Kit or colonies were directly transferred to 96 well plates and sent 
to GATC, Konstanz. 
2.8.3.5 Sequencing 
Sequencing was done at a DNA sequencing facility
 
(Institute for Virology, University of 
Wuerzburg) by 25 cycle sequencing
 
with the SP6 reverse and T7 forward
 
oligonucleotides or 
by GATC, Konstanz, using the same oligonucleotides.  
2.8.3.6 Bioinformatical analysis 
Sequences were analysed by BLAST search in the PlasmoDB database (http://plasmodb.org) 
using the blastn algorithm. Transcripts were entered as target data type to search all available 
target organisms. The expection value was set at 10, maximum alignments (B) and maximum 
descriptions (V) were set at 50. The low complexity filter was used. Resulting coding 
sequences were searched using the BLAST server on the Wellcome Trust Sanger Institute 
homepage (www.sanger.ac.uk) to obtain full sequence information in its genomic context.   
Predicted protein domains were identified with the Simple Modular Architecture Research 
Tool (SMART) (smart.embl-heidelberg.de). 
Epitope prediction was done with help of the SYFPEITHI homepage (www.syfpeithi.de) and 
personal communication with T cell experts.  
 
2.9 Cell culture 
2.9.1 Cultivation of human hepatoma cells Huh7 
Frozen cell stocks of the human hepatoma cell line Huh7 were kept in 80 % FCS, 20% 
DMSO in liquid nitrogen. Thawed cells were immediately transferred into pre-warmed 
DMEM culture medium containing 10 % FCS and 1 % Penicillin/Streptomycin (DMEM 
complete) and centrifuged for 5 minutes at 200 x g. The cell pellet was resuspended in fresh 
DMEM complete and transferred into a cell culture flask (25 cm
2
 or 75 cm
2
). Cells were 
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incubated at 37 °C, 5 % CO2 until a confluent monolayer was reached. For further cultivation 
medium was removed, attached cells were washed once with HBSS and detached with 0.25 % 
Trypsin/EDTA (Gibco) for 3 - 5 minutes at 37 °C. After addition of 10 ml DMEM complete 
cells were transferred to a 15 ml tube and centrifuged for 5 minutes at 200 x g. The cell pellet 
was washed once with HBSS and finally resuspended in 10 ml DMEM complete. Depending 
on the approach an aliquot of 200 #l up to 2 ml of the cell suspension were transferred to a 
new culture flask and filled up to 15 ml with DMEM complete.  
2.9.2 In vitro liver-stage development 
Huh7 cells cultivated to a confluent monolayer were detached with 0.25 % Trypsin/EDTA 
and washed as described (2.9.1). The cell pellet was resuspended in DMEM complete and 
counted diluted in Trypan blue (0.4 %) using a haemocytometer. Either 25,000 cells per well 
on a 8 well chamber slide (nunc) or 200,000 cells per well on a 6 well plate (greiner) were 
seeded and cultivated over night. Mature salivary gland sporozoites were purified (2.10.2.3) 
and 25,000 - 35,000 sporozoites or 100,000 - 200,000 sporozoites were added on the 
cultivated cells on the 8 well chamber slide or 6 well plate, respectively. Sporozoites were 
allowed to invade for at least 90 minutes, afterwards the sporozoite suspension was removed 
and cells were incubated in DMEM complete plus anti-contamination cocktail. Liver-stage 
development was stopped after different time points by harvesting the cells with 0.25 % 
Trypsin/EDTA as described before (2.9.1). Cells were transferred into a 1.5 ml tube and spun 
for 2 minutes at 4500 x g. The cell pellet was resuspended in 0.05 % digitonin in PBS and 
incubated for 5 minutes at room temperature. This digitonin treatment selectively 
permeabilised the host hepatocyte and thereby reduces RNA and DNA contaminations from 
the host cell in the final parasite preparation. The liver-stage parasites were centrifuged for 2 
minutes at 16,000 x g and depending on the application resuspended in RLT buffer, Trizol or 
PBS.  
2.9.3 Isolation and cultivation of bone marrow dendritic cells (BMDCs) 
Dendritic cells were isolated from the bone marrow of naïve C57BL/6 mice. The femur was 
removed from sacrified mice and muscles were carefully removed from the bone. The ethanol 
washed femur was opened sterile with a scalpel at both ends and the bone marrow was 
flushed using a 27 G needle and a 1 ml syringe with PBS into a petri dish. Bone marrow cells 
were washed with IMDM culture medium by centrifugation for 5 minutes at 400 x g and 
dendritic cells were cultivated in IMDM medium supplemented with 30 % GM-CSF in petri 
dishes (greiner). BMDCs were split once on day 4 - 5, for this non-adherent cells in the 
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supernatant were collected in 50 ml tubes. Adherent cells were detached with 2 mM EDTA in 
PBS and added to the supernatant. Cells were spun for 5 minutes at 400 x g and resuspended 
in fresh IMDM/30 % GM-CSF. The BMDCs were used for cultivation with lymphocytes on 
day 7 after isolation. 
 
2.10 Parasitological methods 
2.10.1 Plasmodium methods 
2.10.1.1 Determination of parasitemia in giemsa stained blood smears 
A small drop of blood was obtained from the tail of the infected mouse and a thin blood film 
was prepared on a glass slide. The blood smear was air dried and fixed for 10 seconds with 
methanol. The fixed blood smear was stained with giemsa, diluted 1 : 10 in deionised water, 
for 15 minutes. The stained blood smear was washed with water and parasites were examined 
under the light microscope using the 100 x objective with oil immersion.  
In order to determine the parasitemia the number of all erythrocytes and the infected 
erythrocytes were counted in one field. Subsequently the asexual parasites were counted in 
typically 24 further fields. The parasitemia was calculated using the following formula:  
 
! 
 number of parasites in all fields
number of erythrocytes in 1 field x number of counted fields
 x 100 =  parasitemia %[ ]  
2.10.1.2 Examination of exflagellating gametocytes 
The raptures of male gametocytes from the erythrocytes is called exflagellation, this can be 
observed under the microscope. A high number of exflagellating parasites is important for 
successful transmission to the mosquito and was hence examined routinely before parasite 
transmission (2.10.2.2). For this a drop of tail blood was placed on a glass slide and carefully 
covered with a cover slip. The slide was incubated for 10 minutes at room temperature. 
Erupting parasites were examined under the light microscope using the 40 x objective lenses 
with phase contrast (Ph2). For good transmission at least 3 to 5 exflagellation centres should 
be observed per field.  
2.10.1.3 Cryopreservation of Plasmodium parasites 
Plasmodium parasites were conserved during blood stage development, because infected 
blood can be stored for long periods in liquid nitrogen. For this purpose 100 #l freshly 
withdrawn blood was mixed with 200 #l parasite freezing solution (10 % glycerine in 
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Alsever's solution) in a cryo vial and immediately frozen in liquid nitrogen. Thawed parasite 
stocks can be reinjected into mice to continue the parasite growth.  
2.10.1.4 Parasite transfection 
The rodent Plasmodium parasites, P. berghei and P. yoelii, are transfected with linearised 
DNA (2.8.1.4) using the AMAXA transfection system (Lonza). By a crossing-over event 
between homolog regions the targeting constructs insert into the targeted genomic loci. 
2.10.1.4.1 Overnight culture and merozoite purification 
For one transfection typically 2 - 3 NMRI mice with a high level parasitemia (3 - 5 %  for P. 
berghei ANKA or up to 10 % for P. yoelii NL) were used. Mice were sacrificed and blood 
was collected by heart puncture (2.11.3). The blood was combined in a 50 ml tube with 10 ml 
T-medium containing 250 #l Heparin (200 p.i. in PBS)  and centrifuged for 8 minutes at 400 
x g without brake. The medium was removed and the blood pellet was resuspended in 20 ml 
fresh T-medium. The blood suspension was carefully dropped by gravity into a conical flask 
containing already 100 ml pre-warmed T-medium. The 50 ml tube was washed with 30 ml 
fresh T-medium and this was also dropped carefully into the flask without swirling the blood. 
The parasites were cultivated at 37 °C, 10 % O2, 5 % CO2 and 85 % N2, shaking at 70 rpm. 
To enrich schizonts in the blood culture the incubation took 16 to 18 hours for P. berghei and 
12 to 14 hours for P. yoelii. Mature schizonts were purified by a Nycodenz density gradient 
centrifugation. The Nycodenz stock solution was diluted to 55 % or 60 % working solutions 
in PBS for P. berghei or P. yoelii purification, respectively. The over night parasite culture 
was transferred into four 50 ml tubes (approximately 35 ml per tube) and each tube was 
under-laid with 10 ml Nycodenz solution pre-warmed to room temperature. Tubes were 
exactly balanced and centrifuged for 25 minutes at 200 x g at room temperature without 
brake. The mature schizonts appeared as a brown ring at the interface and were carefully 
collected to two new 50 ml tubes. Tubes were filled up to approximately 40 ml with T-
medium (from top of the gradient) and centrifuged for 8 minutes at 400 x g. The schizont 
pellet was resuspended in fresh T-medium, the volume depended on the size of the pellet and 
the number of constructs the parasites should be transfected with. For one transfection 1 ml 
resuspended schizonts were transferred in a 1.5 ml microcentrifuge tube and spun for 15 
seconds.  
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2.10.1.4.2 AMAXA transfection and selection for transformants 
For each transfection, 100 µL of AMAXA human T cell nucleofector solution (Lonza) was 
added to 5 - 10 µg of digested and precipitated plasmid DNA (2.8.1.11). The DNA solution 
was then added to the schizont pellet (1.3.1), mixed well, transferred to the AMAXA cuvette 
and pulsed once using the U-033 pre-programmed setting on the AMAXA maschine. After 
pulsing 50 #l fresh T-medium was directly added into the cuvette and transfected parasites 
were immediately injected i.v. in naïve NMRI mice. Typically 2 mice per construct were 
used. 24 hours post-infection a giemsa stained blood smear was prepared to record the starting 
parasitemia and pyrimethamine treatment of the mice was started. For this the pyrimethamine 
stock solution was diluted 1 : 100 in tap water (final concentration 70 #g/ml) and provided as 
drinking water. Parasitemia typically decreased to undetectable levels on day 2 post infection 
and first resistant parasites appeared in giemsa stained blood smears from day 7. When 
parasitemia reached at least 0.5 % mice were sacrificed and blood was withdrawn by heart 
puncture. Blood was transferred to new mice, cryopreserved and parasite gDNA was isolated 
(parental population). The transfer animals were further treated with pyrimethamine and mice 
were sacrificed as soon as parasitemia reached sufficient levels. The infected blood was again 
cryopreserved and purified for parasite DNA isolation (transfer population).  
2.10.1.4.3 Isolation of blood stage parasites for genomic DNA purification 
To isolate parasites from infected blood a column was made using a 5 ml syringe. The syringe 
was closed with cotton wool at the bottom. Thereon a 2 - 3 cm thick layer of cellulose powder 
CF11 (Whatman) was put and the column was completed with around 1 cm glass beads 
(diameter 212 - 300 #m, unwashed; Sigma). The column was equilibrated with 2 column 
volumes 1 x PBS and subsequently the infected blood was transferred on the column. The 
erythrocytes were washed off the column with 1 x PBS. Starting from the first red drop 15 ml 
erythrocyte suspension were collected in a respective tube. The suspension was centrifuged 
for 8 minutes at 400 x g, without brake, and the supernatant was carefully removed. The 
erythrocyte pellet was resuspended in 10 - 15 ml 0.2 % saponin in PBS to lyse the red blood 
cells. The suspension was again centrifuged for 8 minutes at 1500 x g and the supernatant was 
discarded. The parasite pellet was resuspended in 1 ml PBS and transferred to a 1.5 ml 
microcentrifuge tube. The isolated parasites were once more centrifuged for 2 minutes at 4500 
x g and finally resuspended in 200 #l PBS. The parasite genomic DNA (gDNA) was 
subsequently isolated using the QIAamp Blood Mini Kit with the "Blood or Body Fluid Spin 
Protocol". For this 20 #l Qiagen protease and 200 #l buffer AL were added to 200 #l parasites 
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in PBS and thoroughly mixed by vortexing. All following steps were performed according to 
the manufacturer's instructions. The parasite gDNA was finally eluted in 100 - 150 #l elution 
buffer AE (10 mM TRIS/HCl; 0.5 mM EDTA; pH 9.0) and stored at - 20 °C.  
2.10.1.4.4 Genotyping PCR of transfected parasites 
The isolated gDNA of parental and transfer transfectants was tested for integration of the 
targeting constructs by PCR. Templates for this genotyping PCR were typically 1 - 2 #l 
parasite gDNA of the transfectants or wildtype (WT) parasites as control. As additional 
control the targeting constructs were diluted 1 : 100 in ddH2O and also used as template for  
the PCR. Usually three different oligonucleotide pairs were used for genotyping PCR. The 
integration test oligonucleotides (test) typically bind inside the selectable marker inserted and 
the parasite's genome. Resulting fragments therefore verify successful integration of the 
targeting construct inside the targeted genomic locus. Control oligonucleotide pairs are 
usually WT or open-reading frame (ORF) specifc oligonucleotides and vector specific 
oligonucleotides (epi). The PCR approach was prepared as described under 2.8.1.1 using the 
standard PCR program (2.8.1.1). Resulting DNA fragments were analysed by agarose  gel 
electrophoresis (2.8.1.2).  
2.10.1.5 Parasite cloning 
Successfully transfected parasite populations were selected for clonal parasites by limited 
dilution. For this a frozen blood stock of the parental or transfer population was injected i.p. 
into a naïve NMRI mouse. Once the parasitemia ideally reached 0.3 - 0.5 % the mouse was 
sacrificed and blood was withdrawn by heart puncture. Parasitemia was determined very 
exactly by counting at least 80 fields (2.10.1.1). Assuming on average 7 x 10
6
 erythrocytes 
per #l mouse blood the number of parasites was determined using the following formula: 
! 
7 "106  "  parasitemia %[ ] "  10-2  =  parasites/µl 
A dilution series was prepared in RPMI medium to inject theoretically one parasite per 
mouse. For this 100 #l blood was diluted 1 : 10 in RPMI, this dilution was again diluted 1 : 10 
in RPMI and so on. Typically the 1 : 10
6
 dilution contained less then one parasite per #l. The 
calculated amount of this dilution that theoretically held one parasite was mixed with fresh 
RPMI medium and 10 to 15 naïve NMRI mice were injected i.v. each with 100 #l medium 
containing one parasite. Mice usually became blood stage positive from day 7 post infection 
and as soon as sufficient levels of blood stage parasites were reached mice were sacrificed 
and blood was collected. Not all injected mice developed a blood stage parasitemia, typically 
mice were declared negative if there were no parasites visible in a giemsa-stained blood smear 
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up to 21 days post infection. Clonal parasites were isolated from infected blood as described 
(2.10.1.4.3) and gDNA was tested for integration of the respective targeting construct by PCR 
(2.8.1.1).  
2.10.2 Anopheles mosquito methods 
2.10.2.1 Mosquito breeding 
Anopheles stephensi mosquitoes were bred at 28 °C, 75% humidity under a 12-h light/12-h 
dark cycle. Larvae were raised in 1 ‰ sea salt ddH2O, pupae were collected and allowed to 
hatch in mosquito cages (BioQuip Products Inc; USA). Adult mosquitoes were fed on a 10%
 
sucrose/PABA solution provided on cotton wool pads. In order to maintain the mosquito life 
cycle, female Anopheles mosquitoes were blood fed on naïve anaesthetized NMRI mice. Four 
days after the blood meal  dishes with 1 ‰ sea salt ddH2O soaked filter paper were put into 
the cages and female mosquitoes laid their eggs. Eggs were washed with 70 % ethanol and 
twice with 1 ‰ sea salt ddH2O and again put in trays filled with 1 ‰ sea salt ddH2O. Hatched 
larvae were fed on cat food (Brekkies) and split depending on the density.  
2.10.2.2 Parasite transmission 
For transmission of P. berghei or P. yoelii parasites 4-5 day old female mosquitoes
 
were 
blood fed on anaesthetized NMRI mice that had been infected i.p. with parasite blood stocks. 
Mice
 
were assayed for high levels of parasitemia (2.10.1.1) and the percentage of 
exflagellating male gametocytes was observed under the microscope (2.10.1.2). After
 
the 
infective blood meal, mosquitoes were maintained at 21 °C, 80 % humidity (P. berghei) or 
24 °C,
 
80% humidity (P. yoelii). On day 10 post feeding, mosquitoes were dissected
 
in RPMI 
1640 medium/ 3 % BSA (X), and isolated midguts were examined for the 
 
infection rate. 
From day 17 post infection mature P. berghei and already from day 14 post infection P. yoelii 
sporozoites could be isolated from the salivary glands (2.10.2.4). In order to maintain a 
continuous Plasmodium cycle naïve rodents could be exposed to bites of infected mosquitoes 
from day 17 or day 14 post feeding, respectively. 
2.10.2.3 Mosquito dissection 
Midguts of infected mosquitoes were dissected 10 days after the blood meal in order to 
observe oocyst formation, 12 -14 days post feeding midgut sporozoites were isolated from 
midgut oocysts. And 17 - 21 days post feeding for P. bergehi or 14- 16 days post feeding for 
P. yoelii, salivary glands were isolated and infectious sporozoites were extracted (2.10.2.4). 
For all dissections infected mosquitoes were anaesthetised on ice. The dissection was 
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performed in RPMI 1640 medium with 3 % BSA under a stereo microscope in the insectary at 
15 °C using two needles (27 G and 23 G). Midguts and salivary glands were kept in RPMI 
1640 medium with 3 % BSA on ice until sporozoite extraction. 
2.10.2.4 Sporozoite extraction from midguts and salivary glands 
Mosquito midguts or salivary glands were disrupted mechanically in RPMI 1640 medium 
with 3 % BSA using a pestle and spun for 3 minutes at 90 x g, 4 °C. The supernatant 
containing the sporozoites was transferred to a fresh tube and the pellet was again squeezed 
with a pestle in fresh RPMI/3 % BSA. A second centrifugation was performed for 3 minutes 
at 100 x g, 4 °C and the supernatant was combined with the first collected. Extracted 
sporozoites were subsequently count under the microscope in a haemocytometer using the 40 
x objective lenses with phase contrast (Ph2). For counting the sporozoite solution was 
typically diluted 1/10 in RPMI/3 % BSA. The number of sporozoites was calculated with the 
following formula: 
! 
number of spz in 4 large squares/4 "  dilution factor "  104 = number of spz/ml 
The quantity of a mosquito infection was typically expressed as number of sporozoites per 
mosquito.  
 
2.11 Animal experimental methods 
Mice were purchased from Charles River Laboratories, Germany with a age of 18 - 20 days 
and animal care was done in a central facility of the University of Heidelberg (Interfakultäre 
Biomedizinische Forschungseinrichtung; IBF). All animal experiments were conducted 
according to the European regulations and approved by the state authorities 
(Regierungspräsidum Karlsruhe). 
2.11.1 Administration of anaesthesia 
Mice were anaesthetised with Ketamine/Xylazine (K/X) administered into the abdominal 
cavity (intraperitoneal; i.p.).  
2.11.2 Infection of rodents with Plasmodium parasites 
In order to transmit Plasmodium parasites to the rodent host the mice were either 
anaesthetised and exposed to bites of infected mosquitoes (2.10.2.2) or isolated salivary gland 
sporozoites were injected in various numbers (1,000 - 50,000 spz) into the tail veins (i.v.). 
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Furthermore blood stages injected either i.v. or i.p. established a Plasmodium infection, 
isolated schizonts, fresh isolated infected blood or frozen blood stocks were used. 
2.11.3 Blood withdrawal by heart puncture 
Mice were terminally anaesthetised with diethyl ether and the heart was uncovered preferably 
fast. Blood was withdrawn using a heparinised needle (23 G) and a 2 ml or 5 ml syringe from 
the right ventricle. Infected blood was immediately put on ice and processed as fast as 
possible. Typically 1 - 1.5 ml blood could be obtained from one mouse. 
2.11.4 Liver perfusion 
Livers were perfused with 0.05 % collagenase (Typ I-A; Sigma) in PBS prior to isolation of 
liver associated lymphocytes. Mice were either terminally anaesthetised with diethyl ether or 
sacrificed with CO2 and the abdominal cavity was opened. The liver was perfused through the 
liver portal vein using a 25 G needle. The collagenase solution was pumped through the organ 
using a peristaltic pump (approximate speed 1 ml/min). Livers were perfused until the colour 
changed from dark red to grey beige, removed and stored on ice in PBS.  
 
2.12 Immunological methods 
2.12.1 Immunisation and parasite challenge experiments  
P. berghei NK65 WT and uis3(-) sporozoites were isolated from salivary glands of infected 
mosquitoes (2.10.2.4). Pb NK65 WT sporozoites were "-irradiated with a dose of 150 Gray 
resulting in radiation-attenuated sporozoites (RAS). Groups of 10 C57BL/6 mice were 
immunised with a single dose of 25,000 or 50,000 Pb RAS or Pb uis3(-) sporozoites followed 
by two booster dose of 20,000 or 10,000 Pb RAS or Pb uis3(-) sporozoites administered by 
i.v. injection into the tail vein. The first boost was given 7-14 days after the priming dose and 
a second boost 7-14 days thereafter. All animals remained blood stage negative after the 
immunisation as monitored by giemsa stained blood smears on days 4-7 after the sporozoite 
injections. Five mice per group were exposed to a challenge with 10,000 Pb NK65 WT 
parasites, injected i.v. into the tail vein on days 7-8 after the last boost. As a control three 
naïve mice were injected to verify infectivity of the sporozoite challenge. Parasitemia was 
monitored by giemsa stained blood smears. Naïve mice reached a parasitemia between 0.3 
and 0.5 % on day 6 after challenge whereas all immunised mice remained blood stage 
negative. Seven days after the last boost or the WT challenge, respectively, mice were 
sacrificed and spleens, livers and blood serum were removed.  
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Besides the immunisation with RAS and GAP also an immunisation with PbC2CP-derived 
peptide T9L was performed. For this the peptide was packed in cell-specific nanocarriers 
called TargoSpheres& by the Rodos BioTarget GmbH (RBT). These nanocarriers provide a 
new adjuvant system to deliver drugs or vaccines directly to antigen-presenting cells (APCs). 
The packing was performed by the company. As control nanocarriers containing a 
FITC:Dextran solution were also provided by the RBT company. The final FITC:Dextran 
concentration in the targosphere solution was 172.8 #g/ml, whereas the final peptide 
concentration in the RBT06.01 targosphere solution was 21.277 #g/ml. Groups of three 
C57BL/6 mice were immunised with the targospheres (TS) using a similar prime-two-boost 
protocol as described before. Four groups received 1 #g or 5 #g RBT06.01 TS or 
FITC:Dextran TS, respectively, a fifth group remained untreated. The solutions were injected 
subcutaneously on day 0, day 7 and day 14. Each of the 15 animals was exposed to bites of 5 
P. berghei NK65 infected mosquitoes 7 days after the last boost. The parasitemia was 
followed by daily blood smears from day 3 post infection. On day 8 post infection mice were 
sacrificed and organs were prepared and cultivated for cytokine ELISpot.  
2.12.2 Cell isolation and purification from spleens, livers and lymph nodes 
Seven days after the last immunisation boost or the WT challenge animals were sacrificed and 
livers were perfused with PBS including 0.05 % collagenase (2.11.4). Spleens, perfused livers 
and where required lymph nodes were removed and cells were isolated. Total spleen cells 
were obtained by passing the organs through a 70 #m nylon cell strainer (BD Biosciences) or 
a fine metal strainer in MACS buffer (1x PBS, 1 % FCS, 2mM EDTA) and subsequently 
washed with culture medium (RPMI, 10 % FCS, Pen/Strep, glutamine, ß-mercaptoethanol). 
Lymph nodes were passed through a 70 #m nylon cell strainer in RPMI culture medium. 
Cells were counted in 0.4 % trypan blue in a haemocytometer. For counting total splenocytes 
4% acetic acid was added to the trypan blue solution. Perfused livers were passed through a 
metall strainer (250 #m) and washed with culture medium. Liver lymphocytes were separated 
using a Percoll density gradient (stock 1.124 g/ml). The 100 % working solution was prepared 
by mixing 9 parts Percoll with 1 part 10 x PBS. The working solution was then diluted with 1 
x PBS to 40 % and 80 %. The liver cell suspension in 4 ml 40 % Percoll was under laid with 3 
ml 80 % Percoll and spun for 20 minutes, 700 x g at room temperature. The middle white 
layer containing the lymphocytes was carefully removed, washed with culture medium and 
cells were counted in a haemocytometer. Age-matched naïve and naïve/challenged mice 
served as controls and were treated equally. 
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2.12.3 In vivo cytotoxicity assay  
Total spleen cell were isolated from naïve donors as described before and finally resuspended 
in 20 ml PBS. To 10 ml of this cell suspension 2 #M peptides were added and incubated for 
20 minutes at 37 °C. The remaining cells were incubated without peptides. Subsequently cells 
were labelled with the fluorescent dye CFSE (5-(and-6)-carboxyfluorescein diacetate, 
succinimidyl ester, Invitrogen) in PBS. For this 10 ml 2 #M CFSE solution (CFSE
high
) or 10 
ml 0.2 #M CFSE (CFSE
low 
) were added to the cells loaded with peptides or incubated 
without, respectively, for further 20 minutes at 37 °C. This results in final CFSE 
concentrations of 1 #M and 0.1 #M. Cells were centrifuged for 7 minutes at 400 x g and 
washed twice with ice cold PBS. Cells were counted in Trypan blue (0.4 %) using a 
heamocytometer. The two cell populations were mixed in equal numbers (1 : 1) and 1 x 10
7 
cells of this mixed population were injected i.v. into tail veins of immunised or naïve control 
animals 18 hours prior cell isolation from the organs. Cell purification from spleens and livers 
was performed as described earlier. CFSE labelled cells were detected by Flow Cytometry. 
The specific lysis was calculated as ratio of CFSE
high
 cells and CFSE
low 
cells and compared to 
the ratio detected in naïve animals with the following formula: 
! 
100 -  
ratio sample
mean ratio naive controls
" 
# 
$ 
% 
& 
' (  100 = specific lysis %[ ]  
2.12.4 Restimulation of lymphocytes from immunised animals in vitro  
1 x 10
6
 total spleen cells, 1 x 10
5 
liver lymphocytes or 1 x 10
5
 lymph node lymphocytes from 
immunised animals or naïve controls were cultivated with 1 x 10
5
 BMDCs per well in 96-well 
plates. Lymphocytes of immunised and naïve animals were restimulated by adding the 
specific peptides to a final concentration of 1 #M per well. As a control lymphocytes were 
either unspecifically restimulated with #CD3 (5 #g/ml) or Concanavalin A (1 #g/ml) or 
cultivated in lymphocyte culture medium without stimulus. 
2.12.5 Flow cytometry 
Lymphocytes of immunised or naïve control animals were cultivated and restimulated over 
night as described. Cell culture supernatant was removed and fresh peptide (1 #M final 
concentration) and Brefeldin A (10 #g/ml) were added to each well. After 5 hours incubation 
the cell surface was stained in a 96-well plate for 15 minutes in the dark on ice using the anti 
CD8a-PacBlue conjugated antibody (1:100, BD biosciences), anti CD44-FITC (1:100, BD 
biosciences), anti CD62L-PE (1:200, BD biosciences) and anti CD25-Alexa647 (1:50, BD 
biosciences) or for subsequent intracellular staining the antiCD8-PE antibody (1:300, BD 
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biosciences) diluted in FACS buffer. Cells were washed once with 400 #l FACS buffer per 
well and centrifuged for 5 minutes at 400 x g. For intracellular staining cells were fixed with 
4% PFA in PBS for 7 minutes on ice and after washing once permeabilised with saponin 
buffer for 20 minutes at room temperature. Fixed cells were centrifuged for 5 minutes at 550 
x g and washed again with FACS buffer. The intracellular staining for IFN-" (IFN"-APC 
antibody, 1:100, BD biosciences) was performed in saponin buffer for 20 minutes in the dark 
at room temperature. Cells were washed once with saponin buffer and subsequently twice 
with MACS buffer. Flow cytometry was performed in MACS buffer and analysis using 
FACSCanto and FACSCalibur. 
2.12.6 Cytokine ELISpot  
MultiScreen Filter plates (Millipore) were coated with purified IFN-" antibody (5 or 10 #g/ml 
in PBS) over night at 4 °C. Plates were washed at least 4 times with PBS and subsequently 
blocked with medium containing 10 % FCS for 1 hour at 37 °C. Cultured lymphocytes were 
restimulated over night as described. Cell culture supernatant was diluted 1:1 with fresh 
medium and cells were transferred onto the Filter plates. After 24 hours incubation at 37 °C, 5 
% CO2, plates were washed at least 4 times with PBS to remove the cells. After incubation 
with the secondary biotinylated IFN-" antibody (5 or 10 #g/ml in PBS) for 1 hour at 37 °C  
Streptavidin-ALP (1:1000 in PBS, Mabtech) was added and plates were incubated for another 
hour at room temperature in the dark. Plates were washed at least 4 times with PBS/0.05 % 
Tween 20 and subsequently twice with PBS. The detection of the Elispot signal was 
performed using the AP Conjugate Substrate Kit (Biorad). The 25 x buffer was diluted to 1 x 
in filtered ddH2O and reagents A and B were added as stated by the manufacturer. Spots on 
the plate were developed shaking for 10 to 30 minutes at room temperature after addition of 
50 #l developing solution per well. The reaction was stopped by washing the plates for 10 
minutes under running deionised water. Plates were dried over night at room temperature and 
spot were counted by eye using a stereo microscope.  
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2.13 Biochemical methods 
2.13.1 Recombinant overexpression of the P. berghei ferlin-like protein as His-tag 
fusionprotein 
The recombinant overexpression of the Pb C2 domain.containing protein (C2CP) as a His-tag 
fusionprotein was performed using the pET15-b expression vector (Novagen) in E. coli 
BL21-CodonPlus (DE3)-RIPL cells (Stratagene). For easier expression the large Pb C2CP 
was divided in three parts. These parts were defined by hydrophobic sections for better 
soluble expression and sequence positions suitable for oligonucleotides for successful 
cloning. Cloning of the expression vector was performed as described for the targeting 
constructs under 2.8.1 using the restriction sites NotI and XhoI on the vector. The inserted 
fragment was subsequently expressed under control of the T7 promotor with an N-terminal 6x 
Histidin-tag (His-tag). E. coli BL21-CodonPlus (DE3)-RIPL competent cells (Stratagene) 
were transformed with the expression constructs according to the manufacturer's manual. A 
single colony was picked for inoculating an over night culture in 3 - 5 ml LB medium 
supplemented with ampicillin (100 #g/ml) and chloramphenicol (50 #g/ml). The next day the 
culture was diluted to an OD600 of 0.1 to 0.2 in 25 - 100 ml LB medium with ampicillin (100 
#g/ml) only and cultivated shaking at 37 °C until it reached an OD600 of 0.5. The expression 
was induced by the addition of 1 mM IPTG (Sigma) and the protein was expressed for 4 
hours at 37 °C, 250 rpm. The culture was subsequently centrifuged for 10 minutes at 3000 x g 
and the cell pellet was resuspended in 10 ml lysis buffer. The bacteria suspension was 
incubated for 30 minutes on ice and cells were cracked by sonication for 2 x 30 seconds on 
ice using the Sonifier& B-12 (Branson Sonic Power Company) at an amplitude of 50 %. The 
cell debris was centrifuged for 10 minutes at 3000 x g, 4 °C and the soluble proteins in the 
supernatant was transferred to a new tube. The cell debris pellet was resuspended in 8 M urea. 
Pellet and supernatant were loaded on a SDS-PAGE as described in the following section.  
2.13.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated according to their size by SDS polyacrylamide gel electrophoresis. 
For one gel with a size of 10 cm x 10 cm x 0.5 mm the following components were mixed in 
the indicated order:  
 
Separating gel (12 %): 3 ml Acrylamide/Bis Solution, 29:1 
    1.875 ml 1.5 M Tris/HCl, pH 8.8 
    75 #l 10 % SDS 
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    2.5 ml ddH2O 
    75 #l 10 % APS 
    7.5 #l TEMED 
 
Loading gel (3.6 %):  350 #l Acrylamide/Bis Solution, 29:1 
    350 #l 1 M Tris/HCl, pH 6.8 
    30 #l 10 % SDS 
    1.75 ml ddH2O 
    20 #l 10 % APS 
    20 #l TEMED 
 
The addition of ammonium persulphate (APS) and TEMED starts the polymerisation. The 
anionic detergent SDS denatures the protein and applies a negative charge therefore by SDS-
PAGE proteins run towards the anode. First the separating gel was poured between the two 
glass plates fixed in the gel caster (Amersham). The gel was overlaid with a thin layer of 
isopropanol and allowed to polymerise. The isopropanol was removed, the loading gel was 
poured on top of the separating gel and a comp was placed in order to create the wells. As 
soon as the loading gel is polymerised as well the comb can be removed and the gel is ready 
for electrophoresis. Protein samples (supernatant and pellet in 8 M urea) were mixed 1 : 1 
with 2 x SDS loading dye and heated to 95 °C for 5 minutes prior to loading on the gel. 
Alongside 15 - 30 #l of the samples 10 #l PageRuler! Prestained Protein Ladder (Fermentas) 
was loaded on the gel. The gel was fixed in the electrophoresis chamber (Amersham) and 
surrounded with running buffer. Electrophoresis was performed for 1 hour at 80 V, 25 mA 
and subsequently for further 1 - 2 hours at 100 V. The gel was then either stained with 
Coomassie brilliant blue to visualise the proteins or proteins were transferred to a 
nitrocellulose membrane and detected with specific antibodies. 
2.13.3 Coomassie staining of SDS polyacrylamide gels 
Proteins separated by SDS PAGE were stained with Coomassie brilliant blue R-250. The gel 
was incubated for 30 minutes in Coomassie staining solution and not bound stain was washed 
off by incubation of the gel in a destaining solution. The destaining solution was exchanged 
regularly until protein bands were nicely visible on the gel.  
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2.13.4 Western Blot analysis  
For specific detection of the His-tagged fusionprotein separated proteins were transferred 
from the SDS gel to a nitrocellulose membrane. For this 4 x Whatman paper and 1 x 
nitrocellulose membrane were cut in gel size and wet together with 4 blotting sponges in 1 x 
transfer buffer. The Western blot sandwich was built starting with 2 blotting sponges on the 
cathode side of the blotting cassette (Amersham), followed by 2 x Whatman paper, the SDS 
gel, the nitrocellulose membrane, 2 x Whatman paper and finally 2 more blotting sponges. 
The cassette was closed with the anode plate and protein transfer occurred for 1 - 1.5 hours at 
125 mA, approximately 20 V in 1 x transfer buffer. The membrane was subsequently blocked 
over night at 4 °C with 5 % milk in TBST and washed three times for 10 minutes with 1 x 
TBST at room temperature. The incubation with the primary mouse anti-His antibody (1 : 
3000 in TBST; Novagen) was carried out for 1 hour at room temperature or again over night 
at 4 °C under continuous shaking. The membrane was again washed three times for 10 
minutes with TBST and the secondary HRP conjugated goat anti-mouse antibody (1 : 10,000 
in TBST; Sigma) was added for 1 hour at room temperature, shaking. Washing was repeated 
as before. The chemiluminescent detection of the labelled His-tagged protein was performed 
with the "ECL Western Blotting Detection Reagents" (GE Healthcare). For this the substrate 
solutions 1 and 2 were mixed 1 : 1 and incubated on the membrane for 1 minute. The 
membrane was subsequently transferred in a film cassette, a film (Kodak) was incubated in 
the dark for 10 seconds up to 10 minutes on the membrane and the light signal on the film 
was developed (Hyperprocessor Amersham Pharmacia Biotech, Freiburg).  
2.13.5 Purification of His-tag fusionproteins by nickel-ion affinity chromatography 
Soluble expressed His-tag fusionprotein was purified using the HIS-Select& Nickel Affinity 
Gel (Sigma). A column was built using a 10 ml syringe and 2 ml resuspended nickel affinity 
gel (in 30 % ethanol). As the gel is a 50 % suspension this results in a column of a final 
volume of 1 ml. The syringe was closed at the bottom with glass wool and the gel matrix was 
allowed to settle. The 30 % ethanol was discarded and the column was equilibrated with 10 
volumes equilibration buffer (5 x 2 ml). Before loading the bacteria lysate (2.13.1) containing 
the His-tag fusionprotein on the column it was filtered through a 0.22 #m filter and a small 
aliquot was kept for following gel electrophoresis. The lysate was passed on the column and 
the flow-through was collected. The His-tag fusionprotein should now be bound to the 
column. The column was washed with 2 x 2 ml washing buffer (= equilibration buffer) and 
the bound protein was eluted with 5 x 1 ml elution buffer. The eluate was collected in 6 
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fractions at 1 ml. Aliquots of all steps were loaded on a SDS gel (2.13.2). The eluate fractions 
containing the purified His-tag fusionprotein were pooled and dialysed against 1 x PBS to get 
rid of the imidazol. For this the protein solution was pipetted into a semi permeable dialysis 
tube membrane with a exclusion size of 10 kDa and the tube was closed. The dialysis was 
performed for at least 6 hours in 2 l 1 x PBS stirring at 4 °C, the PBS was exchanged once. 
Dialysed protein solution in 1 x PBS was stored at 4 °C.  
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3. Results 
3.1 P. yoelii circumsporozoite (CSP) epitope mutant - an elegant tool to study the role of 
CSP in pre-erythrocytic immunity 
The circumsporozoite protein (CSP) is covering almost the entire surface of the Plasmodium 
sporozoites and has historically been considered as the major pre-erythrocytic vaccine 
candidate. Recently, more and more studies revealed, however, that protection could also be 
achieved in the absence of immune responses specific to CSP (Kumar et al. 2006) (Gruner et 
al. 2007). To study pre-erythrocytic immune responses independent of CSP special tools have 
to be designed as csp depletion by targeted gene disruption results in no sporozoite formation 
and consequently no liver-stages (Menard et al. 1997). 
The goal of this work was therefore to generate a P. yoelii mutant parasite line that expresses 
a functional CSP that is no longer recognised by the host's immune system. This should be 
achieved by the insertion of specific point mutations into the described CD8
+
 T-cell epitope 
SYVPSAEQI without affecting protein function.  
3.1.1 Insertion of mutations by a complementation strategy results in repaired epitope 
sequence and an exflagellation defect phenotype 
We aimed for inserting different mutations (all based on alanisation of certain amino acids) as 
we were not able to predict which amino acid is important for folding and therefore for a 
functional CS protein. The amino acid sequences of the different mutant T-cell epitopes me01 
to me04 are shown in table 1. Mutations were inserted into the gene sequence of csp by site-
directed mutagenesis using mutation-specific oligonucleotides (for oligonucleotide sequences 
see appendix 6.1). 
The two amino acids valine (V) and glutamine (Q) are required for anchoring the CD8
+
 T-cell 
epitope on the MHC I molecule. Therefore these two amino acids were exchanged by two 
alanine (A) to generate the mutant me01. For the mutant me02 every second amino acid 
within the epitope was exchanged by an alanine. The amino acids serine (S), valine (V) and 
isoleucine (I) that were chosen for alanisation for the mutant me03 are all neutral amino acids 
with rather short side chains. These properties led to the assumption that these amino acids are 
most probably not important for protein folding and therefore protein functionality. In 
addition the amino acids tyrosine (Y), proline (P), glutamic acid (E) and glutamine (Q) were 
exchanged by alanine, that may be more likely involved in folding and functionality, to 
generate the mutant me04. In 
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of the immune system of certain amino acids correlate is not known. For all mutations the 
respective amino acid codons were exchanged by site-directed mutagenesis on DNA level as 
described (2.8.1.12). Mutations were verified by sequence analysis of the DNA fragments. 
Mutated csp sequences were subsequently cloned into targeting constructs containing the 
TgDHFR/TS selectable marker.  
 
PyCSP CD8
+
 T-cell epitope SYVPSAEQI 
mutant aa sequence 
mutant me01 SYAPSAEAI 
mutant me02 AYAPAAAQA 
mutant me03 AYAPAAEQA 
mutant me04 SAVASAAAI 
 
Table 1. Amino acid sequences of the different mutations inserted in the P. yoelii circumsporozoite protein 
(CSP) by site-directed mutagenesis. The mutations of the Py CSP CD8
+ 
T-cell epitope were inserted on DNA 
level by site-directed mutagenesis. Complementary oligonucleotides spanning the epitope region and containing 
the mutated DNA sequence were used in a standard PCR reaction. Mutated fragments were then inserted in 
targeting constructs by standard cloning procedures.  
 
The initial complementation strategy to insert the mutated Py csp (Py csp*) into the parasite 
genome is shown in figure 5.  
 
 
Figure 5. Knock-in/complementation strategy inserts a mutated CD8
+
 T-cell epitope in the P. yoelii 
circumsporozoite protein (CSP) genomic sequence. The Knock-in constructs pcsp!epi_me01 - me04 contain 
a truncated csp gene that lacks the last 120 base pairs and a mutated sequence coding for the CD8
+
 T-cell epitope 
(Py csp*). An additional XbaI restriction enzyme recognition site is inserted downstream of the CD8
+
 T-cell 
epitope sequence for specific linearisation prior to transfection. The TgDHFR/TS confers resistance to 
pyrimethamine and serves as a selectable marker.  After homologue recombination with the P. yoelii genomic 
locus the integration construct is completely integrated into the parasite´s genome. This results in a truncated csp 
gene (Py csp'3') containing the WT epitope sequence (white star) and a complete csp open-reading-frame with a 
mutated T-cell epitope sequence (black star). 
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For the targeting constructs pcsp!epi_me01 - me04 a C-terminal truncated version of the Py 
csp gene containing the mutation inside the CD8
+
 T-cell epitope was cloned into the vector 
b3D (for vector map see appendix 6.2) using the restriction sites EcoRI and NotI. In order to 
insert a unique XbaI restriction site for subsequent linearisation, Py csp* was amplified in two 
fragments with a length of 882 bp and 96 bp.  
 
Transfection of P. yoelii parasites with the XbaI-linearised targeting construct was performed 
according to the AMAXA transfection protocol as described (2.10.1.4.2) and transfected 
merozoites were directly injected intravenously (i.v.) into NMRI mice. One day after the 
transfection Pyrimethamine (70 #g/ml) was provided with the drinking water to select for 
transfected parasites. First resistant parasites were detected in giemsa-stained blood smears 6 
days post transfection. Mice were sacrificed on day 8 with a parasitemia of 1.6 %.  Infected 
blood was conserved as cryo stock and transferred intraperitonealy (i.p.) to naïve mice and 
further grown under continuous drug pressure. Parasites were isolated from the remaining 
blood and genomic DNA (gDNA) was extracted (parental population). The transferred 
parasite population was also cryo-preserved as blood stock and gDNA was prepared as soon 
as parasitemia reached more than 0.5 %. The integration of the targeting construct into the 
parasite genome was verified by genotyping PCR using test specific oligonucleotide pairs (see 
figure 6).  
 
 
Figure 6. Genotyping PCR of P. yoelii circumsporozoite protein (CSP) epitope mutant me01 after 
transfection with the complementation construct. Standard PCRs were run with ORF, test and episomal (epi) 
specific oligonucleotide pairs (see figure 5). As templates served gDNA of the mutant me01 and P. yoelii wild-
type gDNA (WT) or the complementation construct (v) as PCR controls. Specific DNA fragments were 
seperated by agarose gel electrophoresis.  
 
As expected the ORF specific DNA fragment was amplified with a length of 1104 bp with 
WT and me01 gDNA as templates, but not from the complementation construct. The 
episomal control (int_epi) fragment is amplified from the complementation construct and 
mutant me01 gDNA, the length of 1531 bp was verified on a agarose gel. The integration-
specific DNA fragment (int_test) can only be amplified from mutant gDNA if the 
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complementation construct inserted into the parasite's genome, a respective band with a size 
of 1767 bp was detected on an agarose gel proving successful integration. The 1767 bp long 
int_test specific DNA fragment was purified and cloned into the T/A cloning vector pGEM-T 
Easy (Promega) for sequencing. Sequence analysis revealed the desired mutation me01 inside 
the Py csp open reading frame (ORF), including start and stop codon, and was therefore 
expected to be expressed.  
The mutated parental parasite line Py CSP me01 was subsequently cloned by limited dilution 
in order to achieve a clonal mutant parasite line as described (2.10.1.5). The parasitemia of 
the parental mutant Py CSP me01 reached 0.67 % 3 days post injection of a respective blood 
stock. This mouse was sacrificed and the blood was taken by heart puncture. The infected 
blood was diluted 1 to 1x10
6
 in RPMI medium, 21.3 #l of this dilution was added to 78.7 #l 
RPMI and injected i.v. per mouse. In total 15 NMRI mice were injected with calculated one 
parasite. The parasites were grown under Pyrimethamine selection that was again provided 
within the drinking water. First resistant parasites were detected 7 days post infection in the 
blood of two mice (clones I-2 and III-3). Two more mice displayed blood-stage parasites in a 
giemsa-stained blood smear on day 9 post infection (clones I-5 and II-3). The remaining 11 
mice remained blood-stage negative until day 16 post infection as determined by giemsa-
stained blood smears. gDNA of the different clones served as template for a subsequent 
genotyping PCR with the integration test-specific oligonucleotides. Integration of the 
complementation construct could be detected for the three clones I-2, III-3 and I-5, but not for 
clone II-3 by genotyping PCR using the same specific oligonucleotides as in figure 6. 
Integration specific DNA fragments were cloned via T/A cloning into the pGEM-T Easy 
vector (Promega) and sequenced by conventional techniques. We used the two vector specific 
oligonucleotides T7 and SP6 and the PyCSP_complII_NotI_rev oligonucleotide for 
sequencing in order to cover the whole sequence including the start and stop codon of the csp 
ORF and the epitope sequence. Integration of the vector could be observed in all cases by the 
presence of the selection marker and the inserted restriction sites EcoRI, NotI and XbaI within 
the Py csp ORF. The mutated CD8
+
 T-cell epitope sequence, however, was reverted to the 
WT sequence for all clones.  
The combined sequence of the amplified integration specific DNA fragment of Py CSP me01 
clone I-2 is attached under 6.3. 
As the cloning of the Py CSP mutant me01 failed it was planned in a next step to transmit the 
parental mutant population to Anopheles mosquitoes in order to confirm its viability through 
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the mosquito life cycle and hence normal phenotype comparable to an unaltered CSP i.e. WT 
parasite.  
Typically, male gametes emerge from the erythrocyte after transmission triggered by a drop 
of temperature, change in pH and substances in the mosquito's midgut, such as xanthurenic 
acid (XA). A high percentage of exflagellating gametocytes is important for reasonable 
mosquito infections, therefore this is routinely checked under the microscope before 
transmission of the parasite to the mosquito. Parasites of the Py CSP CD8
+
 T-cell epitope 
mutant line showed a defect in exflagellation as observed under the microscope. This defect 
cannot be explained with targeting of the csp gene itself, but maybe closely located genes 
were also impaired when targeting this genomic locus with the applied genetic strategy. 
3.1.2 A short gene (PY07369) annotated upstream of P. yoelii csp might also be affected 
when gene-targeting csp 
As the exflagellation defect we observed when integrating a targeting construct into the P. 
yoelii csp genomic locus could not be explained with described functions of CSP (Menard et 
al. 1997) we had a closer look at the surrounding genomic loci of Py csp. Sequence 
information and gene annotations were obtained from the PlasmoDB database 
(http://plasmodb.org). There we found a small gene annotated upstream of the P. yoelii csp 
(PlasmoDB annotation PY07368) coding for a hypothetical protein with unknown function 
with the annotation number PY07369. Because of its genetic localisation upstream of csp we 
preliminarily called this gene csprae. The stop codon of csprae was only 140 bp upstream of 
the csp start codon (figure 7). Hence the 5' and 3' regulatory regions of both genes most likely 
overlap. The coding sequence of csprae lies within the promotor region of csp and the coding 
sequence of csp in turn overlaps with the terminator region of csprae.  
 
 
Figure 7. Genomic locus of the P. yoelii csp gene and its neighbouring genomic sequence information. The 
outline shows the PlasmoDB (http://plasmodb.org) genomic sequence AABL01002684 with the coding 
sequences for P. yoelii CSP and a small hypothetical protein, we for now called CSPrae (PY07369). The bold 
numbers indicate the annotated positions of the respective genes on the genomic sequence. The csprae stop 
codon lies at position 993, whereas the csp start codon is at position 853. The two coding sequences of the 
respective genes lie only 140 bp from each other. Large introns of Py csprae are marked as striped boxes. 
 
In order to deplete the csprae gene the targeting construct p!csprae was generated containing 
a 351 bp large DNA fragment of the csprae 5' UTR and a second 324 bp homologue fragment 
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from the N-terminal coding sequence. These two fragments were cloned into the b3D cloning 
vector flanking the TgDHFR/TS selectable marker. As the csp promotor region should not be 
affected and the CSprae protein should not be expressed anymore at the same time only the 
first 28 bp of the csprae genomic sequence should be depleted during integration of this 
construct. As csprae contains two large introns (grey-striped boxes in figures 7 and 8) the 
depletion could be inserted more than 1 kb upstream of the csp start codon. Integration of the 
targeting construct  by homologue recombination resulted in a N-terminally truncated csprae 
as shown in figure 8.  
 
 
Figure 8. Genetic strategy to functionally knock-out the P. yoelii csprae gene. The targeting construct 
p!csprae contains two fragments from the P. yoelii csprae (PY07369) 5' UTR and the N-terminal genomic 
sequence, respectively. Two large introns in the genomic sequence of csprae are shown as striped boxes. 
Integration of the constructs by a double crossing over event results in depletion of the first 28 bp of the csprae 
gene. The TgDFRH/TS selectable marker confers to pyrimethamine resistance.  
 
P. yoelii parasites were transfected twice with the XbaI/KpnI digested p!csprae targeting 
contruct according to the AMAXA transfection protocol (2.10.1.4.2). The parasitemia on day 
one after transfection was above 0.3 % in all four NMRI mice injected in two transfection 
experiments. Under Pyrimethamine selection resistant transfectants were first detected in 
giemsa-stained blood smears on average on day 8.5. It was surprising that in both transfection 
experiments only one out of two injected mice became blood-stage positive under drug 
selection. As soon as the parasitemia reached at least 0.5 % mice were sacrificed and infected 
blood was collected from the heart. Blood was transferred to naïve NMRI mice and cryo-
preserved, parasites were isolated for gDNA extraction from the remaining blood. Transferred 
animals were again sacrificed when reaching a sufficient parasitemia under continuous drug 
cover. Genotyping of the transfectants was performed by standard PCR using integration-
specific oligonucleotides (sequences attached under 6.1).  
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Figure 9. Genotyping PCR of the !csprae transfectant. Standard PCRs were run with WT, test and episomal 
(epi) specific oligonucleotide pairs (see figure 8). As templates served gDNA of the !csprae transfectant and P. 
yoelii wild-type gDNA (WT) or the targeting construct p!csprae (v) as PCR controls. Specific DNA fragments 
were seperated by agarose gel electrophoresis. 
 
The WT specific DNA fragment with a size of 706 bp was amplified from P. yoelii WT 
gDNA and also from the transfectant gDNA using the cloning oligonucleotides 
PyCSprae_5'UTR_XbaI_for and PyCSprae_Nterm_KpnI_rev. For episomal PCR control the 
904 bp large DNA fragment was amplified from the targeting construct and the transfectant 
gDNA with the oligonucleotides PyCSprae_5'UTR_XbaI_for and PyCSprae_test_rev binding 
inside the selectable marker. The combination with the 5'test_for oligonucleotide, however, 
resulted in no DNA fragment with an expected size of 1013 bp as seen on the agarose gel in 
figure 8. This shows that the targeting construct was taken up during transfection, but did not 
integrate into the genomic locus. The same genotyping pattern was seen for both transfectants 
and their transfer populations.  
3.1.3 Replacement of the P. yoelii wild-type csp sequence by a mutated sequence should 
prevent repair mechanisms  
Targeting the P. yoelii csp genomic locus by the mutated complementation construct 
pcsp!epi resulted in repair mechanisms after cloning and an unexpected exflagellation 
phenotype of the parental mutant parasite population, therefore we changed the genetic 
strategy to insert the specific mutations in the endogenous CD8
+
 T-cell epitope. We focused 
on a replacement strategy where the endogenous csp ORF is exchanged by a mutated ORF 
(figure 9).  
 
The replacement constructs pcsprepl!epi_me01 - me04 contain the Py csp ORF starting with 
the ATG start codon and ending with the TAA stop codon. A respective DNA fragement with 
a length of 1104 bp was cloned via the XbaI and BamHI restriction sites into the cloning 
vector b3D (for vector map see appendix 6.2). Before, the mutations inside the CD8
+
 T-cell 
epitope were again inserted by site-directed mutagenesis using the same oligonucleotides as 
described earlier. A second DNA fragment amplified from the 3' untranslated region (UTR) 
of the Py csp gene with a length of 732 bp was cloned into the same vector via the restriction 
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sites KpnI and HindIII. Hence the two homologue regions to the P. yoelii genome flanked the 
selectable marker TgDHFR/TS providing basis for the requested double crossing over event. 
Only targeting constructs with the two mutations me01 and me03 were successfully 
generated.  
 
 
Figure 10. Replacement strategy inserts a mutated CD8
+
 T-cell epitope in the P. yoelii circumsporozoite 
protein (CSP) genomic sequence. The replacement constructs pcsprepl!epi_me01 - me04 contain the complete 
Py csp gene, with the sequence coding for the CD8
+
 T-cell epitope mutated by site-directed mutagenesis (Py 
csp*), and the 3´UTR of the csp open reading frame (thick black line). These homologous regions to the 
parasite´s genome are seperated by a TgDHFR/TS gene serving as selectionmarker. A double crossing-over 
event replaces the WT Py csp gene (grey) by the one with the mutated epitope sequence (white) and inserts the 
selectionmarker at the same time.  
 
Transfection of P. yoelii parasites with the XbaI/KpnI-digested targeting constructs was 
performed as described before. Infected mice carrying the transfected parasites were 
sacrificed 7 days post transfection with parasitemias of 1.6 % and 1.1 % for the mutant me01 
and 0.3 % and 0.9 % for the mutant me03. Genomic DNA isolated from transfected parasites 
was used as template for an integration specific PCR (figure 11).  
 
 
Figure 11. Genotyping PCR of P. yoelii circumsporozoite protein (CSP) epitope mutants me01 and me03 
after transfection with the replacement constructs. Standard PCRs were run with ORF, test and episomal 
(epi) specific oligonucleotide pairs (see figure 9). As templates served gDNA of the mutants me01 and me03 and 
P. yoelii wild-type gDNA (WT) or the replacement construct (v) as PCR controls. Specific DNA fragments were 
seperated by agarose gel electrophoresis.  
 
The genotyping PCR of transfectants generated with the replacement strategy (figure 10) 
amplified the Py csp ORF with a size of 1104 bp from all shown DNA templates using the 
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ORF specific oligonucleotides. The episomal specific fragments with a size of 1657 bp were 
detected on a agarose gel when using the replacement targeting constructs or gDNA of the 
two mutant transfectants me01 and me03 together with the repl_epi specific oligonucleotides 
for PCR amplification. The repl_test specific oligonucleotides prove integration of the 
replacement targeting constructs for both mutants, me01 and me03. The corresponding 
fragments with a size of 1310 bp were detected on an agarose gel. The mutations were again 
controlled by sequence analysis of the respective integration specific DNA fragments. 
Sequence analysis showed that both mutations, me01 and me03, were successfully inserted 
into the sequence coding for the Py CSP CD8
+
 T-cell epitope and integrated with the 
replacement strategy into the genome.   
Cloning of the mutant parasite lines was again conducted by limiting dilution (2.10.1.5). 
Donor mice infected with the mutant parasites were sacrificed with a parasitemia of 0.65 % 
for the mutant me01 and 0.55 % for the mutant me03. The infected blood from both mice was 
diluted 1 to 1x10
6
, 22 #l or 26 #l, respectively, then contain one calculated mutant parasite 
me01 or me03. For both mutant strains 10 NMRI mice were injected i.v. with the indicated 
volumes of the diluted blood. Parasitemia was monitored by giemsa-stained blood smears. 
One mouse infected with the me03 mutant parasite got blood-stage positive on day 7. 
Integration specific PCR with isolated gDNA, however, did not show the integration specific 
fragment on an agarose gel. All other cloning mice remained blood-stage negative up to day 
21 after the infection. The cloning procedure was repeated, but all injected mice remained 
blood-stage negative up to three weeks after infection. So again cloning of the mutant parasite 
lines failed for unknown reasons.  
Again the parental mutant parasites lines were fed to mosquitoes. Exflagellation was 
unimpaired when mutations were inserted by the replacement strategy. However, for the 
mutant me01 we detected no oocysts in dissected mosquito midguts 10 days post 
transmission. Consequently no sporozoites were found in the salivary glands of female 
mosquitos 14 days post transmission. This was different for the mutant parasite line me03. 
Oocysts could be detected in 7 out of 9 dissected midguts 10 days post transmission. The 
infection was rather low with only around 20 oocysts per infected midgut. On day 14 post 
transmission salivary glands were dissected and around 4,200 sporozoites per mosquito were 
isolated. Sporozoites were also transmitted to 2 anesthetised NMRI mice by bite. Four days 
after the by bite infection mice reached a blood-stage parasitemia of 0.6 % and 0.37 %. 
Blood-stage parasites were isolated and gDNA was purified. Genotyping PCR of these blood-
stage parasites, however, showed no integration of the replacement construct when using the 
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repl_int specific oligonucleotides. This finally suggests that only the WT parasites completed 
the life cycle, which were most likely left in the non-homologous parental parasite population. 
Mutants, however, were not able to pass through the entire life cycle as no mutated parasites 
could be detected in blood-stages by genotyping PCR.  
In Summary targeting csp turned out to be a difficult project. Although we tried several 
mutations and integration strategies we were not able to successfully generate a P. yoelii CSP 
CD8
+
 T-cell epitope mutant. Unfortunately also the depletion of the short gene located 
upstream of the Py csp failed. The fact, however, that two genes might be located so close to 
each other that regulatory regions overlap should be considered for future genetic 
manipulations. One should definitely make sure that one is not affecting other neighbouring 
genes when targeting a specific gene because subsequent phenotypes could not be allocated 
clearly.  
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3.2 Comparative analysis of early Plasmodium liver-stages identifies potential targets of 
protective immunity 
Genetically-attenuated parasites (GAP) and radiation-attenuated sporozoites (RAS) arrest 
during liver-stage (LS) development. Antigens expressed during early liver-stage 
development are presented to the immune system and alert protective immune responses in 
the liver. Wild-type (WT) sporozoites also induce immune responses in the liver but lead to 
disease causing blood-stage infection and at most partial protection is acquired. The antigen 
repertoire expressed by GAP and RAS liver-stages is probably reduced due to developmental 
arrest. Though these antigens can induce protection. We therefore compared the transcription 
profile of GAP and RAS liver-stages to that of WT LS and suggest that this method can help 
identifying antigens that are critical targets of pre-erythrocytic immunity. 
3.2.1 Suppression subtractive hybridisation results in a set of specifically up-regulated 
transcripts in attenuated parasites 
We utilised suppression subtractive hybridisation (SSH) to compare the transcripts of WT, 
GAP and RAS parasites after 20 hours LS development. This highly effective method allows 
the identification of differentially expressed transcripts in two different cDNA populations 
(Diatchenko et al. 1996). LS development of Plasmodium parasites was achieved in cultivated 
hepatocytes. It is described that P. berghei sporozoites enter and transform in human 
hepatoma cells (Hollingdale et al. 1983). Therefore the human hepatoma cell line Huh7 was 
used as an adequate host for LS development. This in vitro cultivation allowed to enhance the 
parasite to host-cell ratio and therefore to gain sufficient parasite RNA material for the 
subsequent subtraction. For one cDNA population of either GAP, RAS or WT LS, two to 
three 8-well chamber slides with 25,000 Huh7 cells and 25,000 to 35,000 sporozoites per well 
were inoculated and LS development was stopped after 20 hours. We chose this time point as 
uis3(-) parasites undergo arrested development in the liver at 24 hours and therefore already 
the early genes expressed during this period must be important for pre-erythrocytic immunity. 
Collected cells were treated with 0.05 % digitonin, this selectively permeabilised the host-cell 
plasma membrane without affecting the parasitophorous vacuole membrane (PVM) 
surrounding the intracellular parasite and thus reduced contaminations with host-cell RNA 
(Beckers et al. 1994). Parasite-specific RNA was subsequently isolated using the RNeasy 
Mini Kit (Qiagen). The achieved RNA concentrations reached from around 150 to 250 #g/ml 
in a volume of 40 #l, meaning final amounts of 6 to 10 #g total RNA. The cDNA synthesis 
with the applied SMART method (Clontech; SMART™ PCR cDNA Synthesis Kit, Protocol 
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No. PT3041-1) requires 0.05 to 1 #g total RNA and therefore this technique was especially 
useful for this approach as starting material was limited. Around 0.5 #g total RNA was used 
for cDNA synthesis with the SMART technology and this cDNA was subsequently used for 
subtraction. The subtraction procedure was performed according to the manufacture's manual 
(Clontech; PCR-Select™ cDNA Subtraction Kit, Protocol No. PT1117-1). Resulting cDNA 
fragments were directly cloned into pGEM-T Easy T/A-cloning vector (Promega) and 
sequenced with conventional methods.   
Sequence analysis was performed using the BLAST search tool on the PlasmoDB and 
GeneDB websites (http://plasmodb.org, http://www.genedb.org). The blastn algorithm was 
utilised to identify sequence similarities with annotated gene sequences of different 
Plasmodium species.  
Although the initial screening was performed using P. yoelii parasites we switched during 
sequence analysis to P. berghei orthologues where possible. This was due to better sequence 
information and easier handling of this parasite strain under laboratory conditions. 
The most abundant hits of more than 200 analysed sequences up-regulated in GAP and RAS 
in comparison to WT LS sequences, respectively, are shown in tables 2 and 3.  
 
UAP 1 was identified as C2 domain-containing protein (PB402109.00.0) and contains, beside 
one characteristic C2 domain, one domain with predicted exonuclease activity and one 
predicted ATPase domain. In addition UAP 1 and also UAP 3 (PB402624.00.0) contain signal 
peptides (SP) predicting them as targets of the secretory pathway. The three UAPs 5, 7 and 9 
(PB402174.00.0, PB403022.00.0, PB402387.00.0) contain transmembrane domains (TM) 
suggesting a membrane associated localisation. UAP 7 also contains a PEXEL export signal 
and might therefore be located beyond the parasitophorous vacuole membrane (PVM) (Marti 
et al. 2004). These UAPs, however, are annotated as hypothetical proteins with unknown 
function. UAP 6 (PB402448.00.0) was identified as a predicted serine/threonine phosphatase. 
More precise analysis of the sequences revealed a possible multi-gene family, located 
telomeric and therefore extremely difficult to study. Hence, this hit was excluded from further 
analysis. Several predicted domains in the identified UAPs are associated with transcriptional 
regulation. The krueppel-associated box (KRAB) in UAP 4 (PB402248.00.0) is a protein 
domain that is mainly found N-terminally in certain zinc finger proteins and acts as a 
transcriptional repressor (Vissing et al. 1995) (Urrutia 2003). Whereas UAP 8 
(PB000424.03.0) belongs to the GTP-binding elongation factor family.  
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UAP # 
hits 
systematic 
name 
product primary structure orthologs 
1 5 PB402109.00.0 C2 domain-
containing protein 
 
- 
2 4 PB401378.00.0 hypothetical 
protein  
- 
3 4 PB402624.00.0 hypothetical 
protein 
 
- 
4 3 PB402248.00.0 hypothetical 
protein 
 
- 
5 8 PB402174.00.0 hypothetical 
protein 
 
- 
6 9 PB402448.00.0 serine/threonine 
phosphatase 
NA - 
7 4 PB403022.00.0 hypothetical 
protein 
 
- 
8 4 PB000424.03.0 translation 
elongation factor 
EF-1, subunit 
alpha 
 
PY02338/ 
PY00361/2 
PF13_0304/5 
9 3 PB402387.00.0 hypothetical 
protein 
 
- 
10 1 PB301568.00.0 rhoptry protein 
 
PY06945 
PFE1045c 
Table 2. Genes up-regulated in genetically-attenuated parasites (GAP) in comparison to wild-type (WT) 
parasites during early liver-stage development (20h). Listed are the ten most abundant genes up-regulated in 
GAP liver-stages as identified by suppression subtractive hybridisation (SSH). More than 200 sequences were 
analysed using the BLAST search tool (blastn algorithm) from the PlasmoDB and GeneDB databases 
(http://plasmodb.org, http://www.genedb.org). The table shows the number of hits, the systematic name, the 
annotated gene product, the predicted primary structure, annotated Plasmodium orthologues and a consecutive 
UAP (up-regulated in attenuated parasites) number. SP: signal peptide; exo: exonuclease domain; AAA: ATPase 
domain; TM: transmembrane domain; KRAB: krueppel associated box.  
  
Even more transcription factors could be found in the list of up-regulated transcripts specific 
for RAS. The WW domain of PCIF1 as predicted for UAP 13 (PB000078.02.0) interacts with 
phosphorylated RNA polymerase II and may therefore play a role in mRNA synthesis (Fan et 
al. 2003). UAP 15 (PY05684) is the putative transcriptional repressor Not4hp. UAP 16 
(PB000435.00.0) contains a domain specific for the transcription factor S-II. The RNA 
recognition motif (RRM), like predicted for UAP 11 (PB000378.03.0), obviously binds to 
RNA and proteins containing RRM domains are thereby involved in post-transcriptional 
regulation. Additionally the forkhead-associated (FHA) domain can be found in a variety of 
eukaryotic proteins like kinases, phosphatases, kinesins, but also transcription factors and 
RNA-binding proteins [reviewed in (Durocher and Jackson 2002)].  
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UAP # 
hits 
systematic 
name 
product primary structure orthologs 
1 14 PB402109.00.0 C2 domain-
containing protein 
 
- 
2 4 PB401378.00.0 hypothetical 
protein  
- 
3 5 PB402624.00.0 hypothetical 
protein 
 
- 
4 2 PB402248.00.0 hypothetical 
protein 
 
- 
6 3 PB402448.00.0 serine/threonine 
phosphatase 
NA - 
7 1 PB403022.00.0 hypothetical 
protein 
 
- 
11 6 PB000378.03.0 FHA domain 
 
PY00240 
PF11_0347 
12 2 PB000654.03.0 carbonic 
anhydrase 
 
PY00744 
PF11_0411 
13 1 PB000078.02.0 conserved protein, 
unknown function 
 
PY07228 
MAL8P1.49 
14 3 PB108189.00.0 conserved protein, 
unknown function 
 
PY03538 
PF11_0433 
15 8 PY05684 transcriptional 
repressor Not4hp 
 
- 
16 4 PB000435.00.0 MAEBL 
 
PY3552 
PF11_0289 
17 3 PB001570.02.0 U1 small nuclear 
ribonucleoprotein 
C 
 
PY00121 
PF14_0026 
18 3 PB001388.02.0 conserved protein, 
unknown function  
PY07070 
PFA0350c 
19 2 PB402386.00.0 asparagin-rich 
antigen 
 
PY05735 
PF08_0060 
20 2 PB300550.00.0 osmiophilic body 
protein 
 
PY04958 
PFL2405c 
21 2 PY00149 cytochrome c 
oxidase subunit I-
related  
- 
Table 3. Genes up-regulated in radiation-attenuated sporozoites (RAS) in comparison to wild-type (WT) 
parasites during early liver-stage development (20h). Listed are the 17 most abundant genes up-regulated in 
RAS liver-stages as identified by suppression subtractive hybridisation (SSH). More than 200 sequences were 
analysed using the BLAST search tool (blastn algorithm) from the PlasmoDB and GeneDB databases 
(http://plasmodb.org, http://www.genedb.org). The table shows the number of hits, the systematic name, the 
annotated gene product, the predicted primary structure, annotated Plasmodium orthologues and a consecutive 
UAP (up-regulated in attenuated parasites) number. SP: signal peptide; exo: exonuclease domain; AAA: ATPase 
domain; TM: transmembrane domain; KRAB: krueppel associated box; FHA: forkhead-associated domain; 
RRM: RNA recognition motif; TFIIS_M: transcription factor S-II; COX: cytochrome oxidase.  
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More genes are specifically up-regulated in RAS. Amongst them the carbonic anhydrase UAP 
12 (PB000654.03.0), the conserved protein UAP 14 (PB108189.00.0) probably involved in 
heat shock protein binding, the asparagin-rich antigen UAP 19 (PB402386.00.0), the 
osmiophilic body protein UAP 20 (PB300550.00.0) probably involved in intracellular 
signalling and the cytochrome c oxidase UAP 21 (PY00149). Interestingly also the 
circumsporozoite protein (CSP) came up once during sequence analysis of transcripts up-
regulated in RAS. 
Other UAPs are found up-regulated in both attenuated parasite lines, RAS and GAP. 
Primarily the C2 domain-containing protein (UAP 1), which is the leading hit up-regulated in 
RAS. But also the small hypothetical proteins UAP 2, UAP 3, UAP 4 and UAP 7 are shared 
between RAS and GAP as well as the serine/threonine phosphatase UAP 6. Cellular functions 
during LS development of the different identified UAPs are so far unknown. 
 
The distribution of the UAPs and the classification into functional groups are again illustrated 
in the circle diagram of figure 12. The classification of the identified gene sequences was 
supported by database annotations and predicted protein domains identified with the Simple 
Modular Architecture Research Tool (SMART) (smart.embl-heidelberg.de). 
 
 
Figure 12. Genes differentially expressed in attenuated parasites in comparison to wild-type (WT) 
parasites during early liver-stage development (20h). The circle diagram shows the percentage of certain 
liver-stage transcripts identified in 200 analysed sequences of genetically-attenuated (GAP up-regulated) or 
radiation-attenuated (RAS up-regulated) parasites compared to WT sequences by suppression subtractive 
hybridisation (SSH). Sequence analysis was performed using the BLAST search on PlasmoDB and GeneDB 
homepages (http://plasmodb.org, http://www.genedb.org).  
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The BLAST search in the PlasmoDB and GeneDB databases (http://plasmodb.org, 
http://www.genedb.org) resulted in 49 % and 44 % of the searches, respectively, in no hits. 
These sequences were again entered in the NCBI database (http://www.ncbi.nlm.nih.gov) 
using the blastn algorithm to check for possible similarities to host-cell sequences, however 
no matching human sequences were found. More than 21 % and 6 % of the sequences, 
respectively, were identified as the pGEM-T Easy sequencing vector. Again it becomes 
apparent that a high percentage of transcription factors is up-regulated in attenuated parasites. 
In total it can also be seen that RAS express a much broader up-regulated repertoire if 
compared to GAP.  
 
We also performed the reverse subtraction and thereby identified transcripts that are down-
regulated in attenuated parasites in comparison to WT liver-stages. Results are shown in 
tables 4 and 5. Interestingly one gene up-regulated in RAS is down-regulated in GAP, namely 
the transcriptional repressor Not4hp (UAP 15). Other genes are specifically down-regulated in 
GAP, a tryptophan-rich antigen (PKH_120090) and several hypothetical proteins. The 
hypothetical proteins PY06363 and PY07366 as well as the reverse transcriptase PY07669 are 
assigned to one cluster according to the protein information on the GeneDB homepage. 
 
pos # 
hits 
systematic 
name 
product primary structure orthologs 
1 11 PB402448.00.0 serine/threonine 
phosphatase 
NA - 
2 5 PB401378.00.0 hypothetical 
protein  
- 
3 4 PY05684 transcriptional 
repressor Not4hp 
 
- 
4 4 PB402624.00.0 hypothetical 
protein 
 
- 
5 3 PKH_120090 tryptophan-rich 
antigen 
 
 
MAL13P1.269 
6 3 PY06363 hypothetical 
protein 
 
- 
7 3 PY07366 hypothetical 
protein 
 
- 
8 3 PY07602 hypothetical 
protein  
- 
9 2 PY07668 endo/ exonuclease/ 
phosphatase 
family  
- 
10 2 PY07669 reverse 
transcriptase 
 
- 
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Table 4. Genes down-regulated in genetically-attenuated parasites (GAP) in comparison to wild-type 
(WT) parasites during early liver-stage development (20h). Listed are the 11 most abundant genes down-
regulated in GAP liver-stages as identified by suppression subtractive hybridisation (SSH). More than 200 
sequences were analysed using the BLAST search tool (blastn algorithm) from the PlasmoDB and GeneDB 
databases (http://plasmodb.org, http://www.genedb.org). The table shows the number of hits, the systematic 
name, the annotated gene product, the predicted primary structure and annotated Plasmodium orthologs. SP: 
signal peptide; exo: exonuclease domain; AAA: ATPase domain; TM: transmembrane domain; TryThrA_C: 
Tryptophan-Threonine-rich plasmodium antigen C terminal; RVT_1: reverse transcriprase.  
 
Also the titin-L1-related fusion protein PY07613 down-regulated in RAS is part of this gene 
cluster. Furthermore we identified also in the down-regulated sequences genes that are shared 
between RAS and GAP. The reverse transcriptase PY07669 and PY07668 belonging to the 
endonuclease/exonuclease phosphatase family came up in both down-regulated populations.  
 
Table 5. Genes down-regulated in radiation-attenuated sporozoites (RAS) in comparison to wild-type 
(WT) parasites during early liver-stage development (20h). Listed are the nine most abundant genes down-
regulated in RAS liver-stages as identified by suppression subtractive hybridisation (SSH). More than 200 
sequences were analysed using the BLAST search tool (blastn algorithm) from the PlasmoDB and GeneDB 
databases (http://plasmodb.org, http://www.genedb.org). The table shows the number of hits, the systematic 
name, the annotated gene product, the predicted primary structure and annotated Plasmodium orthologs. SP: 
signal peptide; CAF-1: chromosome assembly factor 1; RVT_1: reverse transcriptase.  
11 2 PB102146.00.0 conserved protein, 
unknown function  
PY06038 
PFE1095w 
pos # 
hits 
systematic 
name 
product primary structure orthologs 
1 7 PB300106.00.0 MAEBL 
 
PY01844 
PFL0315c 
2 5 PB402448.00.0 serine/threonine 
phosphatase 
NA - 
3 3 PY07669 reverse 
transcriptase 
 
- 
4 2 PB401378.00.0 hypothetical 
protein  
- 
5 2 PB402624.00.0 hypothetical 
protein 
 
- 
6 2 PB001050.01.0 nucleolar 
preribosomal 
assembly protein  
PY00572 
PF08_0065 
7 2 PY06985 endo/ exonuclease/ 
phosphatase 
family  
- 
8 2 PY07613 titin-L1 fusion 
protein-related 
 
- 
9 2 PY07668 endo/ exonuclease/ 
phosphatase 
family  
- 
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Unfortunately we had to exclude some of the UAPs after analysis of the down-regulated 
genes as they came up in all subtracted populations, even in their own reverse subtraction.  
UAP 2, UAP 3 and UAP 6 can be considered as false positives and are therefore marked light 
grey in the above shown tables.  
All mentioned annotations and sequence information are based on database searches from 
2008 - 2010. Due to continuous updates regarding the Plasmodium genome sequencing not all 
identified sequences listed here are still available under the described annotations.  
 
The up-regulation of the shared UAPs in GAP and RAS liver-stages was further validated and 
quantified by quantitative real-time PCR (qRT-PCR). As templates served P. berghei GAP, 
RAS and WT RNA isolated from liver-stages after 20 hours LS development and transcribed 
in cDNA. The used primer pairs were chosen according to the sequence fragments received 
after sequencing of the subtracted cDNA libraries resulting from the SSH screening. Figure 
12 shows the copy numbers of mRNA of UAP 1, UAP 4 and UAP 7. The mRNA level for all 
investigated genes ranges from around 100 to 150 copies in WT LS, but is enhanced to a 
mean of 6032 and 7635 copies for UAP 1 in GAP and RAS LS, respectively. The number of 
mRNA copies for UAP 4 increased to a mean of 5223 and 6217 and for UAP 7 to a mean of 
3994 and 4823 copies in GAP and RAS LS, respectively. The qRT-PCR results validate the 
results from the SSH screening. 
 
 
Figure 13. Quantitative real-time PCR of transcripts up-regulated in attenuated parasites (UAP). 
Quantitive real-time RT-PCR with total RNA isolated from 20 h P. berghei liver-stages from either wildtype 
(WT), radiation-attenuated (RAS) or genetically-attenuated (GAP) parasites as templates using gene-specific 
oligonucleotide primer pairs. Shown are the transcript levels of  UAP 1, UAP 4 and UAP 7. Transcript quantity 
is represented as the number of copies (+/- SD) in comparison with an external standard curve produced with 
gene-specific plasmids. 
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In summary the SSH screening resulted in a set of specifically up-regulated transcripts in 
GAP and RAS liver-stage parasites if compared to WT liver-stages. These UAPs (up-
regulated in attenuated parasites) display proteins mainly with unknown functions. Results 
could be validated by qRT-PCR. The antigenic capacity of the identified proteins will be 
determined.  
3.2.2 The Plasmodium ferlin protein family 
The P. berghei C2 domain-containing protein (C2CP) was identified as one of the most 
prominent transcripts up-regulated in attenuated parasites (UAP 1). C2 domains are generally 
involved in Ca
2+
-sensing and -signalling and proteins containing C2 domains are described to 
mediate Ca
2+
-dependent vesicular fusion events. The C. elegans and human ferlins are well 
characterised proteins with characteristic cytosolic C2 domains. Database searches for protein 
orthologues and paralogues revealed beside the Pb C2CP one annotated Pb ferlin (FER) and a 
ferlin-like protein (FLP). So far there is nothing known about the cellular role of Plasmodial 
C2 domain-containing proteins and ferlins. Although the previously mentioned screening 
should primarily serve new antigen identification, the ferlin protein family is also very 
interesting with respect to their cellular functions. A more precise look at the databases also 
revealed several ferlin proteins in other Apicomplexan parasites. The primary structures of 
these proteins are shown in figure 13. Shown are the P. berghei C2 domain-containing protein 
(PB402109.00.0) and the annotated Pb ferlin (PB000505.02.0) and Pb ferlin-like protein 
(PB101952.00.0) paralogues. In the P. falciparum genome there is also one ferlin 
(PF14_0530) and a ferlin-like protein (MAL8P1.134) annotated. The Pb and Pf FER share 
63.7 % amino acid identity whereas the Pb and Pf FLP share even 71.5 % amino acid identity. 
Ferlin (TGVEG_073920) and FLP (TGVEG_093560) orthologues are also found in the 
Apicomplexan parasite Toxoplasma gondii. Except for the Pb C2CP, all other ferlin proteins 
contain at least five characteristic C2 domains. Moreover all ferlins and ferlin-like proteins 
carry transmembrane domains and a signal peptide is found for Pb C2CP. 
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Figure 14. Primary structures of annotated Apicomplexan C2 domain-containing proteins (C2CP) and 
related ferlins. Shown are the P. berghei C2CP and related ferlin and FLP paralogues as well as the P. 
falciparum and Toxoplasma gondii orthologues. Characteristic C2 domains are involved in Ca
2+
 sensing and -
signalling in other described ferlin proteins. Beside these domains SMART analysis (http://smart.embl-
heidelberg.de/) revealed domains with predicted exonuclease (exo) and ATPase activity (A). Bold numbers 
represent amino acid positions. Signal peptides are shown in red, transmembrane domains are marked blue.  
 
To get a first impression in when and where the P. berghei C2CP and ferlin are expressed 
during the parasite life cycle a reverse transcriptase PCR was performed on different stage-
specific cDNAs.  
 
 
Figure 15. Reverse transcriptase PCR detects transcripts of P. berghei ferlin (fer) and C2 domain-
containing protein (c2cp) in different parasite stages. As templates served stage-specific cDNAs synthesised 
from isolated P. berghei WT RNA from mixed blood-stages (mixed BS), midgut (MG spz) and salivary gland 
sporozoites (SG spz) and liver-stages after 20 hours (LS 20h) and 48 hours (LS 48h) in vitro development in 
human hepatoma cells. A standard PCR program was run with specific oligonucleotides for Pb fer and Pb c2cp 
fragments and Pb myosin A (myoA) as constitutively expressed control. DNA fragments were separated by 
agarose gel electrophoresis. +: cDNA samples prepared with reverse transcriptase; -: cDNA samples prepared 
without reverse transcriptase.  
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Transcripts of the P. berghei ferlin (Pb fer) could be amplified from cDNA of P. berghei WT 
mixed blood-stages, midgut sporozoites and late liver-stages (LS 48h). The Pb fer fragment 
amplified from early liver-stages (LS 20h) was very weak suggesting a rather low expression 
of Pb fer during this stage. The gene seems not to be expressed in salivary gland sporozoites 
as no fragment could be amplified from the respective cDNA preparation. The transcript of P. 
berghei C2CP (Pb c2cp) could only be detected in blood-stages. A hardly detectable DNA 
band was also found on the agarose gel when using P. berghei WT early liver-stage cDNA 
(LS 20h) as a template. The constitutively expressed myosin A could be amplified from the 
cDNA templates of all stages. This control showed the presence of cDNA in all preparations 
with reverse transcriptase (+) and no gDNA contaminations in the respective RNA 
preparations transcribed without reverse transcriptase (-).  
3.2.3 P. berghei ferlins are essential during blood-stage development  
In order to functionally characterise the P. berghei C2 domain-containing protein (C2CP) and 
the related ferlin (FER) a targeted gene depletion should be performed. Resulting depletion 
phenotypes could suggest potential functions of the protein. Targeted gene depletion in 
Plasmodium is conducted in blood-stage parasites. Therefore genes essential during blood-
stage development cannot be targeted. A failing integration of the targeting construct, 
however, can also be due to poor accessibility of the genomic locus for homologous 
recombination. We therefore generated a knock-out construct and a complementation 
construct for Pb fer and Pb c2cp, that were transfected separately during the same experiment. 
  
The different genetic strategies are shown in figure 15. For the knock-out targeting construct 
two fragments from the 5' and 3' untranslated regions (UTR) of the respective gene were 
amplified with specific oligonucleotides (for sequences see appendix 6.1). Expected 
fragments sizes were confirmed by agarose gel electrophoresis. The Pb fer fragments were 
676 bp and 773 bp for the 5' and the 3' UTR fragment, respectively. The Pb c2cp fragments 
had a lenght of 678 bp and 612 bp, respectively. The two corresponding fragments were 
cloned into the targeting vector b3D (for vector map see appendix 6.2) as described, flanking 
the TgDHFR/TS selectable marker, resulting in the constructs p'fer and p'c2cp. For the 
control complementation constructs C-terminal fragments including the stop codon were 
amplified in two parts to insert a unique restriction site necessary for linearisation prior to 
transfection. The sizes of 952 bp and 744 bp for the Pb fer complementation and of 497 bp 
and 481 bp for the Pb c2cp complementation, respectively, were again confirmed by agarose 
gel electrophoresis. Cloning of two corresponding fragments one after another into the 
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clonign vector b3D+ (for vector map see appendix 6.2) resulted in the complementation 
constructs pferCONT and pc2cpCONT.  
 
 
Figure 16. Knock-out (A) and complementation (B) strategy of the P. berghei ferlin (FER) and C2 domain-
containing protein (C2CP). A. The replacement construct contains the 5’ and 3’ untranslated regions of the P. 
berghei fer or c2cp open reading frames flanking the TgDHFR/TS selectable marker. The wildtype (WT) 
genomic locus is targeted with the linearised KpnI/XbaI targeting vector. A double crossing-over event replaces 
the endogenous fer or c2cp ORF, respectively, by the selectable marker. B. The complementation control 
construct (pCONT) contains a N-terminal truncated version of the P. berghei  fer or c2cp ORF (fer*/c2cp*) and 
the TgDHFR/Ts selectable marker. A XbaI-linearised plasmid is targeting the fer or c2cp WT genomic locus, 
respectively, and inserts the selection marker and an additional truncated fer* or c2cp* copy.  
 
The P. berghei ANKA GFPcon strain (Franke-Fayard et al. 2004) was transfected with the 
KpnI/XbaI digested p'fer and p'c2cp constructs, as well as with the XbaI-linearised 
constructs pferCONT and pc2cpCONT according to the described AMAXA transfection 
protocol. Transfected merozoites were directly injected intravenously (i.v.) into NMRI mice. 
Parasitemia was checked by giemsa-stained blood smears on day 1 after transfection. Starting 
parasitemias were quite low with 0.1 % to 0.3 % for three independent experiments. From day 
1 Pyrimethamine was provided with the drinking water to select for transfected parasites. On 
day 2 parasitemias decreased to undetectable levels in giemsa-stained blood smears. Under 
continuous drug selection resistant parasites first appeared from day 7 to 9 in the blood. 
Resistant parasites transfected with the knock-out constructs took on average 9 days for 
p'c2cp and 8.5 days for p'fer until detectable in thin blood smears. Parasites transfected with 
the complementation constructs, pferCONT and pc2cpCONT, were slightly faster and 
respective mice got blood-stage positive on average 7.5 days after transfection. As soon as 
parasite levels in the blood increased to 0.5 % to 1 % mice were sacrificed. Infected blood 
was saved as cryo stock and isolated parasites were kept as parental populations for genomic 
DNA (gDNA). Around 50 to 100 #l infected blood was transferred intraperitonealy (i.p.) into 
naïve NMRI mice and parasitemia was monitored under drug selection. Upcoming parasites 
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were again collected from infected blood and kept as transfer population. Transfectants were 
checked by specific PCRs for integration of the targeting constructs (figure 17).  
 
 
Figure 17. Genotyping PCR of P. berghei ferlin (fer) and C2 domain-containing protein (c2cp) knock-out 
(A) or complementation (B) transfectants. Standard PCRs were run with ORF, test and episomal (epi) specific 
oligonucleotide pairs (see figure 16). As templates served gDNA of the different transfer transfectants 
(%c2cp/%fer/c2cpCONT/ferCONT) and P. berghei wild-type gDNA (WT) or respective targeting constructs (v) 
as PCR controls. Specific DNA fragments were separated by agarose gel electrophoresis.  
 
Specific oligonucleotide pairs ORF I and ORF II amplified different parts of the Pb fer or Pb 
c2cp open-reading frames. For the knock-out genotyping PCR (figure 16A) the DNA 
fragments amplified with ORF I oligonucleotides are expected to be 978 bp for Pb c2cp and 
1696 bp for Pb fer. Respective bands could be seen on a agarose gel when using WT gDNA 
or 'c2cp/'fer gDNA as PCR templates. As expected there is no ORF I specific DNA 
fragment amplified when the targeting knock-out constructs were used as a template. The 
episomal specific oligonucleotide pairs epi I and epi II amplify vector specific fragments. 
Therefore epi I specific DNA bands, with the expected sizes of 1165 bp and 1326 bp for Pb 
c2cp and Pb fer, respectively, can be detected on a agarose gel when using respective 
targeting constructs, p'c2cp and p'fer, as a template as well as the gDNA of resistant 
transfectants, 'c2cp and 'fer, that carry the plasmids. Test oligonucleotide pairs test I and II 
prove integration of the targeting constructs into the parasite genome and can therefore only 
be amplified from gDNA of positive transfectants. The expected test I specific DNA 
fragments with sizes of 1301 bp and 1557 bp cannot be amplified from the transfectants 
gDNA indicating no integration of the targeting constructs, p'c2cp and p'fer, and therefore 
no depletion of the respective genes, Pb c2cp and Pb fer. That looks different for the control 
complementation genotyping PCR. ORF II specific DNA fragments have a size of 978 bp or 
1068 bp and can be visualised on a agarose gel when using WT gDNA or gDNA of the 
transfectants c2cpCONT and ferCONT as templates and not be amplified from the CONT 
complemenation constructs. Epi II specific DNA bands can be detected on a agarose gel with 
a size of 1478 bp and 2196 bp, respectively, for transfectants' gDNA and vector control only. 
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The test II specific DNA fragments with sizes of 2879 bp for c2cpCONT and 4304 bp for 
ferCONT demonstrate a successful integration of the control complementation constructs, 
pc2cpCONT and pferCONT. By that the accessibility of both genomic loci could be proven. 
Same genotyping results were achieved from three independent transfection experiments.  
In summary this experiment shows that the Pb c2cp and Pb fer genomic loci are accessible for 
homologous recombination, the genes, however, cannot be depleted by targeted gene 
disruption. From these results we conclude an essential role for Pb C2CP and Pb FER during 
blood-stage development. 
3.2.4 Immunological characterisation of P. berghei C2 domain-containing protein 
(C2CP) reveals specific immune responses in immunised animals 
The initial goal of this study was to identify new potential antigen candidates by comparative 
analysis of early GAP, RAS and WT liver-stage parasites. The attenuated parasite lines, GAP 
and RAS, arrest during liver-stage development, alert the immune system and by that confer 
to stage-specific protection. We hypothesised that due to this arrestment GAP and RAS liver-
stages express a different, probably reduced set of transcripts in comparison to WT liver-
stages. The expressed antigens, however, are sufficient for the induction of protection. This 
comparative analysis should therefore narrow down antigen candidates involved in pre-
erythrocytic immunity.  
 
The P. berghei C2 domain-containing protein (C2CP) was one of the most prominent up-
regulated transcripts in attenuated parasites (UAP 1) if compared to WT. Its potential as 
antigen candidate became apparent as four predicted H-2
b
-restricted CD8
+
 T-cell epitopes 
were detected with help of several prediction programs (table 6). Therefore we tested whether 
these Pb C2CP-derived peptides are specifically recognised in GAP and RAS immunised 
C57BL/6 mice. 
The amino acid sequences of the predicted Pb C2CP CD8
+
 T cell epitopes, A9I, T9L, S8V 
and A8I are shown in table 6. In total two H-2
b
-restricted nonamers and two octamers were 
predicted with help from the epitope prediction program SYFPEITHI 
(http://www.syfpeithi.de) and personal help from T-cell experts. The MHC-binding of T9L 
could later also be validated in vitro by a collaborating group in Copenhagen, Denmark 
(Harndahl et al. 2009).  
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sequence abbreviation position half-life [h] 
AYIAPHTII A9I 141-149 - 
TIRSFYKRL T9L 417-425 5.81 
SPYLFNIV S8V 671-678 - 
AIYRFNAI A8I 827-834 - 
 
Table 6. Predicted CD8
+
 T-cell epitopes of the P. berghei C2 domain-containing protein (C2CP). Shown are 
the H-2
b
-restricted CD8
+
 T-cell epitopes of Pb C2CP as predicted with help from the SYFPEITHI epitope 
prediction program (http://www.syfpeithi.de) and personal communication with T-cell experts. In the shown 
primary structure the bold black bars indicate the schematic localisation of the predicted T-cell epitopes. The 
amino acid sequences and positions of the epitopes are shown in the table. The binding affinity of T9L is 
determined as half-life of the MHC I-peptide complex as measured in an in vitro assay by collaborating partners 
in Copenhagen, Denmark and accounts for on average 5.81 h (mean of two independent measurements) 
(Harndahl et al. 2009). 
 
Five independent immunisations with genetically-attenuated parasites (GAP; uis3(-)) and 
radiation-attenuated sporozoites (RAS) were performed according to the prime-two-boost 
protocol shown in figure 18. Injected sporozoites of these attenuated parasite lines invade 
hepatocytes and transform into liver-stages normally. But then parasites arrest during liver-
stage development and do not proceed to blood-stage infection. These arresting parasites 
confer to stage-specific protection against subsequent WT sporozoite challenges. The 
attenuated parasite vaccination model is routinely used for experimental immunisations of 
rodents.  
 
 
Figure 18. Schematic diagram of the prime-two-boost immunisation protocol. C57BL/6 mice were injected 
i.v. with P. berghei RAS or GAP on day 0. The first boost was typically administered 14 days later and the 
second boost 14 days thereafter. Booster doses were typically lower than the priming dose. 7 days after the final 
boost animals were either challenged with WT sporozoites (spz) or organs were dissected for immunological 
studies (harvest prior challenge). The challenged mice were sacrificed 7 days after the WT challenge (harvest 
after challenge).  
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Groups of five C57BL/6 mice were typically immunised in 14 days intervals according to the 
shown protocol (figure 18). Due to reasons of time the protocol was sometimes shorten. The 
first boost was then administered 7 days after the priming and the second boost 7 days 
thereafter. P. berghei GAP and WT sporozoites were isolated from mosquitoes' infected 
salivary glands on days 17 to 21 post infectious blood meal as described. WT sporozoites 
were "-irradiated with a dose of 150 Gray resulting in RAS. The isolated sporozoite numbers 
per mosquito reached from 10,000 to 25,000 with a mean of 14,980 sporozoites per mosquito 
for GAP and 14,400 for WT. Either 7 days after the final boost or 7 days after a subsequent 
WT challenge, immunised mice were sacrificed and serum, livers and spleens were collected. 
All naïve challenge control mice developed blood-stage parasitemias of 0.3 % to 0.5 % when 
they were sacrificed on day 7 after the challenge, whereas all immunised mice remained 
blood-stage negative. Liver lymphocytes and splenocytes were isolated as described (2.12.2) 
and cultured over night in the presence of the Pb C2CP-derived peptides (2.12.4). Thereby 
lymphocytes from immunised mice specific to these peptides get restimulated, proliferate and 
produce cytokines.  
 
The establishment of an effector memory T-cell response is important for vaccination and 
builds the basis for adaptive immune responses. We therefore had a look at the expression of 
specific surface marker of T-cells in the liver of GAP and RAS immunised animals. 
The staining for surface activation marker of lymphocytes from GAP and RAS immunised 
mice showed a clearly enhanced effector memory T-cell population (TEM; 
CD8
+
CD44
high
CD62L
low
) in comparison to naïve mice (figure 19). This indicates the 
establishment of a memory immune response during GAP immunisation which was hitherto 
unpublished. Mean percentages of TEM-cells of 6.47 % in livers of naïve mice, increased 
significantly to 63.3 % in RAS immunised and to 47.3 % in GAP immunised animals (p = 
0.0003 and p = 0.024; unpaired t test). In naïve WT challenged mice 18.8 % of the CD8
+
 T-
cells expressed the activation marker CD44
high
CD62L
low
, this did not differ significantly from 
naïve controls. Also the absolute cell numbers of TEM-cells in the liver increased significantly 
after GAP and RAS immunisation. While a mean of 84,144 CD8
+
CD44
high
CD62L
low
 cells 
could be counted in the liver of naïve mice, the number increased significantly to on average 
1,889,755 TEM-cells and 1,289,110 TEM-cells in RAS and GAP immunised mice, respectively 
(p = 0.0142 and p = 0.0089; unpaired t test). In WT challenged mice the cell number also 
increased if compared to naïve mice, a mean of 405,262.5 TEM-cells were detected in the 
liver. This increase, however, is not significant.  
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Figure 19. Effector memory T-cell population (CD8
+
CD44
high
CD62L
low
) in the liver increases after GAP 
and RAS immunisation. Liver lymphocytes of naïve, immunised and WT challenged animals were incubated 
over night with BMDCs and the Pb C2CP-specific peptide T9L. Surface staining was performed with anti 
CD8a-PacBlue conjugated antibody (1:100, BD biosciences), antiCD44-FITC (1:100, BD biosciences), anti 
CD62L-PE (1:200, BD biosciences) and anti CD25-Alexa647 (1:50, BD biosciences). Analysis of the stained 
cells was performed by flow cytometry using the FACSCanto system (BD biosciences). Resulting data were 
further analysed using the flowjo analysis software (http://www.flowjo.com). A. Mean percentages of 
CD8
+
CD44
high
CD62L
low
 cells; B. Absolute cell numbers of CD8
+
CD44
high
CD62L
low
 cells; C. Representative dot 
plots from single mice (n=5).  
 
Subsequently an in vivo cytotoxicity assay should shed light on the capacity of GAP and RAS 
immunised animals to recognise and kill cells that carry Pb C2CP-derived peptides on their 
surface. Therefore a pool of either three (A9I, S8V and A8I) or all four predicted CD8
+
 T-cell 
epitope peptides A9I, T9L, S8V and A8I was loaded on CFSE-labelled splenocytes and 
injected i.v. into immunised mice together with a control cell population that carried no 
peptides and was labelled with a lower concentration of CFSE (2.12.3). Mice were sacrificed 
18 hours later and liver lymphocytes and splenocytes were isolated as before. For the 
cytotoxicity assay some of these cells were directly tracked by flow cytometry where the 
CFSE-labelled cells can be seen in the FL1 channel of the BD FACSCalibur (excitation 488 
nm, emission 517 nm). The percentage of  specifically lysed cells was calculated with the 
following mathematical function: 
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! 
specific lysis %[ ]= 100 "
ratio CFSE high CFSE low sample( )
mean ratio CFSE high CFSE low  naive controls( )
*100  
 
The percentages of specifically lysed cells in spleens and livers of RAS and GAP immunised 
mice 7 days after a subsequent WT challenge is shown in figures 20 and 21. 
 
 
Figure 20. In vivo cytotoxicity assay shows lysis of target cells pulsed with the Pb C2CP-derived peptides 
A9I, S8V and A8I. Naïve splenocytes were loaded with Pb C2CP-derived peptides A9I, S8V and A8I and 
labelled with 2 #M CFSE (CFSE
high
) (5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester, Invitrogen). A 
control cell-population was labelled with 0.2 #M CFSE (CFSE
low
). Cell-populations were mixed in equal 
numbers (1:1) resulting in final CFSE concentrations of 1 #M or 0.1 #M, respectively. 1 x 10
7 
cells of this mixed 
population were injected i.v. into tail veins of immunised or naïve control animals 18 hours prior to cell 
isolation. CFSE-labelled cells were tracked by flow cytometry in spleen and liver. The specific lysis was 
calculated as ratio of CFSE
high
 cells and CFSE
low 
cells and compared to the ratio detected in naïve animals. 
Shown are the mean percentages of lysed cells from groups of 3 - 5 mice. 
 
There is no specific cytotoxic lysis detectable in the spleens of immunised and challenged 
animals when using a pool of the three Pb C2CP-derived peptides A9I, S8V, A8I. Specific 
lysis, however, could be observed in the liver. A significant increase from less than 0.0001 % 
in naïve animals to 11.6 % in RAS immunised animals could be observed. We could also 
detect an average of 11.8 % specific lysis in the livers of GAP immunised animals. Though 
this increase was not significant to naïve mice due to a very high standard deviation. The 
specific cytotoxic lysis in livers of WT challenged mice accounted for on average 6.3 %. 
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Figure 21. In vivo cytotoxicity assay shows lysis of target cells pulsed with a pool of all four Pb C2CP-
derived peptides in immunised animals. Naïve splenocytes were loaded with a pool of all four Pb C2CP-
derived peptides (A9I, T9L, S8V and A8I) and labelled with CFSE together with a control cell-population as 
described before. 1 x 10
7 
cells were injected i.v. into tail veins of immunised or naïve control animals 18 hours 
prior to cell isolation. CFSE-labelled cells were tracked by flow cytometry in spleen and liver. The specific lysis 
was calculated as ratio of CFSE
high
 cells and CFSE
low 
cells and compared to the ratio detected in naïve animals. 
Shown are the mean percentages of lysed cells in three independent experiments, each with 3 - 5 mice per group. 
 
When adding the peptide T9L to the pool there was also no specific cytotoxic lysis detected in 
the spleen of immunised animals. In the livers of RAS and GAP immunised mice, however, 
11.8 % and 19.6 % Pb C2CP-specific cells, respectively, get lysed. This is significantly more 
than in naïve control animals were on average less than 0.001 % of the fluorescently labelled 
Pb C2CP-specific cells get lysed. In WT challenged mice also 10.5 % of the Pb C2CP-
specific are killed. These mice had seen P. berghei WT liver-stages before but in contrast to 
immunised mice had developed a blood-stage infection. These results demonstrate that Pb 
C2CP-specifc cells get indeed recognised and killed in immunised or exposed animals. 
Immune responses directed against the Pb C2CP-derived peptides could be detected.  
 
To decipher Pb C2CP-specific immune responses in RAS and GAP immunised animals in 
more detail, the single Pb C2CP-derived peptides A9I, S8V, A8I T9L were used for 
restimulation in the following experiments. Below mice were not challenged with WT 
sporozoites after GAP and RAS immunisation.  
 
The ELISpot (Enzyme-linked immunosorbent spot) is an extremely sensitive assay that 
allows the detection of cytokines on single cell level. We therefore applied this method to 
measure low IFN-" responses in the livers and spleens of RAS and GAP immunised mice that 
could not be detected by FACS (data not shown). Purified liver lymphocytes or total 
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splenocytes from immunised mice were restimulated over night with the Pb C2CP-derived 
peptides A9I, S8V, A8I and T9L as described before. Prior to the transfer of restimulated cells 
to IFN-" coated MultiScreen filter plates, culture medium was exchanged by fresh medium to 
dilute secreted IFN-" in the culture supernatant and reduce background. After 24 hours 
incubation of the stimulated cells on filter plates spots were detected by a secondary 
biotinylated anti IFN-" antibody. Every spot that developed on the membrane represented a 
single reactive cell. Spots were counted under a dissection microscope. Controls for the 
stimulated cells from immunised animals were cells incubated without stimulus and cells 
isolated from naïve animals. A positive control, naïve lymphocytes activated with an anti-
CD3 antibody, was run along to prove that the assay is working.  
 
In two independent immunisation experiments we restimulated with the three single Pb 
C2CP-derived peptides A9I, S8V and A8I. The measured IFN-" responses in spleens and 
livers are shown in figure 22.  
 
 
Figure 22. Interferon-"  (IFN-") responses of effector T-cells measured by cytokine-based ELISpot after 
restimulation with the Pb C2CP-derived peptides A9I, S8V, A8I. Cultured lymphocytes from immunised 
animals were restimulated over night with 1 #M of the Pb C2CP-derived peptides A9I, S8V, A8I or incubated 
without stimulus (w/o). Cells were subsequently transferred to MultiScreen filter plates coated with 5 #g/ml 
IFN-" antibody. The IFN-" response is shown as counted spots per million cultivated cells. Counts of naïve 
control animals were subtracted. Shown are the means of counted tripletts from two independent experiments (n 
= 5). 
 
The detected IFN-" responses were low in spleens of immunised animals reaching from 25 to 
125 reactive cells per million cultivated splenocytes. We measured no differences in the IFN-
" production of restimulated cells if compared to non-stimulated controls in the spleen. In the 
liver of immunised animals the IFN-" responses are also unexpectedly low. This was due to 
extremely high responses in naïve animals that were subtracted. The data analysis revealed no 
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enhanced IFN-" responses in livers of immunised animals after restimulation with the Pb 
C2CP-derived peptides A9I, S8V and A8I. 
 
In two more independent immunisation experiments we used the single Pb C2CP-derived 
peptide T9L for specific restimulation of splenocytes and liver lymphocytes after RAS and 
GAP immunisation. The respective results are shown in figure 23. 
 
 
Figure 23. Cytokine-based ELISpot measures Interferon-"  (IFN-") responses of effector T-cells from RAS 
and GAP immunised mice. Cultured lymphocytes from immunised animals were restimulated over night with 1 
#M of the Pb C2CP-derived peptide T9L or incubated without stimulus (w/o). Cells were subsequently 
transferred to MultiScreen filter plates coated with 5 #g/ml IFN-" antibody. The detected IFN-" response is 
shown as counted spots per million cultivated cells. Counts of naïve control animals were subtracted. Shown are 
the means of counted tripletts from two independent experiments (n = 5). 
 
The IFN-" responses of restimulated splenocytes after GAP and RAS immunisation where 
also low (figure 21). The anti-CD3 positive control, however, showed similar responses 
compared to the T9L stimulated cells, with a mean of 168 spots per million total splenocytes. 
This indicates a low number of IFN-" producing cells in the spleen. Though the IFN-" 
response increased significantly in spleens of RAS and GAP immunised C57BL/6 mice when 
restimulated with the Pb C2CP-derived peptide T9L (p = 0.0023 and p = 0.003; unpaired t 
test). The IFN-" responses of purified liver lymphocytes where in total higher than those of 
the splenocytes suggesting more activated T-cells in the liver were the parasite infection 
occurs. When specifically restimulating liver lymphocytes from GAP-immunised animals 
with Pb C2CP-derived peptide T9L the responses of 911 reactive cells, from RAS-immunised 
animals even 1078 responding lymphocytes per million cells were detected. As control, 
unspecific stimulation of naïve cells with anti-CD3 antibody resulted in on average 681 
reactive cells per one million liver lymphocytes. The detected IFN-" responses after 
restimulation with T9L were significantly enhanced in RAS and GAP immunised animals (p 
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= 0.0032 and p = 0.0266; unpaired t test). These results shown, that T-cells from GAP and 
RAS immunised C57BL/6 mice can indeed be specifically restimulated with at least one Pb 
C2CP-derived peptide. 
3.2.5 First immunisation studies with P. berghei C2CP-derived peptide T9L  
Cells carrying P. berghei C2CP-derived peptides were recognised and attacked by the 
immune system in GAP and RAS immunised mice and the peptide T9L was able to 
specifically restimulate T-cells. Therefore immunisation studies with this peptide should be 
performed in C57BL/6 mice in order to have a first impression in the protective potential of 
this single peptide. For immunisations with peptides a suitable adjuvant system is very 
important. Here we used the TargoSphere& delivery system from Rodos Bio Target GmbH 
(RBT; http://www.biotargeting.eu). These nanocarrier target professional antigen-presenting 
cells (APCs) via their C-type lectin receptors (CLRs) on the surface and enter the cells’ 
endolysosomal system. The content of the nanocarrier by that gain access to the intracellular 
antigen presentation pathways. The Pb C2CP-derived peptide T9L was packed by the 
company into nanocarrier then called RBT06.01 TS. The packing efficiency was 10 % 
resulting in a Targosphere solution with a final peptide concentration of 21.277 #g/ml. As 
control served nanocarrier packed with a FITC:Dextran mixture (FITC:Dextran TS). The final 
FITC:Dextran concentration in the Targosphere solution was 172.8 #g/ml.  
Groups of C57BL/6 mice (n = 3) were immunised with 5 #g or 1 #g peptide or FITC:Dextran, 
respectively. Per mouse aliquots of 47 #l or 235 #l RBT06.01 TS or 5.8 #l or 29 #l 
FITC:Dextran TS were prepared. In order to inject same volumes the FITC:Dextran TS 
solution was filled up to 47 #l or 235 #l, respectively, with PBS. The solutions were 
administered subcutaneously into a skin fold at the back. Immunisation was performed 
according to the shorten prime-two-boost protocol described earlier (3.2.4; figure 17). That 
means injections were made every 7 days. Seven days after the final boost immunised mice 
were exposed to the bites of 5 infected mosquitoes each. As challenge control three naïve 
mice were also exposed. Subsequent dissection of the mosquitoes revealed a rather low 
infectivity with only around 8,000 salivary gland sporozoites per mosquito. Parasitemia was 
followed by daily giemsa-stained blood smears from day 3 post challenge. 
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vaccine dose challenge pre-patency 
RBT06.01 TS 1 "g 5 infected mosquitoes 4.3 days (3 / 3) 
RBT06.01 TS 5 "g 5 infected mosquitoes 6.3 days (3 / 3) 
FITC:Dextran 1 "g 5 infected mosquitoes 5 days (3 / 3) 
FITC:Dextran 5 "g 5 infected mosquitoes 5 days (3 / 3) 
no  5 infected mosquitoes 5 days (3 / 3) 
 
Table 7. Pre-patency of mice immunised with nanocarrier RBT06.01 TS packed with P. berghei C2CP-
derived peptide T9L. The peptide T9L was packed into specialised nanocarrier (TargoSpheres&) by the Rodos 
Bio Target GmbH. Different doses of RBT06.01 TS or control nanocarrier packed with FITC:Dextran were 
administered subcutaneously into C57BL/6 mice thrice in a 7 days interval. Seven days after the last boost mice 
were exposed to bites of infected mosquitoes. All mice developed blood-stage parasitemia as observed by daily 
giemsa-stained blood smears from day 3 post challenge. The pre-patency was determined as time until the first 
appearance of a single parasites in the peripheral blood. 
 
The P. berghei NK65 CS-GFP strain was used for sporozoite challenge (Natarajan et al. 
2001). This strain expresses the cytoplasmic green fluorescent protein (GFP) under the 
control of the stage-specific circumsporozoite protein (CSP) promotor. Sporozoites of this 
strain therefore fluoresce bright green. This again allows the pre-selection of infected 
mosquitoes under a fluorescent stereo-microscope. All challenged mice developed a blood-
stage parasitemia between day 4 and day 7 post infection. The non-immunised mice 
developed a detectable blood-stage parasitemia by day 5. This is rather late as parasites are 
expected to come up on day 3 to 4 in naïve animals after sporozoite challenge. Interestingly a 
slight delay in pre-patency was observed in animals immunised with 5 #g RBT06.01 TS in 
comparison to FITC:Dextran immunised controls. The time until the first parasites could be 
detected in giemsa-stained blood smears extended on average from 5 to 6.3 days post wild-
type sporozoite challenge. 
Eight days post challenge animals were sacrificed, lymphocytes were isolated from livers 
spleens and lymph nodes and cells were prepared for cytokine ELISpot as described earlier 
(2.12.2 / 2.12.4 / 2.12.6). As a control organs from naïve C57BL/6 mice were treated equally. 
Cells from the groups were pooled and restimulated with T9L or cultured without stimulus 
over night prior to transfer on the MultiScreen filter plates. IFN-" production was measured as 
a read-out for activated T-cells.  
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Figure 24. Cytokine-based ELISpot to measure Interferon-"  (IFN-") responses of activated T-cells from 
RBT06.01 TS immunised mice. Pools of cultured lymphocytes from immunised animals were restimulated 
over night with 1 #M of the Pb C2CP-derived peptide T9L or incubated without stimulus (w/o). Cells were 
subsequently transferred to MultiScreen filter plates coated with 5 #g/ml IFN-" antibody. The detected IFN-" 
response is shown as counted spots per million cultivated cells. Counts of naïve control animals were subtracted. 
Shown are the means of counted tripletts from groups of three mice.  
 
Measured T-cell responses varied quite strong between the different organs as seen on the 
scale of the y axis. In total the IFN-" responses were the highest in the liver and only little 
responding cells were detected in the lymph nodes. The group treated with 1 #g 
FITC:Dextran Targospheres shows exceptional high responses if compared to the other 
groups. This however was not due to a single outlier.  
In summary we detected no enhanced IFN-" responses after specific restimulation of effector 
T-cells in mice immunised with the P. berghei C2CP-derived peptide T9L packed in 
specialised nanocarrier (RBT06.01). This suggests that either this system is not suitable for 
immunisation with single peptides or the single peptide alone has not enough potential in 
stimulating protective immune responses.  
3.2.6 Recombinant expression of P. berghei C2 domain-containing protein (C2CP)  
For recombinant over-expression in E. coli the P. berghei C2CP was divided in three parts. 
This should simplify expression and improve solubility of the otherwise very large protein. 
The division of the protein was done on the one hand with respect to hydrophobic regions as 
determined by the ProtScale analysis tool on the ExPASy Proteomics Server 
(http://www.expasy.ch/tools/protscale.html) using the Kyte & Doolittle scale. Numbers > 0 
display hydrophilic regions, whereas number < 0 display hydrophobic regions. Thus the Pb 
C2CP parts I - III (table 8) were defined at the end of hydrophilic protein regions expecting a 
better solubility of the expressed protein parts. On the other hand the protein was also divided 
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with respect to the guanine/cytosine (GC) content of the DNA sequence coding for Pb C2CP. 
This was important to consider in order to design suitable oligonucleotides for cloning of the 
expression constructs. The positions of the different chosen protein parts are shown in table 8.  
 
 
protein aa position molecular weight 
Pb C2CPI 10 - 303 34 kDa 
Pb C2CPII 489 - 814 37.5 kDa 
Pb C2CPIII 809 - 1265 56 kDa 
 
Table 8. Division of the P. berghei C2 domain-containing protein (C2CP) for recombinant expression. The 
1280 amino acid protein Pb C2CP was sub-divided into the three parts C2CPI, C2CPII and C2CPIII for easier 
expression. The rough position is indicated by the black bars in the primary structure. Detailed amino acid (aa) 
positions and calculated molecular weights are listed in the table. The molecular weight was calculated with help 
of the ProtParam tool on the ExPASy Proteomics Server (http://www.expasy.ch/tools/protparam.html).  
 
The sequences coding for Pb C2CPI - III were cloned into the expression vector pET15b 
(Novagen). This results in the expression of fusion proteins with a N-terminal 6 x Histidin-tag 
(C2CPI-III-His). The DNA sequences coding for C2CPI, C2CPII and C2CPIII with a size of 
882 bp, 978 bp and 1371 bp, respectively, were cloned using the restriction endonuclease 
recognition sites NdeI and XhoI. Cloning was successful for all three constructs (vector maps 
attached under 6.2), however, expression was only performed for C2CPI-His.  
For recombinant over-expression codon optimised E. coli BL21 competent cells (BL21-
CodonPlus (DE3)-RIPL, Stratagene) were transformed with the pETc2cpI construct. 
Expression was performed in 25 ml LB-medium with ampicillin (100 #g/ml). The culture 
starting with an OD600 of 0.1 - 0.2 was cultivated shaking at 37 °C until an OD600 of 0.5 was 
reached. Expression was induced by the addition of 1 mM IPTG to the culture and good 
expression was achieved after 4 hours at 37 °C, 250 rpm, as tested by applying samples on a 
SDS-PAGE after different time points. To test the solubility of the expressed C2CPI-His 
bacteria cells were lysed by sonication. For this the cell pellet was resuspended in a lysis 
buffer containing 0.05 % Tween 20 and lysozyme (1 mg/ml). The lysozyme was allowed to 
crack the bacterial cell wall for 30 minutes on ice, a subsequent sonication for 2 x 30 seconds 
should completely lyse the cells. After centrifugation soluble protein was in the supernatant, 
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whereas insoluble protein expressed as inclusion bodies or potentially bound to membranes 
would be in the pellet together with the cell debris.  
 
 
Figure 25. Recombinant overexpression of the P. berghei C2CPI-His fusion protein in E. coli BL21. The 
Coomassie stained SDS gel shows insoluble pellet (P) fraction alongside with the soluble supernatant (S) 
fraction. Expression was performed in codon optimised E. coli BL21 (Stratagene) at 37 °C, 250 rpm. 4 hours 
after induction with 1 mM IPTG cells were centrifuged and sonicated in lysis buffer. Supernatant and pellet in 8 
M urea were mixed 1 : 1 with 2 x SDS loading dye and heated for 5 minutes at 95 °C prior to loading on the gel. 
As protein standard served the PageRuler! Prestained Protein Ladder (Fermentas).  
 
As seen in figure 25 only around half of the expressed C2CPI-His with a calculated molecular 
weight of 34 kDa was found in the supernatant. Efforts to increase the amount of soluble 
protein unfortunately failed. Neither induction with lower IPTG concentrations (0.1 mM, 0.25 
mM or 0.5 mM) nor expression at lower temperatures (room temperature or 16 °C) improved 
the solubility. Even when scaling-up the culture volume to 100 ml in order to obtain more 
protein the solubility was impaired. Therefore the expression was finally performed in 4 
flasks with 25 ml culture each as described initially. Supernatants were combined and C2CPI-
His was purified by nickel ion affinity chromatography. For an optimal binding of the His-
tagged fusion protein on the HIS-Select& Nickel Affinity Gel (Sigma) lysis of the cells was 
performed in a sodium phosphate buffer with a pH of 8.0.  
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Figure 26. Purification of the C2CPI-His fusion protein by nickel ion affinity chromatography. The 
Coomassie stained SDS gel shows the single fractions collected during column purification of the C2CPI-His 
fusion protein using the HIS-Select& Nickel Affinity Gel (Sigma). 1. cell lysate prior to purification; 2. flow-
through; 3./4. washing steps; 5. - 9. elution. The samples were mixed with 2 x SDS loading dye and heated for 5 
minutes at 95 °C prior to loading on the gel. As protein standard served the PageRuler! Prestained Protein 
Ladder (Fermentas). 
 
All fractions collected during column purification were applied to a SDS gel shown in figure 
26. The fusion protein did not bind properly on the column matrix. Therefore C2CPI-His 
could partly be detected in the flow-through and the two following washing steps. The His-
tagged fusion protein, however, could be concentrated by elution with 250 mM imidazol in 5 
fractions with 1 ml each. Fractions 1 to 4 were combined and dialysed against PBS to remove 
the imidazol.  
 
 
Figure 27. Coomassie stained SDS gel (A) and Western Blot (B) of purified C2CPI-His after dialysis 
against PBS. Pb C2CPI-His was purified by nickel ion affinity chromatograph and subsequently dialysed 
against PBS to remove the imidazol from the elution buffer. The sample was mixed with 2 x SDS loading dye 
and heated for 5 minutes at 95 °C prior to loading on the gel. As protein standard served the PageRuler! 
Prestained Protein Ladder (Fermentas). 
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The purified C2CPI-His sample was not absolutely clean. Therefore the purification should be 
optimised by the addition of low concentrations of imidazol to the equilibration and washing 
buffer. Imidazol concentrations between 2 and 6 mM resulted in no improved purification and 
showed similar protein patterns on a SDS-PAGE in the purified protein samples. An imidazol 
concentration of 10 mM however was too high as the C2CPI-His protein did not bind on the 
column at all and the complete protein was found in the flow-through. Finally no cleanly 
purified protein sample could be obtained with the used protocols. Different expression 
conditions or  buffers have to be tested in order to improve solubility and purity of the protein 
sample.  
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4. Discussion 
Even more than 60 years after its discovery the malaria liver-stage still remains the most 
elusive stage of the Plasmodium life cycle (Shortt and Garnham 1948). Though this clinically 
silent stage provides an ideal target for causal-prophylactic drugs and vaccination as it is the 
only stage that can be completely eliminated by sterilising protective immunity. 
Administration of radiation-attenuated sporozoites (RAS) remains still the "gold standard" in 
vaccination against malaria (Nussenzweig et al. 1967). Recently, a new generation of 
attenuated parasites have been generated by depletion of a single liver-stage essential gene, 
the genetically-attenuated parasites (GAP) (Mueller et al. 2005a). Like RAS, GAP arrest 
during liver-stage development and by that confer stage-specific sterile protection against 
subsequent WT sporozoite challenges. Thereby these live-attenuated parasites provide us with 
an ideal tool to study protective pre-erythrocytic immune responses in the mammalian host.  
To date only little is known about GAP-mediated immunity. Studies in knock-out mice 
revealed that CD8
+
 T-cells are the major players in conferring this protection (Mueller et al. 
2007). In order to study the underlying mechanisms, however, and to specifically enhance 
effector T-cell numbers in vitro we need immunogenic antigens recognised in GAP-
immunised mice for specific restimulation of T-cells ex vivo. Unfortunately, no defined and 
presented antigen epitope so far exist in the here used GAP experimental vaccine model. In 
Balb/c inbred mice around 90 % protection can be achieved with a single dose of RAS, this is 
associated with a strong immune response against the main surface protein of the sporozoites, 
the circumsporozoite protein (CSP). The presentation of a single protective H-2K
d
-restricted 
CD8
+
 T-cell epitope of CSP, SYIPSAEKI for P. berghei and SYVPSAEQI for P. yoelii, 
could be shown (Rodrigues M. M. et al. 1991). For the GAP vaccination model in this study, 
however, the rodent strain Plasmodium berghei was used, whose most susceptible host for 
liver-stage development is the inbred mouse strain C57BL/6 (Scheller et al. 1994). In the 
C57BL/6 genetic mouse background there is no CSP epitope defined as these mice express 
the MHC haplotype H-2
b
. Protective immunity, however, can be achieved when using a 
prime-two-boost immunisation protocol (Mueller et al. 2005a). We therefore believe that 
other pre-erythrocytic antigens must mediate this immunity that are so far not identified. The 
goal of this study was to perform a detailed analysis and dissect protective immune responses 
induced by GAP. In particular we firstly wanted to validate that GAP-mediated immunity is 
independent of immune responses specific to CSP and secondly we searched for new antigen 
candidates involved in GAP-mediated immunity, whose identified epitopes might then be 
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used for a specific and in-depth immunological study by e.g. restimulation of  antigen-specific 
T-cells.  
P. yoelii CSP CD8
+
 T-cell epitope mutants - different strategies and unexpected 
outcomes 
CSP has historically been considered the major antigen involved in pre-erythrocytic 
immunity. Strong immune responses against defined epitopes were characterised extensively 
(Nardin and Nussenzweig 1993). Recently, several studies showed immune responses 
independent of CSP (Gruner et al. 2007) (Kumar et al. 2006) and also in the GAP model used 
in here protection is achieved despite the absence of CSP-specific immune responses (Mueller 
et al. 2007). As CSP is essential for sporozoite development (Menard et al. 1997), CSP 
disruption by targeted gene depletion results in no infectious sporozoites and consequently no 
CSP knock-out liver-stages are available. Therefore it is difficult to study pre-erythrocytic 
immune responses independent of CSP. We designed an experimental tool by mutating the P. 
yoelii CD8
+
 T-cell epitope so that the epitope will no longer be recognised by the host’s 
immune system without affecting CSP functionality within the parasite. As we were not fully 
aware of which amino acids might be essential for proper folding and therefore protein 
function, we inserted different mutations into the sequence coding for the CD8
+
 T-cell epitope 
inside the Py csp gene. Mutation of the DNA sequence was successful for basically two 
different approaches leading to alanisation of either the two amino acids that are important for 
anchoring the P. yoelii CSP CD8
+ 
T-cell epitope onto MHC class I complex (V282 and Q287; 
mutant me01) or the alanisation of the amino acids whose residues are potentially not 
important for folding and functionality (S280, V282, S284 and I288; mutant me03) as predicted by 
a protein expert colleague (see table 1). When inserting these mutated sequences into the 
parasite’s genome via homologous recombination, however, we had to face several problems. 
The initial complementation targeting construct pcsp!epi me01 successfully integrated into 
the genomic locus after P. yoelii transfection (see figures 5 and 6). After parasite cloning by 
limited dilution, however, the mutated sequence coding for the CSP CD8
+
 T-cell epitope 
reverted to the wild-type epitope sequence by DNA repair mechanisms. This was detected 
after subsequent sequence analysis of the resulting clones. The analysed sequences still 
showed integration of the targeting construct as both the selectable marker and the inserted 
restriction sites could be confirmed within the analysed DNA sequence (figure 38). Indeed, 
there are several DNA repair mechanisms reported in Plasmodium. It was shown that a cell-
free lysate of asexual P. falciparum blood-stage parasites repaired DNA lesions by the long-
patch base excision repair (BER) pathway. This pathway fills apurinic/apyrimidinic sites (AP 
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sites) with several nucleotides, whereas in other organisms like yeast, E. coli and also humans 
AP sites are predominantly repaired by the replacement of single nucleotides (short-patch 
BER pathway) (Haltiwanger et al. 2000). Further studies demonstrated, that bulky DNA 
lesions induced by ultraviolet (UV) light could also be repaired by a P. falciparum lysate 
(Trotta et al. 2004). This indicates the presence of the nucleotide excision repair (NER) 
pathway, that is involved in the repair of larger DNA lesions than the BER pathway. 
Interestingly, this repair mechanisms is impaired in the highly drug-resistant human P. 
falciparum W2 isolate and therefore defects in DNA repair may be one mechanism of the 
rapid development of drug resistance in Plasmodium (Trotta et al. 2004). This was recently 
supported by another study, where a third DNA repair mechanism in P. falciparum, the 
mismatch repair (MMR), was also linked to the development of resistance (Castellini et al. 
2011). This MMR pathway generally corrects mismatch DNA during replication. Disruption 
of the MMR gene MSH2-2 in P. berghei indeed led to an increased number of DNA 
polymorphisms in comparison to a control parasite after less than 40 life cycles (Bethke et al. 
2007). The most supposable DNA repair mechanism that reverted the P. yoelii CSP CD8
+
 T-
cell epitope in this study may be the BER pathway, because we modified at most two or three 
consecutive nucleotides in the respective DNA sequence.  
Subsequently we wanted to transmit the mutated parental population Py CSP me01 to 
mosquitoes, but we observed an unexpected exflagellation defect prior to transmission. As 
this exflagellation defect could not be explained with the described CSP function we had a 
closer look at the P. yoelii csp genomic locus and its surrounding genetic environment. And 
indeed, in the PlasmoDB database we found an extremely closely located gene upstream of 
the P. yoelii csp annotated as a hypothetical protein, for now, called csprae (PY07369) (see 
figure 7). The flanking regions of the two genes, probably involved in regulation of gene 
expression, overlap because of this extremely close proximity meaning that csprae most 
likely is located within the csp 5' UTR and csp is found within the csprae 3' UTR. For that it 
would be difficult to target csp by insertion of a large complementation construct without 
affecting the 3' regulatory region of the neighbouring gene. The integration of the whole 
targeting construct into the csp genomic locus disrupts the natural genomic sequence and 
thereby potentially interrupts the 3' UTR of the upstream located gene (see figure 5). That 3' 
regulatory regions are highly important for expression in Plasmodium was described before. 
The 3' UTR of group A var genes, that code for PfEMP1 proteins, for example regulates the 
expression of these genes (Muhle et al. 2009). It was demonstrated that the DownsA 3' UTR 
of this var genes can regulate gene expression by the suppression of the UpsA promotor. For 
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the P. falciparum pfs25 protein, a surface protein important for parasite development inside 
the mosquito, it was shown that several elements in the 3' gene-flanking region are necessary 
for expression (Oguariri et al. 2006). This study revealed the required role of an AT-rich 
region 137-231 nucleotides (nt) from the stop codon for gene expression, as well as the 
presence of a specific nonamer sequence 360 nt from the stop codon, that enhanced 
expression by more than 50 %. With our genetic strategy we indeed targeted the genomic 
sequence 140 nt from the stop codon of csprae by insertion of the complete targeting 
construct, even though the first additional nucleotides were inserted about 880 nt from the 
stop codon, namely the XbaI recognition site (see figure 5).  
Therefore it should be proven whether this exflagellation phenotype was indeed a 
consequence of affecting P. yoelii csprae gene expression. The targeting construct p!csprae 
was generated to functionally degrade csprae by deletion of the sequence coding for the first 
9 amino acids (see figure 8). With this strategy the promotor region of the csp gene should be 
untouched as the deletion would be inserted around 1 kb upstream of the csp start codon. 
Despite the close proximity of Py csp and the small hypothetical protein Py csprae, this was 
possible because of two large introns in the csprae coding sequence. The csprae endogenous 
locus could not be genetically depleted in at least two independent transfection experiments. 
Unfortunately it could not be solved whether the transfections failed because csprae is 
essential during blood-stage development or because of technical issues. Maybe the damage 
of the csprae 3' regulatory region by insertion of the knock-in construct pcsp!epi only 
reduced the csprae expression to a lower extent leading to an exflagellation defect, similar to 
the above described region downstream of the pfs25 gene, that regulates expression intensity 
(Oguariri et al. 2006). Whereas depletion of parts of the gene coding sequence by integration 
of the p!csprae targeting construct resulted in a complete loss-of-function and therefore in 
non-viable parasites. Similar annotations of this closely located gene upstream of csp were not 
found for the P. berghei or P. falciparum genome in the PlasmoDB database. The 
neighbouring annotated genes localise 1.5 kb and 1.4 kb upstream of the Pb and the Pf csp 
coding sequence, respectively (from stop codon neighbouring gene to start codon csp). 
In order to circumvent the initially observed repair mechanisms we subsequently focussed on 
another genetic strategy to insert the mutations into the P. yoelii genome (figure 9). The initial 
complementation strategy left the sequence coding for the WT CD8
+
 T-cell epitope in a 
truncated csp gene, that is not expressed as a functional protein. As this WT epitope sequence 
might have been served as a template for the observed repair mechanisms we then inserted the 
mutated sequences by a double cross-over event. Another advantage of this so-called 
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replacement strategy is the more stable integration of the targeting construct into the parasite 
genome in comparison to the initial complementation strategy. After parasite transfection with 
the targeting constructs pcsprepl!epi me01 and me03 genotyping PCRs showed successful 
integration of the constructs (figure 11). However cloning never succeeded for unknown 
reasons. Unfortunately, both parental mutant lines me01 and me03 generated by integration of 
the replacement construct pcsprepl!epi did not complete the parasite life cycle within the 
mosquito. Maybe the functionality of CSP was yet affected due to the inserted point 
mutations in the epitope sequence. Recently, the protein structure of recombinant P. 
falciparum CSP was analysed showing the folding of the C-terminal located thrombospondin-
like type I repeat (TSR) domain and therein the localisation of disulfid bonds important for 
stabilisation of the protein (Plassmeyer et al. 2009). If not protein folding maybe also function 
of the TSR domain (amino acids 297-345 for P. yoelii CSP) might be impaired by the 
mutation of closely located amino acid residues inside the Py CSP CD8
+ 
T-cell epitope 
(amino acids 280-288).  
What exactly caused the observed phenotypes is not known. In order to overcome all these 
challenges probably more mutations and maybe even other genetic strategies have to be 
considered. Like for the csp knock-out generated by Menard et al. where an additional 1.4 kb 
fragment upstream of the csp gene was included into the targeting vector (Menard et al. 
1997). This at least would prevent double-strand breaks in the endogenous csp promotor and 
ensure normal expression of the gene. In the long run we aimed at generating P. yoelii CSP 
CD8
+
 T-cell epitope mutants in the GAP (uis3(-)) background. Immunisation studies with 
such mutant GAPs would finally aid dissecting the role of CSP in GAP-mediated immunity. 
These GAP CSP-mutants, that do not induce CSP-specific CD8
+
 T-cells clones, would 
provide a tool to study induced protective immune responses independent of CSP. If animals 
immunised with the CSP-mutant GAPs were still protected, this would further validate that 
GAP-induced protection is independent to immune responses specific to CSP.  
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RAS liver-stages express a broader up-regulated transcript repertoire in comparison to 
GAP 
Within this part of my thesis we aimed at identifying possible novel antigen candidates 
involved in GAP-mediated immunity, that may potentially act as vaccine targets, when 
comparing the transcriptional repertoire expressed by RAS, GAP and WT liver-stages by 
suppression subtractive hybridisation (SSH). This approach differs fundamentally from recent 
studies, that also aimed at the identification of potential target antigens. For example another 
comparative transcriptional analysis identified differentially expressed transcripts in P. yoelii 
WT and RAS sporozoites as well as in early (24 h) and late (48 h) WT and RAS LS in 
comparison to mixed blood-stages (Williams and Azad 2010). This analysis, however, does 
not comprise potential multi-stage antigen candidates as transcripts that are expressed in pre-
erythrocytic as well as in blood-stages are excluded with this method. In the here presented 
study we compared the transcript repertoire expressed in attenuated parasites to that expressed 
in WT parasites during early liver-stage development. We believe that in the protection-
inducing attenuated parasites antigens may accumulate, due to developmental arrest, that are 
important for protection. The time point of 20 hours liver-stage development was chosen as 
the uis3(-) GAPs arrest at mid liver-stage development (24 hours) and therefore antigens 
expressed at this early time point must be sufficient to induce the GAP-mediated protective 
immunity. The SSH screening identified a set of specifically up-regulated transcripts in 
attenuated parasites (UAPs) in comparison to WT liver-stages. The reverse subtractions also 
revealed several transcripts that are down-regulated in attenuated parasites if compared to 
WT. Unfortunately we had to exclude the three UAPs 2, 3 and 6 after analysis of the down-
regulated transcripts as they were detected in all subtracted populations tested. The down-
regulated transcripts were not investigated in detail as they can be considered as not important 
for protective immunity induced by RAS or GAP, respectively. In the here performed SSH 
screening transcripts are enriched that are more abundant in one cDNA population if 
compared to another. Therefore down-regulation in attenuated parasites concurrently means 
that these transcripts are up-regulated in WT liver-stages. As WT LS per se do not confer 
sterile protection, this suggests that transcripts that are more abundant in WT in comparison to 
attenuated LS do not code for antigens involved in protective immune responses.  
Although some of the identified UAPs are shared between RAS and GAP liver-stages there 
are also differences in the up-regulated transcript repertoire of the two attenuated parasite 
lines (tables 2 and 3; figure 12). RAS liver-stages expressed a more diverse up-regulated 
transcript repertoire whereas we identified less differentially expressed transcripts in GAP 
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liver-stages. This is conceivable if considering that irradiation of sporozoites results in 
multiple random point mutations, while GAPs are generated by specific gene depletion of a 
single liver-stage essential gene, in this study uis3. Therefore GAP liver-stages differ from 
WT only by one single gene, whereas RAS comprise a heterogenous parasite population with 
an undefined genetic background. This is why RAS liver-stages arrest at different time points 
and thereby different developmental stages resulting in the expression of a more 
heterogeneous set of transcripts. Whereas transcript expression by GAP is similar to this of 
WT liver-stages. The most striking difference between the up-regulated transcript repertoire 
of RAS and GAP liver-stages is the circumsporozoite protein (CSP). In RAS liver-stages CSP 
appeared as up-regulated transcript in comparison to WT liver-stages. In contrast there was no 
CSP transcript up-regulated in GAP liver-stages. This might serve as a proof-of-concept for 
the here performed screening. While CSP plays a dominant role as protective antigen in RAS-
mediated immunity [reviewed in (Nardin and Nussenzweig 1993)], no CSP-specific immune 
responses were detected for the here used GAP vaccination model (Mueller et al. 2007). This 
demonstrates that the here performed screening indeed enriched transcripts that code for 
antigens involved in RAS and GAP mediated immunity, respectively.  
UAPs - up-regulated in attenuated parasites 
In total 21 UAPs were identified, of which some are specific for RAS or GAP, respectively, 
but interestingly also several UAPs are shared between both attenuated parasite lines. The 
most prominent transcript identified as up-regulated in RAS and GAP, UAP 1, coded for a 
putative C2 domain-containing protein (C2CP; plasmoDB annotation PB402109.00.0). Such 
C2 domains are found in several proteins and are characteristic for the ferlin protein family 
(see below). Beside one C2 domain the P. berghei C2CP had a predicted exonuclease domain 
and a predicted triple A domain (ATPases Associated with diverse cellular Activities; AAA+ 
ATPase). Although these AAA+ ATPases are known to mediate diverse cellular processes, 
like proteolysis, membrane fusion, microtubule serving or biogenesis of endosomes. A 
common underlying mechanism of all described functions of AAA+ proteins is the energy-
dependent unfolding of proteins (Lupas and Martin 2002). Such a AAA+ ATPase was 
recently described as energy source of the P. falciparum protein export machine PTEX 
transporting proteins beyond the PVM (de Koning-Ward et al. 2009).  
Furthermore the small hypothetical proteins UAP 4 and UAP 7 are up-regulated in both 
attenuated parasite lines if compared to WT liver-stages. UAP 4 holds a predicted Krueppel-
associated box (KRAB domain) and may therefore mediate transcriptional repression (see 
below). The hypothetical protein UAP 7 has a pexel export signal and a transmembrane (TM) 
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domain. This export signal was shown to be important for the transport of proteins through 
the parasitophorous vacuole membrane (PVM) (Marti et al. 2004). UAP 7 may therefore 
either be located within the PVM, because of its TM domain, or its final destination may be 
the cytoplasm of the host hepatocyte. There Plasmodium proteins can facilitate liver-stage 
development e.g. by adapting the host's gene expression like it is described for CSP (Singh A. 
P. et al. 2007).  
Interestingly several predicted domains characteristic for eukaryotic transcription factors or 
domains involved in post-transcriptional regulation were identified for UAP 4, UAP 8, UAP 
11, UAP 13, UAP 15 and UAP 16. In Plasmodium transcriptional regulation is only poorly 
understood. A genome-wide database search for transcription factors in P. falciparum 
revealed that most detected transcription factors were CCCH-type zinc finger proteins 
(Coulson et al. 2004). This type of zinc finger is described to bind to mRNA indicating rather 
post-transcriptional control in Plasmodium (Lai et al. 2000). The Krueppel-associated box 
(KRAB domain) as predicted for UAP 4 is present in the largest family of zinc finger 
transcription factors where the N-terminally located KRAB domain acts as a transcriptional 
repressor by binding to corepressor proteins whereas the zinc finger motif binds to DNA. By 
that these KRAB domain containing zinc finger repressor proteins function as transcriptional 
repressors [reviewed in (Urrutia 2003)]. Whether this type of transcriptional repression is also 
present in Plasmodium is not described so far. The translation elongation factor UAP 8 
belongs to the EF-1 alpha (EF-Tu) type, which binds GTP and an aminoacyl-tRNA and 
delivers the latter to the A site of ribosomes. Another predicted domain potentially involved 
in transcriptional regulation is the forkhead-associated domain (FHA domain) of UAP 11. 
This FHA domain was initially/historically called like that because it have been found in a 
small subset of forkhead-type transcription factors (Hofmann and Bucher 1995). Meanwhile 
the FHA domain could be associated with proteins involved in numerous processes including 
intracellular signal transduction, transcription, protein transport, DNA repair and protein 
degradation by recognising phosphothreonine epitopes on proteins [reviewed in (Durocher 
and Jackson 2002)]. The function of FHA domains in Plasmodium is unknown. In at least two 
genome-wide database searches no forkhead transcription factors were described in 
Plasmodium (Templeton et al. 2004) (Coulson et al. 2004). A second predicted protein 
domain of UAP 11 is the RNA-recognition motifs (RRM). This domain typically binds to 
mRNA and is involved in post-transcriptional regulation. Recently, also protein-protein 
interactions were described for RRM domains [reviewed in (Clery et al. 2008)]. The WW 
domain of UAP 13 is described for the human phosphorylated CTD interacting factor 1 
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(PCIF1), which interacts with the phosphorylated C-terminal domain of the RNA polymerase 
II (Fan et al. 2003). Further characterisation of PCIF1 suggests a role in negative regulation of 
gene expression (Hirose et al. 2008). Furthermore UAP 15 is annotated as potential 
transcriptional repressor Not4hp and the TFSII_M domain of UAP 16 is characteristic for the 
transcription factor S-II. This transcription factor binds to RNA polymerase II and by that 
induces mRNA cleavage (Kettenberger et al. 2003). In total it is not as surprising that 
transcriptional regulation is extremely important during early liver-stage development. During 
the complex reorganisation of the extracellular sporozoite to the intracellular liver-stage and 
the fast growth of the parasite the regulation of gene expression have to built the basis for the 
morphological changes. How this critical developmental step is accomplished remains elusive 
and is under extensive investigations (Prudencio et al. 2006). However, recently, two protein 
families were described that may be involved in gene regulation in Plasmodium. The AP2 
(Apetala2)-integrase DNA binding domains were discovered in different apicomplexan 
parasites and especially expression was shown in Plasmodium blood-stages (Balaji et al. 
2005). Furthermore the sporozoite and liver-stages asparagine-rich protein SLARP/SAP1 was 
described as transcriptional regulator during liver-stage development (Silvie et al. 2008) (Aly 
et al. 2011). The large P. falciparum genome with more than 5000 genes (Gardner et al. 
2002), that are differentially expressed during the various stages of the complex life cycle, is 
one of the impediments in malaria vaccine development and hinders the selection of highly 
immunogenic and potentially protective antigen candidates. Therefore the detailed 
understanding of gene regulation in Plasmodium may also help to identify potential antigen 
candidates and be important for the development of an effective malaria vaccine. 
Predicted export signals like signal peptides or PEXEL motifs as well as transmembrane 
domains make some of the UAPs even more interesting with respect to their antigenic 
function. At first glance it seems to be important that potential antigens have to be exported or 
at least protrude into the host-cell cytoplasm in order to gain access to the host's immune 
system. Such intracellular antigens inside the host-cell are typically coupled to MHC class I 
molecules and transported to the host's cell surface. Recently, it was described that processing 
and presentation of sporozoite antigen is dependent on TAP-mediated transport of MHC class 
I epitopes to the endoplasmic reticulum (Cockburn et al. 2011). MHC class I presented 
antigens can then be recognised by CD8
+ 
cytotoxic T-cells and target cells are subsequently 
killed. But there are also modes of action how intracellular antigens inside the parasite can get 
access to recognition by CD8
+
 T-cells. One way may be the cross-presentation of extracellular 
antigens released after apoptosis of host-cells by dendritic cells (DCs). Indeed cross-
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presentation of sporozoite antigens by DCs to CD8
+ 
T-cells was described in the skin-draining 
lymph nodes after by bite immunisation (Chakravarty et al. 2007). While WT liver-stages 
prevent infected hepatocytes to undergo apoptosis (van de Sand et al. 2005) (Leiriao et al. 
2005b) it is reported that apoptosis is increased in RAS infected hepatocytes (Leiriao et al. 
2005a). Moreover it was demonstrated that GAP infected hepatocytes undergo apoptosis even 
more frequently than WT or RAS infected ones (van Dijk et al. 2005). Thereby the chance 
increases that antigens of attenuated parasites are indeed released into the extracellular matrix 
of the liver. Interestingly cross-presentation was also reported for intracellular antigens from 
live HIV-infected cells (Maranon et al. 2004). The active uptake of intracellular antigens from 
live cells by DCs is contact-dependent but the mechanism behind this transfer is unknown. 
Importantly this cross-presentation is more effective in activating CD8
+
 T-cells than antigen 
presentation by infected cells. Additionally a recent study indicated that antigen presentation 
of CSP to CD8
+
 T cells may not depend on the presence of the PEXEL signal, that is required 
for the export of Plasmodium proteins into the erythrocyte cytosol (Cockburn et al. 2011) 
(Marti et al. 2004). This suggests that parasite proteins do not necessarily have to hold export 
signals in order to reach the host-cell cytoplasm. In summary this shows that all identified 
parasite proteins may act as potential antigens independent of their localisation in the parasite 
or the host-cell or the existence of at first glance important domains or characteristics.  
The ferlin protein family  
Beside the potential antigenic function of the identified UAPs the P. berghei C2CP (UAP 1) 
also have awakened our interest with respect to its cellbiological function in the Plasmodium 
parasite. The function of C2 domains in general and C2 domain-containing proteins, like the 
identified UAP 1 or other Plasmodial ferlins, in particular are not described so far. In other 
organisms, however, C2 domains are attributed conserved functions in Ca
2+
-dependent 
membrane fusion events [reviewed in (Lek et al. 2012)]. As Plasmodium has a complex life 
cycle with different invasive and intracellular stages, where membrane fusion might play an 
important role, Plasmodial ferlins may take over several conceivable functions (see below). 
We therefore believe that Plasmodial ferlins may also be involved in vesicular trafficking and 
membrane fusion e.g. during host-cell invasion, establishment of the parasitophorous vacuole 
or parasite release from hepatocytes. The comprehensive understanding of the complex 
cellular processes that lead to successful parasite invasion and establishment of an infection 
are also important for the selection of new potential antigen targets and the development of an 
effective malaria vaccine.  
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Searching the PlasmoDB and GeneDB databases (www.plasmodb.org and www.genedb.org) 
for orthologues and paralogues in other apicomplexan parasites revealed an annotated 
putative P. berghei ferlin (PB000505.02.0), a P. berghei ferlin-like protein (PB101952.00.0) 
and a the P. falciparum orthologues PF14_0530 (FER) and MAL8P1.134 (FLP), two putative 
P. yoelii ferlins (PY05745 and PY04695) and annotated genes for a Toxoplasma gondii ferlin 
(TGVEG_073920) and a Tg FLP (TGVEG_093560) paralogue. Although ferlins are 
ubiquitous proteins well characterised in Caenorhabditis elegans and humans, there is nothing 
known about their function in apicomplexan parasites. Recently, the Pf ferlin was 
evolutionary classified as ferlin-like gene with at least five C2 domains and a C2-FerI-C2 
motif (Lek et al. 2010). The ferlin protein family is generally characterised by multiple 
tandem C2 domains and a C-terminal transmembrane domain (Bansal and Campbell 2004). 
Such tandem C2 domains are also present in other proteins and have been well characterised 
in synaptotagmin [reviewed in (Bai and Chapman 2004)]. The C2 domains of synaptotagmin 
bind Ca
2+
 and by that mediate protein-protein interactions between the SNAREs (soluble N-
ethyl-maleimide-sensitive fusion protein (NSF) attachment protein receptor), synaptobrevin 
and syntaxin. This triggers the fast exocytotic membrane fusion and thereby the release of 
neurotransmitter at the synaptic cleft (Chapman 2002). The first described ferlin, the C. 
elegans FER-1, is required for Ca
2+
-mediated membrane fusion during spermatogenesis 
(Washington and Ward 2006). Mutations in fer-1 thus led to a fertilisation defect, an effect 
that was eponymous for the ferlin protein family (Achanzar and Ward 1997). Furthermore the 
human dysferlin is important for Ca
2+
-dependent resealing of the sarcolemma in muscle fibres 
(Bansal and Campbell 2004). And additionally, the human otoferlin serves as a calcium 
sensor that regulates SNARE-mediated membrane fusion in cochlear hair cells (Johnson and 
Chapman 2010). Mutations in both human ferlins, dysferlin as well as otoferlin, are associated 
with inherited diseases like muscular dystrophy and deafness, respectively. All this suggests 
the common function of Ca
2+
-sensing and Ca
2+
-dependent membrane fusion for C2 domains 
in general and ferlin proteins in particular. The cellular function and subcellular localisation 
of ferlins and ferlin-like proteins in Apicomplexan parasites, however, is so far not defined 
and was focus of this work.  
The P. berghei C2 domain-containing protein and related ferlin perform vital functions 
in blood-stages  
Targeted gene disruption is a commonly used method to study potential protein functions in 
Plasmodium. The resulting phenotypes of knock-out parasites subsequently allow conclusions 
of the protein function. The fact that Plasmodium is haploid almost throughout its entire life 
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cycle facilitates this purpose and leads to distinct phenotypes in most cases. As targeted gene 
disruptions are typically performed in Plasmodium blood-stages the depletion of genes 
essential for blood-stage development lead to non-viable parasites. This was the case for the 
P. berghei fer and c2cp. We were not able to specifically deplete the one or the other gene in 
three independent transfection experiments and at the same time a control complementation 
constructs proved that the genomic locus is generally accessible and hence not resistant to 
gene-targeting. Therefore we conclude a vital function of P. berghei ferlin and C2 domain-
containing protein during blood-stage development.  
The expression profile of Pb fer and c2cp supports their essential role in blood-stages as 
transcripts of both genes were found in P. berghei blood-stage parasites. This probably also 
explains why no Plasmodial ferlin was detected in RAS liver-stages during a previous screen, 
where the transcriptional profile of RAS and WT sporozoites as well as liver-stages was 
compared to mixed blood-stages (Williams and Azad 2010). Proteins that are expressed 
during liver-stage as well as blood-stage development were not detect by this experimental 
set-up. Furthermore transcripts of Pb c2cp were found in early WT liver-stages (20 h). A 
respective band is only very slightly shown in figure 15. This suggests an extremely weak 
expression of Pb c2cp in early liver-stages. This is in agreement with the quantitative real-
time PCR data (figure 13) where the Pb c2cp is also only expressed very weak in WT liver-
stages after 20 hours development (100 copies in qRT-PCR). In contrast transcripts of Pb fer 
were detected in WT midgut sporozoites and late liver-stages (48 h). Whereas the expression 
was only very weak in early liver-stages (20 h) and no transcripts could be detected in 
salivary gland sporozoites. This indicated a Pb fer expression in intracellular stages (blood-
stages, midgut sporozoites and liver-stages) rather than extracellular stages (salivary gland 
sporozoites). In order to prove this hypothesis other extracellular parasite stages like purified 
merozoites or ookinetes have to be tested. Typically intracellular Plasmodium blood and 
liver-stages build a surrounding parasitophorous vacuole (PV) immediately after invasion of 
the respective host-cell. This involves a rapid assembly of the PV membrane (PVM) around 
the intracellular parasite. Other described ferlins play important roles in different membrane 
fusion events. For example the above described human ferlins, dysferlin and otoferlin. 
Additionally the C. elegans FER-1, that mediates the fusion of specialized membranous 
organelles during spermatogenesis (Washington and Ward 2006) or the ferlin of the sea 
urchin, that regulates ATP release from vesicles after membrane wounding (Covian-Nares et 
al. 2010). Thus a potential role of the Plasmodial ferlins in establishment of the PVM is more 
than conceivable. This hypothesis is supported by described interaction partners of Plasmodial 
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ferlins. In a yeast two-hybrid (Y2H) screening the P. berghei C2CP was identified as an 
interaction partner of the N-terminal portion of UIS4, a small protein that protrude into the PV 
of intrahepatic liver-stages (Sabine Fraschka, unpublished) (Mueller et al. 2005b). We 
hypothesize that this interaction may serve as a trigger for e.g. membrane fusion of vesicles 
containing UIS4 with the PVM and furthermore across the PVM to other compartments of the 
infected cell e.g. the host's sorting compartment. Additionally a high-throughput yeast two-
hybrid assay revealed the interaction of a putative P. falciparum ferlin-like protein (FLP, 
MAL8P1.134) with the parasitophorous vacuole resident protein exported protein 2 (EXP-2, 
PF14_0678) (LaCount et al. 2005). EXP-2 is associated with the PVM potentially via an N-
terminal amphipathic helix and directed into the vacuolar space, the cellular function of the 
protein, however, are not described so far (Fischer et al. 1998). Recently, EXP-2 was also 
associated with the PTEX export machinery that exports parasite proteins into the cytosol of 
infected erythrocytes. In the PTEX protein complex EXP-2 is suggested to form the pore 
because of its strong membrane association (de Koning-Ward et al. 2009). This interaction 
further supports the hypothesis that Plasmodial ferlins may transport vesicles to and maybe 
beyond the PVM. Interestingly, these two interactions of Pb C2CP and Pf FLP with the two 
stage-specific PVM resident proteins UIS4 and EXP-2 suggest a role of ferlin proteins during 
liver-stage as well as blood-stage development in Plasmodium. 
As a protein family of 18 SNAREs is described for P. falciparum (Ayong et al. 2007) it may 
also be reasonable that C2 domains of Plasmodial ferlins are involved in SNARE-mediated 
membrane fusion events. SNARE molecules typically mediate the fusion of synaptic vesicles 
with the pre-synaptic plasma membrane, resulting in the release of neurotransmitter. Thereby 
SNAREs are involved in all stages of the fusion process, from bringing the two opposing 
membranes into close proximity up to the expansion of the fusion pore (Risselada and 
Grubmuller 2012). Nevertheless it is debated whether SNAREs are indeed essential for 
membrane merger or whether they just establish membrane attachment by formation of a 
trans-SNARE complex between complementary SNAREs in the two membranes, while 
fusion itself is then executed by other proteins. Evidence therefore provide several studies on 
the fusion of yeast vacuoles (Wickner and Haas 2000). For example it was shown that protein 
phospholipase 1 and calmodulin are involved in the final bilayer mixing step of membrane 
fusion (Peters et al. 1999) (Peters and Mayer 1998). Thus, also ferlin proteins may contribute 
to the fusion process initiated by SNAREs in Plasmodium.  
In summary the RT-PCR data support the results from the screening and the functional 
analysis. The low expression of Pb c2cp (UAP 1) in early WT LS is in good agreement with 
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the SSH screening. An up-regulation of Pb c2cp in attenuated parasites means low abundance 
in WT LS, because we always compared to WT as a reference and this was also shown by 
qRT-PCR. Additionally the expression of Pb c2cp and Pb fer in blood-stage parasites 
supports a functional role of these proteins during the erythrocytic phase. Finally both, the 
expression of Pb C2CP in attenuated liver-stages as shown by the SSH screening and the here 
demonstrated expression and essential role also in blood-stages, makes the Pb C2CP and 
interesting candidate for incorporation into a multi-stage malaria vaccine.  
GAP immunisation establishes a memory T-cell response 
Immunisation with genetically-attenuated parasites (GAP) leads to sterile protection in 
C57BL/6 mice. This protection can be achieved by injection of uis3(-) sporozoites according 
to a three dose immunisation protocol (figure 18). Two booster dose are required to establish 
full protection in this vaccination model as no immunodominant CD8
+
 T-cell epitope is 
available in C57BL/6 mice expressing the H-2
b
 MHC I haplotype. A similar observation has 
been described for experimental RAS immunisation in a transgenic mouse model that is 
tolerant to the immunodominant CSP (Kumar et al. 2006). Suggesting that other probably less 
immunodominant antigens, hitherto unidentified, can also induce protection and may also be 
involved in GAP-mediated immunity.  
In this study we showed that GAP immunisation induces effector T-cells and establishes a 
memory T-cell response. FACS analysis revealed an enhanced CD8
+
CD44
high
CD62L
low
 
effector memory T-cell population in the liver after immunisation if compared to non-
immunised controls (figure 19). The induction of effector cells and the development of 
memory-recall responses following a pathogen infection are hallmarks of adaptive immunity 
and the basis of vaccination. In order to study underlying mechanisms like the induced 
effector cytokines produced by this T-cell subset, however, T-cell numbers have to be 
enhanced ex vivo as low responses of a small number of specific effector T-cells can hardly be 
detected in whole organs e.g. in the liver. One approach in our lab is the generation of stage-
specific ovalbumin (OVA)-expressing model parasites. The strong immunogenic and easy to 
track OVA is used in many models as both a general and strong T-cell activator [reviewed in 
(Plebanski et al. 2010)]. Though the here presented study aimed at another more specific 
approach. Antigen-specific T-cell clones are activated during immunisation and migrate to the 
liver, where they direct their cytotoxic activity against infected hepatocytes. These T-cell 
clones are difficult to track, as specific T-cell numbers are low compared to the number of 
liver infiltrating cells. Especially in the GAP vaccination model no presented antigen is 
described making it impossible to study specific T-cell responses. Therefore the aim of this 
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study was the identification and characterisation of new potential antigens involved in GAP-
mediated immunity, essentially to specifically restimulate T-cells from immunised animals in 
vitro. The P. berghei C2 domain-containing protein (C2CP) was considered a promising 
candidate. This candidate antigen was identified by comparative analysis of early Plasmodium 
liver-stages as one of the most abundant transcript up-regulated in attenuated parasites (UAP 
1). We believe that one characteristic of potential antigens involved in GAP-induced 
protection may be the high expression of the respective protein during early liver-stage 
development. Additionally we found several predicted C2CP-specific strong binding MHC 
class I epitopes, that are H-2
b
-restricted and may therefore be presented in the here used 
C57BL/6 mouse background. Hence we investigated this antigen candidate with respect to its 
potential in elicit specific immune responses after GAP and RAS immunisation.  
Plasmodium berghei C2CP-specific cells are recognised and killed in GAP and RAS 
immunised animals  
The P. berghei C2CP (UAP 1) contains the four predicted H-2
b
-restricted CD8
+
 T-cell 
epitopes A9I, T9L, S8V and A8I. The MHC class I binding of the peptide T9L, that showed 
the highest binding affinity to H-2
b
 MHC molecules also by prediction, was further validated 
and in vitro binding affinity was determined by colleagues from Copenhagen with an adapted 
LOCI assay (luminescent oxygen channelling immunoassay) (Harndahl et al. 2009). 
Naïve splenocytes were pulsed with a pool of either three (A9I, S8V and A8I) or all four 
peptides and injected into RAS and GAP immunised mice. After 18 hours we had a look if 
these cells became specifically lysed in spleens and livers. Although there was no specific 
lysis of Pb C2CP-specific cells shown in spleens of immunised animals, these cells were 
recognised and lysed in livers of immunised and WT infected C57BL/6 mice. When using the 
three Pb C2CP-derived peptides A9I, S8V and A8I this cytotoxic lysis increased significantly 
in the livers of RAS immunised mice when compared to naïve animals. In order to achieve a 
significant higher cytotoxic lysis after RAS and GAP immunisation, however, we had to add 
the fourth Pb C2CP-derived peptide T9L. Interestingly, activated cytotoxic CD8
+
 T-cells are 
primarily located in the liver after GAP or RAS immunisation. Indeed it has been 
demonstrated that CSP-specific effector CD8
+
 T-cells have to home to the liver in order to 
induce protective immunity in the RAS model while effector T-cells located in lymphoid 
organs were not sufficient for protection (Morrot et al. 2005). Cytotoxic CD8
+
 T-cells 
accomplish their anti-parasitic activity via recognition of MHC class I-presented epitopes by 
infected hepatocytes (White et al. 1996). By that infected hepatocytes get specifically lysed 
by so far not fully understood effector mechanisms. The injected peptide-pulsed splenocytes 
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probably became recognised and killed by similar effector mechanisms by the antigen specific 
cytotoxic T-lymphocytes that were activated during immunisation. The observation that Pb 
C2CP-specific cells were also lysed in WT infected animals is not really surprising as WT 
sporozoites also induce immune responses under natural malaria transmission. Repeated 
exposure to WT sporozoites leads to a degree of protection in endemic areas. This naturally 
acquired immunity protects against severe symptoms rather than infection (Artavanis-
Tsakonas et al. 2003) and primarily depends on antibodies, but T-cells seem to be important 
to develop and maintain immunity (Langhorne et al. 2008). Immune responses induced by 
WT sporozoites, however, can even be protective if blood-stage infection is prohibited 
(Belnoue et al. 2004) and therefore may potentially be similar to the protective immune 
responses induced by GAP and RAS.  
That activated effector T-cells indeed home to the liver were infection occurs and antigen is 
presented was further supported by a cytokine-based ELISpot analysis.  
P. berghei C2CP-derived peptides are able to specifically restimulate T-cells from GAP 
and RAS immunised animals 
For a long time it is known that CD8
+
 T-cells perform an important role in protective 
immunity after immunisation with RAS (Schofield et al. 1987b) (Weiss et al. 1988). Later it 
was shown that transferred CD8
+
 T-cell clones against the immunodominant CD8
+
 T-cell 
epitope of CSP confer this protection and are capable of killing malaria liver stages 
(Rodrigues M. M. et al. 1991). For GAP-mediated immunity it could also be demonstrated 
that CD8
+
 T-cells are the key players in mediating protective immunity (Mueller et al. 2007). 
The role of IFN-" as the effector cytokine in RAS mediated immunity was demonstrated in 
several studies (Ferreira et al. 1986) (Schofield et al. 1987b) (Tsuji et al. 1995). Recently, 
however, the contribution of IFN-" in liver-stage immunology was questioned as protective 
immune responses induced by recombinant viral vaccines expressing CSP were independent 
of IFN-" (Rodrigues E. G. et al. 2000) (Chakravarty et al. 2008). Though in GAP-mediated 
immunity IFN-" plays an important role as protection was abrogated in IFN-" (-/-) mice 
(Mueller et al. 2007). 
In this study we therefore measured IFN-" responses as a read-out for effector T-cell function 
after RAS and GAP immunisation in a cytokine-based ELISpot. Effector T-cells from 
immunised animals were specifically restimulated in vitro for 24 hours with P. berghei C2CP-
derived peptides. In two independent experiments the Pb C2CP-derived peptides A9I, S8V 
and A8I where not able to restimulate T-cells in the spleen or the liver of immunised animals. 
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Though the predicted H-2
b
-restricted CD8
+
 T-cell epitope T9L was highly immunogenic and 
hence potent to specifically enhance IFN-" responses after restimulation in vitro in RAS and 
GAP immunised C57BL/6 mice in comparison to naïve controls. Ultimately, in very good 
agreement with the previous described cytotoxicity assay this suggests the peptide T9L 
derived from Plasmodium C2CP displays high immunogenicity in GAP-vaccinated animals. 
This is the very first immunogenic peptide specified in the herein described P. berghei GAP 
model and the first specific restimulation of T-cells in this vaccination model. 
The basis of this study will now facilitate to examine underlying effector mechanisms of 
protective immune responses induced by GAP. Hence, an extensive FACS analysis could help 
to decipher antigen-specific T-cell populations and respective phenotypes involved in GAP-
mediated immunity. For this T-cell numbers may probably be increased by prolonged antigen 
exposure e.g. by administration of additional booster dose or decrease of the periods between 
the single boosts. It then would be interesting to also study the contribution of CD4
+
 T-cells 
and innate immune responses in GAP mediated pre-erythrocytic immunity.  
Immunisation study with Pb C2CP-derived peptides and recombinant overexpression of 
P. berghei C2CP - first results  
Apparently the question emerges, if the PbC2CP-derived peptide T9L is highly immunogenic, 
is it also protective? Indeed it could be shown, that mice immunised with the protective CD8
+
 
T-cell epitope SYVPSAEQI of P. yoelii CSP alone, developed a strongly proliferating CD8
+
 
T-cell response, indicating that the peptide itself is strongly immunogenic. This T-cell 
population, however, failed to acquire effector functions, when administrating the peptide in 
PBS (Overstreet et al. 2010). Hence we carried out a first immunisation trial using the peptide 
T9L delivered in specialised nanocarrier, called TargoSpheres, from the Rodos BioTarget 
GmbH (RBT; www.biotargeting.eu). These Targospheres directly target antigen-presenting 
cells (APCs) and release their content into the APCs. Thereby the peptide should gain access 
to the professional antigen-presentation pathway via MHC molecules. Of course we had to 
test both the administered dose and the administration route. The decision was made to inject 
two different dose into the skin of mice. The skin is also the entry port of Plasmodial antigens 
during natural transmission and distinct subsets of skin-resident migratory DCs have been 
characterised, Langerhans cells, dermal DCs and, recently, langerin
+
CD103
+
 dermal DCs 
(Eidsmo et al. 2009). As some sporozoites stay in the skin for more than one hour after an 
infectious bite (Yamauchi et al. 2007) skin-resident DCs may play an important role, as they 
may acquire sporozoite antigen directly in the skin before they migrate to the draining lymph-
nodes to prime CD8
+
 T-cells (Chakravarty et al. 2007).  
Discussion   104  
Firstly we examined the pre-patency of immunised animals. All immunised as well as control 
animals developed a blood-stage parasitemia after WT sporozoite challenge. Though a slight 
delay in pre-patency could be observed in the group of mice immunised with the higher 
peptide dose (5 #g). The delay of on average 1.3 days if compared to FITC:Dextran injected 
controls could be interesting with respect to disease outcome. Early studies showed that the P. 
berghei ANKA clone present mature liver schizonts as early as 43 hours after inoculation of 
infectious sporozoites, whereas the less virulent P. berghei NK65 clone showed first mature 
schizonts not before 51 hours after infection in the liver (Bafort et al. 1968). This extended 
liver phase might be coupled with a milder disease outcome as the latter does not cause 
cerebral symptoms. A vaccine that will prevent malaria symptoms and saves patients from 
death rather than inhibiting an infection completely would probably also be useful for 
endemic areas. Such a vaccine virtual mimics naturally acquired immunity that is dependent 
on repeated exposure and develops only slowly in the course of time. One high risk group, 
however, suffering from severe malaria and associated deaths are children under the age of 
five. A vaccine that would overcome the exposure-dependence of naturally acquired 
immunity and rapidly elicit protection against severe malaria would therefore especially help 
to reduce mortality in children.  
Secondly, an immunological examination of the immunised animals was performed 8 days 
after sporozoite challenge. Lymphnode dissection was included in this analysis as we 
immunised subcutaneously into the skin of the animals. In by bite immunisations, where 
sporozoites passage the skin, the draining lymph nodes are ascribed an important role in CD8
+
 
T-cell priming (Chakravarty et al. 2007). Not all sporozoites injected into the skin enter blood 
vessels to reach the liver, in fact some sporozoites are drained with the lymphatic system to 
regional lymph nodes (Amino et al. 2006). There sporozoites get internalised by resident 
dendritic cells and antigens are cross-presented to naïve CD8
+
 T-cells. T-cell priming in the 
lymph nodes is followed by dissemination of effector T-cells into different organs including 
spleen and liver (Chakravarty et al. 2007). In these organs specifically activated T-cells were 
analysed by IFN-" ELISpot. High immune responses could be detected in the liver. We 
counted between 500 and 1000 IFN-" producing T-cells per million liver lymphocytes in all 
immunised and control groups (see figure 24). An exception was the control group injected 
with 1 #g FITC:Dextran, that showed up to 3480 responding cells per one million liver 
lymphocytes. This result was not caused by a single outlier, but high IFN-" responses were 
rather consistent throughout the whole group. Interestingly the high responses of the 1 #g 
FITC:Dextran group proceed also in the spleen. These responses might possibly have been 
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due to a contamination in the respective vial. The same FITC:Dextran and PBS solutions, 
however, from the same vials were used for injection of the group treated with 5 #g 
FITC:Dextran that did not show this high responses. In the spleen IFN-" responses were lower 
than in the liver reaching from 200 to 300 responding cells per million splenocytes in the 
immunised groups. This is consistent with the previous ELISpot, where most of the IFN-" 
producing effector T-cells were localised to the liver rather than the spleen (see figure 23) and 
published results, where effector T-cells had to localise to the liver in order to induce 
protection in RAS immunised animals (Morrot et al. 2005). The IFN-" responses were the 
lowest in the draining lymph nodes, only 10 to 60 responding cells were measured per one 
million lymphocytes in all immunised groups. Interestingly, the not immunised challenged 
group showed more than 100 IFN-" producing cells per million lymphocytes in the lymph 
nodes. This skin-draining lymph nodes are the priming site for IFN-" producing effector 
CD8
+
 T-cell that subsequently migrate to the liver in order to kill infected hepatocytes 
(Chakravarty et al. 2007). Another explanation might be that sporozoites inoculated into the 
skin, in this experiment by bite of infected mosquitoes, are partly drained with the lymphatics 
to the proximal lymph nodes, where they can even start to differentiate into exo-erythrocytic 
stages (Amino et al. 2006). These parasite stages probably may also be attacked by IFN-" 
producing effector T-cells, like it was shown for exo-erythrocytic forms in the liver (Schofield 
et al. 1987a). This may explain the presence of IFN-" producing cells in the lymph node of 
naïve challenged mice. Maybe the lower IFN-" responses in lymph nodes of immunised 
animals could be due to induced immune responses in the skin that potentially capture 
sporozoites already at the entry. In total, however, for all measured IFN-" responses after 
immunisation with these nanocarrier we did not observe any specificity after restimulation 
with the peptide T9L. In future studies other adjuvant systems should be tested with the Pb 
C2CP-derived peptide T9L and also in combination with other antigens identified in the here 
presented screen. Maybe also coupling of the peptide to a highly immunogenic carrier should 
be tested like e.g. the tetanus toxoid, that was coupled to CSP-derived petides, inducing high 
antibody titres and protection against malaria infection (Zavala et al. 1987) (Etlinger et al. 
1988). A more promising approach, however, would probably be the delivery of the 
recombinant C2CP protein in its native form and formulated with the right adjuvant. That a 
strong and suitable adjuvant system is very important shows the development of the RTS,S 
vaccine. Only the formulation with the novel clinically approved AS adjuvant system lead to 
strong humoral and cell-mediated responses in rhesus monkeys and partial protection in 
human volunteers [reviewed in (Cohen et al. 2010)]. 
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We also aimed at the recombinant expression of the P. berghei C2CP. Therefore we used the 
codon-optimised E. coli BL21-CodonPlus (DE3)-RIPL strain provided as transformation 
competent cells from Stratagene. Recombinant expression of Pb C2CP protein parts fused to a 
6x-histidin-tag was performed according to standard E. coli expression protocols (see 3.2.6). 
The expressed fusion protein C2CPI-his was only partly expressed as soluble protein and 
solubility was not improved by different strategies like reduction of expression temperature or 
induction of protein expression with a low concentration of IPTG. Also the purification via 
column chromatography succeeded only partially and could not be improved by using 
different imidazol concentrations. The AT-rich Plasmodium genome may hamper the high-
level expression in E. coli. Therefore the use of codon-optimised protein-constructs was 
described for other Plasmodium proteins e.g. the Pf falcipain-2 in order to achieve good 
expression results in E. coli (Salas Sarduy et al. 2012). The usage of codon-optimised 
synthetic genes specifically generated for the respective organism, that is used for 
recombinant expression, was also described for Pf CSP in E. coli and also in Pichia pastoris 
yeast cells (Plassmeyer et al. 2009). Probably the endogenous gene sequence we used for the 
generation of the expression-constructs was not suitable for high-level expression in E. coli. 
But also the use of different host organisms for recombinant expression of Plasmodium 
protein is demonstrated reaching from bacterial and viral cells to eukaryotic yeast cells, but 
also the use of more unusual hosts is described e.g the slime mold Dictyostelium discoideum 
(van Bemmelen et al. 2000) (Birkholtz et al. 2008). Therefore the expression of the Pb C2CP 
could probably be optimised to a valuable amount when testing different other expression 
systems. Also new technologies including new promotor systems, like the Gateway System 
using the tightly manageable araBAD promoter, were successfully applied for high-
throughput cloning and expression of functional proteins in P. falciparum (Aguiar et al. 
2004). There is a multitude of distinct heterologous expression systems used for the 
recombinant expression of Plasmodial proteins, although the here used pET/BL21 
combination seems to be the most popular one, the suitable system has to be found for each 
protein [reviewed in (Birkholtz et al. 2008)].   
The recombinant P. berghei C2CP then enables e.g. the production of antibodies by 
immunisation of animals with the protein. On the one hand we could show the intracellular 
localisation of C2CP in fixed and immunofluorescently labelled preparations with specific 
antibodies. This would further uncover potential cellular functions of the protein. Secondly 
Western blot analysis of stage-specific parasite lysates would eventually demonstrate 
expression on protein level rather than transcripts. Finally recombinant Pb C2CP could be 
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formulated and tested as subunit vaccine candidate. The most advanced recombinant protein 
subunit vaccines is RTS,S based on the recombinant P. falciparum circumsporozoite protein 
(CSP). Only a long lasting journey, however, led to the today's vaccine currently tested in a 
clinical phase III trial (Leach et al. 2011) (Casares et al. 2010). The expression in 
Saccharomyces cerevisae in combination with the hepatitis B virus surface antigen as a 
matrix carrier and the assembly of the fusion protein in virus-like particles was important for 
proper delivery of the CSP antigen (Cohen et al. 2010). Additionally the formulation with a 
strong and appropriate adjuvant system was necessary in order to reach sufficient 
immunogenicity of the antigen. This development of a safe, immunogenic and partly 
protective vaccine lasts already more than 25 years, but also started with the expression of a 
recombinant protein (Ballou 2009).  
Concluding remarks  
The here presented study describes the identification and characterisation of the first specific 
antigen Pb C2CP and its immunogenic CD8
+
 T-cell epitope T9L involved in GAP-mediated 
immunity. It shows the first antigen-specific immune response of C57BL/6 mice immunised 
with GAP. This now enables the investigation of GAP-induced effector mechanisms in more 
detail. Hence T-cells from GAP-immunised animals can be specifically restimulated and 
thereby T-cell numbers can be enhanced in vitro. This facilitates the analysis of the whole 
cascade of downstream effector mechanisms following immunisation. Therefore this work is 
of fundamental importance to understanding the mechanisms of pre-erythrocytic immunity to 
malaria. In the long run this work may further pave the way for the composition of an anti-
infective multi-component subunit malarial vaccine in combination with antigens derived 
from the herein described differential profiling and known malarial pre-erythrocytic vaccine 
candidates such as CSP. This finally would emulate the attenuated parasite in a safe and 
effective malaria vaccine.  
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6. Appendix 
6.1 Oligonucleotide sequences 
6.1.1 PyCSP complementation 
PyCSP_complI_EcoRI_for 5'-CGGAATTCATGAAGAAGTGTACC-3' 
PyCSP_complI_XbaI_rev  5'-GCTCTAGACTGTTTAACAAATTC-3' 
PyCSP_complII_XbaI_for 5'-GCTCTAGAATAAGTAGTCAACTC-3' 
PyCSP_complII_NotI_rev 5'-ATTTGCGGCCGCTGGTTGCTTGTTTAC-3' 
PyCSP_int_test_for    5'-CCCGCACGGACGAATCCAGATGG-3'   
PyCSP_int_test_rev   5'-GTTTCGATATCGTCATAACAAG-3' 
PyCSP_int_epi_for    5'-CCCGCACGGACGAATCCAGATGG-3' 
PyCSP_int_epi_rev  5'-ATTTGCGGCCGCTGGTTGCTTGTTTAC-3' 
6.1.2 PyCSP epitope mutagenesis 
PyCSP_me01_for  5'-GAAGATTCTTATGCCCCAAGCGCGGAAGCAATACTAGAATTTG-3' 
PyCSP_me01_rev  5'-CAAATTCTAGTATTGCTTCCGCGCTTGGGGCATAAGAATCTTC-3' 
PyCSP_me02_for  5'-GAAGATGCTTATGCCCCAGCCGCGGCACAAGCACTAGAATTTG-3' 
PyCSP_me02_rev  5'-CAAATTCTAGTGCTTGTGCCGCGGCTGGGGCATAAGCATCTTC-3' 
PyCSP_me03_for  5'-GAAGATGCTTATGCCCCAGCCGCGGAACAAGCACTAGAATTTG-3' 
PyCSP_me03_rev  5'-CAAATTCTAGTGCTTGTTCCGCGGCTGGGGCATAAGCATCTTC-3' 
PyCSP_me04_for  5'-GAAGATTCTGCTGTCGCAAGCGCGGCAGCAATACTAGAATTTG-3' 
PyCSP_me04_rev  5'-CAAATTCTAGTATTGCTGCCGCGCTTGCGACAGCAGAATCTTC-3' 
6.1.3 PyCSprae knock-out 
PyCSprae_5'UTR_XbaI_for   5'-GCTCTAGACCGTTGGTACAAATCTTGCAAGCTTTG-3'  
PyCSprae_5'UTR_BamHI_rev  5'-CGGGATCCGCATATTTGTTACGTAGGGGAATATAC-3'  
PyCSprae_Nterm_HindIII_for  5'-CCCAAGCTTGGGGCTATTTGTACATAAAAGTTGTTC-3'  
PyCSprae_Nterm_KpnI_rev   5'-GGGGTACCGCATAACACATTACCCAACAATTTTATGC-3'  
PyCSprae_5' test_for   5'-CTCTCTCTTTCTCGCTCTCTTTCTCTC-3' 
PyCSprae_test_rev    5'-CCCGCACGGACGAATCCAGATGG-3'  
6.1.4 PyCSP replacement 
PyCSP_ORF_XbaI_for  5'-GCTCTAGAATGAAGAAGTGTACCATTTTAG-3' 
PyCSP_ORF_BamHI_rev  5'-CGGGATCCTTAATTAAAGAATACTAATAC-3' 
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PyCSP_3'UTR_HindIII_for  5'-CCCAAGCTTGTTATGACGATATCGAAAC-3' 
PyCSP_3'UTR_KpnI_rev  5'-GGGGTACCGCTAGTTGGAATTATTTAC-3' 
PyCSP_repl_test_for   5'-CGCATTATATGAGTTCATTTTACACAATCC-3'   
PyCSP_repl_test_rev  5'-CCTTTCTTTGGTTTGTATTAACCTG-3' 
PyCSP_repl_epi_for   5'-CCCGCACGGACGAATCCAGATGG-3'   
PyCSP_repl_epi_rev  5'-GCTCTAGAATGAAGAAGTGTACCATTTTAG-3' 
6.1.5 PbFER knock-out and complementation 
PbFER_5'UTR_KpnI_for 5'-GGGGTACCGCGTGTTATGCTCCCAATAAAATAC-3' 
PbFER_5'UTR_HindIII_rev 5'-CCCAAGCTTCCAAGATTGAGATCTGCCTCAATGTAAG-3' 
PbFER_3'UTR_BamHI_for  5'-CGGGATCCGACGCTGGACTATGGGACCCTATGG-3' 
PbFER_3'UTR_XbaI_rev 5'-GCTCTAGAGCAGCTTCGTCTAACGAATTGTTACCC-3' 
PbFER_ORFI_for   5'-TCCCCGCGGCCATCGAGTTTCGGTCGATGGAATATTGG-3' 
PbFER_ORFI_rev   5'-GGACTAGTTTATAGCAACATGGCGGGATAAATAAAGG-3' 
PbFER_testI_for   5'-CCCGCACGGACGAATCCAGATGG-3' 
PbFER_testI_rev  5'-CAATCCGATACTCACATATCTTCC-3' 
PbFER_epiI_for   5'-CCCGCACGGACGAATCCAGATGG-3' 
PbFER_epiI_rev   5'-GCTCTAGAGCAGCTTCGTCTAACGAATTGTTACCC-3' 
PbFER_complI_SacII_for  5'-TCCCCGCGGCCATCGAGTTTCGGTCGATGGAATATTGG-3' 
PbFER_complI_XbaI_rev  5'-GCTCTAGAGACCCACATTTCAAGCAACCC-3' 
PbFER_complII_XbaI_for  5'-GCTCTAGAGAAATTATGGGCTATGAAGAGGCAGC-3' 
PbFER_complII_BamHI_rev5'-CGGGATCCTTATAGCAACATGGCGGGATAAATAAAGG-3' 
PbFER_ORFII_for    5'-CCGCTCGAGATGGGTTCTATACTTGTTAATTTAG-3' 
PbFER_ORFII_rev   5'-CGGGATCCCAATGGCACATCAATATCAAAATTTTC-3' 
PbFER_testII_for    5'-CCGCTCGAGATGGGTTCTATACTTGTTAATTTAG-3' 
PbFER_testII_rev   5'-CCTTGCTCATTTACCTGCTAATACGATTGC-3' 
PbFER_epiII_for   5'-TCCCCGCGGCCATCGAGTTTCGGTCGATGGAATATTGG-3' 
PbFER_epiII_rev   5'-CCTTGCTCATTTACCTGCTAATACGATTGC-3' 
6.1.6 PbC2CP knock-out and complementation 
PbC2CP_5'UTR_KpnI_for  5'-GGGGTACCGCAGTAAGGGAGAAAGGTC-3' 
PbC2CP_5'UTR_HindIII_rev  5'-CCCAAGCTTCCTTTGATGAGTATGAAGTG-3' 
PbC2CP_3'UTR_BamHI_for  5'-CGGGATCCGCAAAACACATGAAACTCAAG-3' 
PbC2CP_3'UTR_XbaI_rev  5'-GCTCTAGAGCTCATTTACATTTCCAATGC-3' 
PbC2CP_ORFI_for   5'-GGAATTCCATATGCAGACCTTCAAAGAAGATC-3' 
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PbC2CP_ORFI_rev   5'-CCGCTCGAGGCCAATCCATGAGCATGGGAG-3' 
PbC2CP_testI_for   5'-CCCGCACGGACGAATCCAGATGG-3' 
PbC2CP_testI_rev  5'-GTGAACAGCTACACTTCAGCCTCCCTATC-3' 
PbC2CP_epiI_for   5'-CCCGCACGGACGAATCCAGATGG-3' 
PbC2CP_epiI_rev   5'-GCTCTAGAGCTCATTTACATTTCCAATGC-3' 
PbC2CP_complI_SacII_for  5'-TCCCCGCGGGATCCATTCCTATCTCCTTGTAC-3' 
PbC2CP_complI_XbaI_rev  5'-GCTCTAGAGTGAGGTGGAATCTCAGGGTTG-3' 
PbC2CP_complII_XbaI_for  5'-GCTCTAGAACCAGTCAGAATGGCTAAGATC-3' 
PbC2CP_complII_SpeI_rev  5'-GGACTAGTCTAATATCCACTTATCAGTGAGTAC-3' 
PbC2CP_ORFII_for   5'-GGAATTCCATATGCAGACCTTCAAAGAAGATC-3' 
PbC2CP_ORFII_rev   5'-CCGCTCGAGGCCAATCCATGAGCATGGGAG-3' 
PbC2CP_testII_for   5'-GGAATTCCATATGCAGACCTTCAAAGAAGATC-3' 
PbC2CP_testII_rev   5'-CCTTGCTCATTTACCTGCTAATACGATTGC-3' 
PbC2CP_epiII_for   5'-TCCCCGCGGGATCCATTCCTATCTCCTTGTAC-3' 
PbC2CP_epiII_rev   5'-CCTTGCTCATTTACCTGCTAATACGATTGC-3' 
6.1.7 Reverse transcriptase PCR 
Cloning oligonucleotides for the pferCONT and pc2cpCONT constructs were also used for 
reverse transcriptase PCR (RT PCR). 
PbFER_complII_XbaI_for  5'-GCTCTAGAGAAATTATGGGCTATGAAGAGGCAGC-3' 
PbFER_complII_BamHI_rev5'-CGGGATCCTTATAGCAACATGGCGGGATAAATAAAGG-3' 
PbC2CP_complII_XbaI_for  5'-GCTCTAGAACCAGTCAGAATGGCTAAGATC-3' 
PbC2CP_complII_SpeI_rev  5'-GGACTAGTCTAATATCCACTTATCAGTGAGTAC-3' 
6.1.8 Quantitative RT PCR 
UIS4_sense   5'- CAGAGCCCAAACCAAGCGATCATAC-3' 
UIS4_antisense   5'- CCATGTTATAAACGTTATTTC-3' 
LSA1_sense   5'- CTCTGATCCAGGGACGCCTAAGGGAG-3' 
LSA1_antisense   5'- GTCCCCCGTTTTCTACTGAT-3' 
UAP1_sense   5'- AGGATAGCAAAAACTCTTCTAAAGG-3' 
UAP1_antisense   5'- GCTCCCTTGTCAAAG-3' 
UAP4_sense   5'- GGTTTCTCTGTGTAGCCCTGG-3' 
UAP4_antisense   5'- CATATTTCAACAACCACTG-3' 
UAP7_sense   5'- GCAGGTCTCTGTGTCCATACC-3' 
UAP7_antisense   5'- GGACAGCCAGGGCTAC-3' 
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6.1.9 Sequencing 
T7    5'-TAATACGACTCACTATAGGG-3'    
SP6    5'-ATTTAGGTGACACTATAGAA-3' 
6.1.10 PbC2CP overexpression 
PbC2CPI_NdeI_for  5'-GGAATTCCATATGGGGAGCAACAATTACTTTTC-3' 
PbC2CPI_XhoI_rev  5'-CCGCTCGAGTCTTAGAAATGCTTTCATTG-3' 
PbC2CPII_NdeI_for  5'-GGAATTCCATATGCAGACCTTCAAAGAAGATC-3' 
PbC2CPII_XhoI_rev  5'-CCGCTCGAGGCCAATCCATGAGCATGGGAG-3'  
PbC2CPIII_NdeI_for  5'-GGAATTCCATATGCCATGCTCATGGATTGGC-3' 
PbC2CPIII_XhoI_rev  5'-CCGCTCGAGTGATTGGGTTACCTCACTCAGGATG-3' 
 
6.2 Vector maps 
All vector maps were generated using the XPlasMap 0.96 software. Shown are all unique 
restriction endonuclease recognition sites and recognition sites used for cloning. 
 
 
Figure 28. Vector map of the cloning vector b3D. The b3D vector contains the gene coding for the 
Toxoplasma gondii dihydrofolate reductase-thymidylate synthase (DHFR/TS) conferring to pyrimethamine 
resistance serving as selectable marker of transfected parasites. This marker is flanked by two multiple cloning 
sites. An additional gene conferring to ampicillin resistance (Amp) enables selection for resistant bacteria during 
cloning.  
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Figure 29. Vector map of the cloning vector b3D+. The cloning vector b3D+ contains in comparison to the 
vector b3D an additional P. berghei DHFR/TS 3' UTR. The respective fragment with a size of 1.2 kb was cloned 
using the restriction sites BamHI (forward) and EcoRI (reverse) into the b3D vector backbone.  
 
 
Figure 30. Vector map of the targeting construct pcsp!epi. The truncated P. yoelii csp ORF was cloned into 
the vector b3D in two parts in order to insert an unique XbaI restriction site for linearisation prior to parasite 
transfection. The EcoRI (forward) and NotI (reverse) restriction sites were used for cloning of the truncated 
ORF. The black star shows the position of the CD8
+
 T-cell epitope that was mutated by site-directed 
mutagenesis.  
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Figure 31. Vector map of the targeting construct p!csprae. Two fragments of the P. yoelii csprae gene 
(PY07369) were cloned into the vector b3D flanking the selectable marker using the restriction sites XbaI 
(forward) and BamHI (reverse) or HindIII (forward) and KpnI (reverse), respectively. Prior to transfection the 
construct was digested with XbaI and KpnI.   
 
 
Figure 32. Vector map of the targeting construct pcsprepl!epi. The complete P. yoelii csp ORF and a 
fragment from the Py csp 3'UTR were cloned into the vector b3D using the restriction sites XbaI (forward) and 
EcoRI (reverse) or HindIII (forward) and KpnI (reverse), respectively. The black star shows the position of the 
CD8+ T-cell epitope that was mutated by site-directed mutagenesis. Prior to transfection the construct was 
digested with XbaI and KpnI.  
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Figure 33. Vector map of the targeting construct p!fer. Fragments of the P. berghei ferlin 5'UTR and 3'UTR 
were cloned into the cloning vector b3D flanking the selectable marker. The restriction enzymes KpnI (forward) 
and HindIII (reverse) and BamHI (forward) and XbaI (reverse) were used for construction, respectively. Prior to 
transfection the construct was digested with KpnI and XbaI.  
 
 
Figure 34. Vector map of the targeting construct pferCONT. Two fragments coding for the C-terminal part 
of the P. berghei ferlin were cloned into the vector b3D+ upstream of the Pb DHFR/TS 3'UTR. The restriction 
sites for SacII (forward) and XbaI (reverse) and XbaI (forward) and SpeI (reverse) were used for cloning. The 
construct was linearised with XbaI prior to transfection. 
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Figure 35. Vector map of the targeting construct p!c2cp. Fragments of the P. berghei c2cp 5'UTR and 
3'UTR were cloned into the cloning vector b3D flanking the selectable marker. The restriction enzymes KpnI 
(forward) and HindIII (reverse) and BamHI (forward) and XbaI (reverse) were used for construction, 
respectively. Prior to transfection the construct was digested with KpnI and XbaI.  
 
 
Figure 36. Vector map of the targeting construct pc2cpCONT. Two fragments coding for the C-terminal part 
of the P. berghei C2CP were cloned into the vector b3D+ upstream of the Pb DHFR/TS 3'UTR. The restriction 
sites for SacII (forward) and XbaI (reverse) and XbaI (forward) and SpeI (reverse) were used for cloning. The 
construct was linearised with XbaI prior to transfection 
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Figure 37. Vector map of the expression vector pETc2cpI. A fragment coding for the N-terminal part of the 
P. berghei C2CP (C2CPI) was cloned into the expression vector pET-15b (Novagen) using the restriction sites 
NdeI (forward) and XhoI (reverse). By that C2CPI is expressed as fusion protein with a N-terminal His-tag under 
control of the T7 promotor.  The lacI coding sequence and the bla gene (Amp) serve as selection marker. 
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6.3 Sequence analysis of the Py CSP mutant clone I-2 
 
 
Figure 38. Sequence of the CD8
+
 T-cell epitope mutant Py CSP me01 clone I-2. Shown is the combined 
sequence of the amplified integration-specific DNA fragment of the Py CSP me01 clone I-2 (see also figure 5; 
test fragment). Sequencing was performed using the oligonucleotides T7, SP6 and PyCSP_complII_NotI_rev. 
The respective oligonucleotide binding sites are indicadte with an arrow. The EcoRI and XbaI restriction 
recognition sites are highlighted bold. The red nucleotides indicate the wild-type (non-mutated) sequence coding 
for the CD8
+
 T-cell epitope in a complete csp ORF (including start and stop codon). Light grey nucleotides 
derive from the b3D cloning vector.  
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